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Summary
Parenteral nutrition (PN) support is well established for neonatal and paediatric patients. 
This form of nutrition support is however highly invasive and therefore not without risk. 
Multidisciplinary approach is essential for the successful management of parenteral 
nutrition in hospitals and health-care professionals can refer to international 
recommendations for guidance.
Review of the literature established that little is known about how well guidelines are 
translated into practice and how hospitals throughout Europe actually manage PN for 
neonatal and paediatric patients.
Knowledge of current practice is important for evaluations of quality of care, and in 
order to identify areas for future improvements.
This research project investigated prescribing, administration, and manufacturing 
practice of parenteral nutrition for paediatric and neonatal patients in five European 
countries. Practice was found to be diverse, especially with regard to the involvement of 
pharmacy compounding units. Several hospitals used internally manufactured 
standardised parenteral nutrition for neonates.
Prescribing practice for neonates was subsequently studied in more detail in sixteen 
hospitals across Europe. Prescribing practice was analysed for neonates of differing 
weight, the influence of enteral feeding on parenteral nutrition prescription was 
investigated, and other clinical factors were studied. Intake of nutrients, especially 
amino acids, was found to be below current recommendations, and on a significant 
number of days less than eighty percent of prescribed nutrition was administered.
The method of administration of lipid emulsions remains controversial in the literature. 
One aspect of pharmaceutical quality control, lipid peroxidation, was therefore 
investigated in more detail, in order to inform the discussion regarding administration of 
lipids as separate infusions, or in combination with other parenteral nutrition 
components.
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1. Literature review
1.1. Definition of parenteral nutrition
Parenteral nutrition (PN) has been defined by the American Society for Parenteral and 
Enteral Nutrition (ASPEN) as ‘nutrients provided intravenously’.1
1.2. Historical aspects of parenteral nutrition
The earliest experimental attempts of intravenous nutrient administration occurred in the 
1600s, when milk and wine were administered to dogs.2 In the 1800s, intravenous saline 
was used to treat cholera, and, by 1930, glucose 5% was used to maintain fluid balance 
intravenously. Glucose administration was limited due to the susceptibility of 
peripheral veins to hyperosmolar solutions.3 The first attempts to provide protein 
intravenously occurred in Sweden during the 1940s in the form of protein hydrolysate.4 
The main drawbacks of this practice were incidences of severe allergic reaction. 
Additionally it was difficult to provide adequate calories to utilize the protein because 
glucose administration was restricted.5 In order to increase calories provided without 
having to increase glucose concentrations, alcohol and lipid emulsion were used.
Alcohol proved to have severe side effects, but lipid emulsions, first from cottonseed oil 
and later from soybean oil, were well tolerated 4 A major breakthrough was the 
introduction of central venous catheters in 1967, which allowed the infusion of
<7
hyperosmolar fluids.
Since then, crystalline amino acid solutions have been developed for adult and 
paediatric use, and several types of lipid emulsions have become commercially 
available.6'8
Paediatric patients have been the focus of nutrition support, due to their vulnerability to 
malnutrition, and one of the first reports of successful continuous intravenous feeding of 
premature neonates dates back to 1975.9
1
1.3. Indications for parenteral nutrition
1.3.1. Neonates
PN is only indicated if  oral or enteral nutrition is not sufficiently digested or absorbed, 
for example in premature neonates, whose gastrointestinal tract is not fully developed.10 
Other indications include congenital malformations such as gastroschisis and 
omphalocele. These are abnormalities in the formation of the abdominal wall that 
require PN administration until surgical corrections have been undertaken. Another 
important indication for PN in neonates is necrotizing enterocolitis (NEC). NEC can 
develop in the event of an ischemic or toxic insult to the bowel mucosa. In neonates, 
this can be due to perinatal hypoxia. Breast milk has been shown to reduce the incident 
of NEC, but the role enteral feeding plays in the prevention of NEC is still unclear.11 
Indications for PN not related to the gastrointestinal tract include cardiac anomalies, 
such as ductus arteriosus, and respiratory insufficiencies, such as respiratory distress 
syndrome.3
1.3.2. Infants and children
Infants and children represent a very diverse group of patients to receive PN. Indications 
include gastrointestinal (Table 1.1) or hypermetabolic (Table 1.2) conditions.12
Gastrointestinal conditions















Metabolic disease Cystic fibrosis
Table 1.2: Indication for PN in children (hypermetabolic)
In some cases, if a large part of the bowel has been surgically removed, long-term PN, 
which can be administered at home, is required.13,14
In recent years, data have been published about the role of both parenteral and enteral 
nutritional support in children with malignancies.15 In 1998, Andrassy and colleagues 
stated that starvation has no role in the treatment of the paediatric cancer patient and 
that malnutrition should be prevented or treated.16
3
1.4. Nutritional requirements of neonates and children
1.4.1. Neonates
Premature neonates (bom before 38 weeks of gestation) have low fat and carbohydrate
1 n
stores, elevated metabolic rates, and immature gastrointestinal tracts. They therefore 
require special attention with regard to nutritional support with the aim to achieve 
growth rates matching those in utero}
Recent ASPEN guidelines recommend the following PN provision to stable preterm 
infants:1 glucose and amino acids should be started on the first day of life in infants 
weighing less than 1500 g at birth; glucose should be advanced as tolerated up to 10 to 
13 mg/kg/min (equivalent to 14.4 to 18.7 g/kg/day); amino acids should be given at 
rates of 1 to 1.5 g/kg/day in the first weeks of life, but should be increased to 3.5 to 3.85 
g/kg/day for stable infants; total calorie intake should be 100-120 kcal/kg/day in stable 
infants; lipids should be commenced within the first three days of life, then advanced up 
to 3 g/kg/day.
The guidelines also highlight the fact that enteral feeding should be administered in 
parallel to PN if at all possible, even if only very small amounts can be given. This 
recommendation was made because it had been shown that enteral feeding promotes gut 
maturation and increases feeding tolerance.
Recommended intake of sodium, potassium, and chloride is 2 to 3 mmol/kg/day, but 
should be subject to continuous evaluation. Recommended intake of other minerals 
includes 60 to 90 mg/kg/day of calcium, 48 to 68 mg/kg/day of magnesium, and 48 to 
68 mg/kg/day of phosphorous, although concentrations of these minerals sometimes 
have to be restricted due to stability limitations.18,19
00Vitamins and trace elements form an important part of PN support. These 
micronutrients are available in the form of commercial micronutrient admixtures 
(details are shown in section 1.10.1 of this thesis).3 In some instances trace elements 
might have to be discontinued, for example copper and manganese in patients exhibiting 
cholestatic jaundice.3
4
1.4.2. Infants and children
Children require nutrients not only for maintenance of metabolism, but also for growth, 
and requirements change considerably with age. Estimated energy needs are 
summarised in Table 1.3.






Table 1.3: Estimated energy needs in children
*5
Typical fluid requirement in infants and children are shown in Table 1.4.
Body weight (kg) Daily fluid requirements
1-10 100 mL/kg
11-20 1000 mL + 50 mL/kg for each kg > 10 kg
>20 1500 mL + 20 mL/kg for each kg > 20 kg
Table 1.4: Typical fluid requirements in infants and children
The following recommendations have been made with regard to nutritional intake in 
paediatric patients:1
a) Protein requirements decrease from 3-4 g/kg/day in premature infants to 1.0-1.2 
g/kg/day in children aged one to ten years. Male adolescents require 0.9 g/kg/day; 
female adolescents require 0.8 g/kg/day.
b) Carbohydrates should make up 40-50% of caloric intake in infants and children.
c) Infants and young children should have unrestricted lipid intake; older children 
should limit lipid intake to 30% of total energy.
d) Micronutrients should be components of all PN solutions and enteral nutrition 
formulas, and blood levels of micronutrients should be monitored periodically.
e) Surgical infants do not require a substantial increase in energy provision, unlike adult 
surgical patients.
5
1.5. Nutrients and their intravenous application
1.5.1. Amino acids
Proteins are the dietary source of amino acids. Proteins are required as catalysts and 
enzymes for metabolic reactions, as hormones, and as structural components of cells.
In an oral diet, indigested protein is denatured in the stomach and then hydrolysed, first 
by pepsin into small fragments, and then by carboxypeptidase into amino acids. Amino
9 1acids are then absorbed in the small intestine by active transport.
Nine amino acids are essential in humans: thryptophan, threonine, isoleucin, lysine, 
valine, leucine, methionine, histidine and phenylalanine. Other amino acids might 
become essential in certain conditions, such as prematurity.17 Cysteine and tyrosine for 
example are considered essential in neonates and young infants because of the 
immaturity of enzyme activities involved in their synthesis.22 
The amino acid glutamine (Figure 1.1) has received particular attention in the 
literature.23,24 Glutamine can be synthesised from glutamic acid and ammonia under 
normal circumstances, but it has been shown that glutamine can be deficient in
*yc
prematurity and in hypermetabolic conditions. Glutamine plays a fundamental role in
9 f \the oxidative defence in the form of glutathione peroxidase; it is therefore important 
that sufficient levels of this amino acid are maintained.
OH
NH2
Figure 1.1: Chemical structure of glutamine
97Glutamine dissolves poorly in water and is highly unstable. In recent years, products 
have been developed that allow intravenous administration of glutamine as alanyl-
9Rglutamine. This dipeptide is highly soluble and stable in aqueous solutions.
Amin and colleagues investigated arginine in preventing necrotizing enterocolitis 
(NEC) in a double blind placebo controlled, randomised trial. The researchers found
9Qthat this amino acid provided significant levels of protection from NEC.
6
Branched-chain amino acids have been investigated with regard to the prevention of gut
*5 A
atrophy in rats. Branched-chain amino acid metabolism is directly related to glutamine 
metabolism and can therefore potentially have similar benefits as glutamine.
1.5.2. Carbohydrates
Glucose is the most commonly used carbohydrate for intravenous infusions. Although 
glucose is not an essential nutrient (it can be synthesized from pyruvate and lactate), it is 
an important source of energy and thus able to spare proteins from being used as a 
source of energy. Intravenously infused glucose can be readily used and excess can be 
stored as fat. Administration of intravenous glucose can cause hyperglycaemia, 
especially in neonates where insulin production can be insufficient. One way of 
avoiding hyperglycaemia is to reduce the infusion rate of glucose. However, this will 
inevitably lead to an insufficient amount of calories provided. It has been suggested that 
therapeutic concomitant infusion of insulin in neonates receiving parenteral nutrition 
(PN) can enable continuous provision of glucose and thereby improve nutritional 
outcome.32 Glucose contributes substantially to the overall osmolarity of PN solutions. 
To avoid irritation of peripheral veins, solutions with an osmolarity greater than 900 
mOsm/L should be administered via a central vein.
1.5.3. Lipids
Lipids form an important part of nutrition because they provide high-density calories 
and essential fatty acids. Essential fatty acids, which include linoleic acid (C 18:2 ct>-6) 
and a-linolenic acid (C 18:3 co-3), play a vital role in the synthesis of prostaglandins, 
leucotrienes, and thromboxanes.27 In an oral diet, lipids are absorbed into epithelial cells 
in the lower gastrointestinal tract, complexed with protein and phospholipids to form 
chylomicrons, and released into the lymphatic system. They are then discharged into the
A 1
venous blood at the thoracic duct. Several lipid emulsions are commercially available, 
including soybean oil, olive oil, structured lipids, and mixtures of medium-chain- 
triglycerides (MCT) and long-chain-triglycerides (LCT).7’33’34 New lipid emulsions for 
intravenous use are being researched and developed with the aim to provide emulsions, 
which not only provide high caloric nutrition and fatty acids, but also have the potential
O f
to modulate immune function. An intravenous application of fish oil, which is 
particularly rich in co-3 fatty acids, has also been studied.34
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Rubin and colleagues investigated the importance of the ratio of medium-chain- 
triglycerides (MCT) and long-chain-triglycerides (LCT) in parenteral lipid 
formulations. LCT fatty acids have a chain length of 16-20 carbon atoms; while MCT 
have 8-12 carbon atoms. They each have different physiological properties with regard 
to their solubility in plasma and affinity to albumin, and a mixture of both is considered 
preferable. Rubin and colleagues concluded that MCT fatty acids were safe for use in 
PN, and that MCT was preferable in hyperbilirubinemia.
Structured lipids are triglycerides that have medium-chain and long-chain fatty acids on 
one backbone of glycerol, and it has been hypothesised that such emulsions might offer 
protection from liver dysfunction associated with PN (see also 1.7.2).
1.5.4. Vitamins and trace elements
Vitamins are essential for normal growth and development. They are grouped into 
water-soluble and lipid-soluble vitamins. Lipid-soluble vitamins are E (tocopherol), A 
(retinol), D (ergocalciferol/ cholecalciferol), and K (phylloquinone/ menaquinone). 
Tocopherols naturally occur in the form of various isomers: alpha, beta, gamma, and 
delta tocopherol. Alpha tocopherol is the biologically most active isomer.
Lipid soluble vitamins are important for the following physiological processes: 
inhibition of lipid peroxidation (E), division of cells (A), homeostasis of calcium and 
phosphorous (D), and synthesis of coagulation factors (K).3 
Water-soluble vitamins are the B-group (Bi, 2,6,12, pantothenic acid, nicotinamide), 
vitamin C, folic acid, and biotin. These vitamins form part of enzymes in many 
physiologically important pathways. Vitamin C is required for synthesis of collagen, 
absorption of iron, hydroxylation of cholesterol for its excretion in bile acids, and 
reductive protection of folic acid and vitamin E.3
Recent American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines state 
that vitamins and trace elements should be added to all PN solutions.1
1.5.5. Fluids and electrolytes
Fluid and electrolyte management during PN requires continuous evaluation.3 In 
particular, premature neonates require close monitoring. These patients have 




Parenteral fluids are slowly introduced in neonates, starting at a rate of 60-100 mL per 
day depending on gestational age. Sodium and potassium are administered according to
'XHblood levels, which should be monitored regularly. Normal blood levels for sodium 
are 133-146 mmol/L and for potassium 3.2-6.0 mmol/L.38 Chloride intake should not 
exceed sodium intake in order to prevent metabolic acidosis, and it has been suggested
IQ
to replace chloride with acetate as an anionic counter ion if necessary.
Children typically require less fluid per kg body weight than neonates. Normal sodium 
levels range from 133 to 146 mmol/L, and normal potassium levels range from 3.5 to 
5.5 mmol/L.38
1.5.6. Minerals
Calcium is one of the body’s most abundant ions and is important for neuromuscular 
and enzymatic functions. The vast majority of calcium in the body is stored in bones 
and teeth, and its metabolism is carefully regulated by parathyroid hormone, calcitonin, 
and vitamin D.40
Magnesium is crucial for many cell functions, such as myocardial function, central 
nervous system activity, and the activation of enzymes involved in protein and 
carbohydrate metabolism.3
Phosphorous is a structural component of bones and teeth. It also facilitates nerve and 
muscle function and acts as an acid-base buffer in the urine. It is added to PN solutions 
in the form of phosphate.
Due to the physiological importance of minerals, it is essential to include them in PN, 
especially for paediatric patients.41 However, their effect on PN stability has been of 
great concern, especially the precipitation of calcium phosphate in paediatric PN.18,42*45 
In more recent years, organic phosphates, which can be incorporated in PN in greater 
concentrations than inorganic phosphates without causing precipitation have been used 
(see also section 1.8.3).46
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1.6. Oral and enteral nutrition
Enteral nutrition (EN) is often given concomitant to PN. It has been recommended that 
EN should be commenced in infants receiving PN as soon as possible, in order to 
promote normal gut motility and reduce the risk of NEC.1 EN can be administered via 
an oro- or naso-enteric tube. These tubes are either placed in the stomach or in the small 
bowel. For patients on long-term EN, tubes are placed via gastrostomy. Prescribers of 
EN can choose from a wide range of enteral products that are designed for premature 
neonates, neonates, infants, patients with fluid restriction and patients with other 
conditions (details of enteral formulae for neonates are shown in Table 4.2). The use of 
breast milk, even if administered by tube feeding, has been shown to be advantageous 
for future developments of infants.47 In preterm infants, breast milk requires 
fortification in order to provide sufficient amounts of energy.
1.7. Infectious, metabolic, and mechanical complications
PN is an important, often life-saving, form of nutrition support, but administration of 
PN is also highly invasive and therefore not without risks.48 Complications can be 
related to catheter-induced infections, metabolic disturbances due to the composition of
^ 4 0
the nutrition solution, or mechanical processes of intravenous administration of PN.
1.7.1. Infectious complications
Microbiological infections related to the use of intravenous catheters can either be local 
or systemic 49 Catheter related infections remain an important cause of hospital-acquired 
infection and result in significant morbidity and mortality. Colomb and colleagues 
studied the incidence of central venous catheter-related infections in children receiving 
PN at home.50 They found that, on average, infections occurred on 2.1 of 1000 days of 
PN treatment. The incidence was much higher in hospitalised patients (6%). 
Microorganisms causing catheter related infections originate most commonly from
AQ
patients’ skin, e.g. staphylococcus species. Treatment of these infections depends on
whether it is local or systemic. Local infections require catheter removal and antiseptic
or antibiotic treatment. Systemic infections are sometimes treated with antibiotic
without removing the catheter, but catheter removal is usually necessary to clear the
infection 49 ASPEN has published the following guidelines with regard to the
prevention of catheter related infections: chlorhexidine should be used to disinfect the
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skin before catheter insertion, aseptic techniques should be applied at all times during 
catheter insertion and care, catheter hub should be disinfected before access, 
antimicrobial-impregnated catheters should be used in high-risk care settings, and 
specialised nursing teams should care for venous access devices in patients receiving 
PN.1
1.7.2. Metabolic complications
As nutrients are provided intravenously in PN, the function of the gut in regulating 
nutrient uptake and excretion is circumvented. This can lead to metabolic disturbances, 
especially with regard to vitamin and trace element deficiencies, electrolyte 
abnormalities, acid-base imbalances, and complications related to carbohydrate
4 o
metabolism. These complications are caused by either excess or inadequate supply of 
nutrients, and careful consideration of patient requirements and monitoring of 
biochemical markers can usually prevent these complications.
The most important complication related to PN in paediatrics is hepatobiliary 
dysfunction, which most commonly manifests itself as cholestasis.51 This complication 
is particularly common in long-term PN, and it occurs in 40-60% of children in this 
group.51 The aetiology of PN induced cholestasis is mutifactorial and has been linked to 
recurrent episodes of sepsis, lack of enteral stimulation, and excess lipid intake.51,52
1.7.3. Mechanical complications
Intravenous feeding is highly invasive and can cause mechanical injury. Mechanical 
complications can occur during the placement of catheters, such as venous perforation, 
myocardial perforation, and pneumothorax.48
It has been recommended that the correct placement of central catheters should be 
verified by X-ray.1
The Department of Health in the UK recently conducted a review into the death of four 
infants. These deaths were related to cardiac tamponade during the placement of central
r  'y
venous catheters into the right atrium. Recommendations in this report state that
central venous catheter should not be advanced into the right atrium in neonates.
This recommendation has been, however, controversially discussed, and some still
recommend to advance catheters into the right atrium.[Sobotka, 2000 #379]
It has to be pointed out that myocardial perforation is extremely rare, compared to other
events, such as line blockage, catheter-related sepsis, and lack of venous access.
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1.8. Pharmaceutical quality of parenteral nutrition solutions
PN admixtures are complex chemical and physical entities. The manufacture, storage, 
and administration of these admixtures require careful consideration of pharmaceutical 
product quality.54 Product quality with regard to PN can be classified as microbiological 
quality, physical and chemical stability.
1.8.1. Microbiological quality
Medicinal products for intravenous use must be sterile in order to prevent the risk of 
systemic infections. Microbial contamination can occur during the manufacture or 
administration of PN. Therefore, from a pharmaceutical point of view it is important 
that PN solutions are compounded under strict aseptic conditions. Ideally, PN would be 
terminally sterilised.55
Macronutrients can be administered intravenously in the form of binary admixtures 
containing glucose and amino acids. Lipid emulsions can either be provided separately 
from this binary admixture, or in the form of total nutrient admixtures (TNA). TNA are 
tertiary admixtures containing glucose, amino acids, and lipids in one single container. 
The incidence of microbial contaminations in PN solutions has been found to be very 
low, both in TNA and separate lipid emulsions.56,57 However, if contamination does 
occur, the consequences can be fatal. This was the case when PN solutions were 
contaminated with Enterobacter cloacae. These solutions were administered to neonates
fO
and resulted in two deaths. It was subsequently established that the drainage system in 
the PN preparation area had been the source of microbial growth.
Typical contaminants in PN solutions include Staphylococcus aureus, Staphylococcus 
epidermidis, Escherichia coli, Enterobacter cloacae, and Candida albicans.56
1.8.2. Chemical stability
Many of the components in PN can undergo degradation or interact with other 
components during storage. Investigations have particularly focused on the stability of 
vitamins,59'64 amino acids, and glucose. The formation of peroxides has also been 
studied,65'68 and will be discussed in detail later in this thesis (Chapter 5).
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Vitamin C, ascorbic acid, is one of the least stable components of PN. It rapidly 
undergoes reduction to dehydroascorbic acid in the presence of oxygen (see also Figure 
5.1).69 Dehydroascrobic acid is biologically active, but further degradation can lead to 
the formation of oxalic acid.70 Oxalic acid can precipitate with calcium and its 
generation should be minimised. This can be achieved by using containers that prevent 
the diffusion of oxygen into the solution.71
10 10Other unstable vitamins include thiamine and the photosensitive vitamin A.
Manning and Washington reviewed amino acid stability in detail.61 One of the least 
stable amino acids is glutamine. Glutamine can, however, be included in PN solutions in
Oftthe form of dipeptides.
Glucose can undergo degradation during heat sterilisation and during storage. During 
exposure to heat, glucose molecules can react to 5- hydroxymethyl-2-furanaldehyde, 
which can further degrade to levulinic acid and formic acid.54 Glucose can also undergo 
complex reactions with amino acids to form N-substituted glucosylamine (Maillard 
reaction).61
Manufacturers of PN components offer stability and compatibility advice for hospital 
staff involved in the compounding and application of PN. This advice is either derived 
from extensive stability databases, or rigorous testing of individual formulae.74
1.8.3. Physical stability
Precipitation
The most likely source for precipitation in PN solutions is calcium and phosphate 
(Figure 1.2).71
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Figure 1.2: Precipitation of calcium and phosphate
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Factors influencing the compatibility of calcium and phosphate include pH of final 
mixture, choice of salts, final concentrations, temperature, order of mixing, and source 
and concentration of amino acids. ’ This problem has now been largely addressed 
with the introduction of organic phosphates (e.g. glucose-1-phosphate and 
glycerophosphate). Organic phosphates can be included in PN solutions in greater 
concentrations than inorganic phosphate without the risk of precipitation with calcium.46 
Trace elements can also form insoluble entities in PN admixtures, for example iron 
phosphate, ferrous citrate, and sodium selenite.61
Emulsion stability
Lipids and fatty acid form an important part of PN and are administered to patients 
intravenously in the form of lipid emulsions. Naturally occurring chylomicrons have a 
diameter of 0.5-1.0 pm. Particles larger than 6 pm are thought to cause obstruction in 
pulmonary capillaries, although it has been suggested that particles larger than 7.5 pm
7 f \in diameter can pass through capillaries due to deformation.
77Lipids in commercial products for PN are emulsified by egg phosphatides. The lipid 
droplet dispersion is maintained by an electrostatic barrier. This barrier derives from a 
negative surface charge of the emulsifiers phosphate groups. If these stable emulsions 
are added to the binary PN solutions to form TNA, the physicochemical properties of
78the emulsion change, and instabilities can occur. The negative surface charge of the 
lipid droplets can be disturbed by increased concentrations of higher valence cations, 
such as calcium and magnesium.
Figure 1.3 shows how lipid droplets in a previously stable emulsion (I) can flocculate 
and rise to the surface (II). If the electrostatic barrier to coalescence is reduced, lipid 
droplets merge to form larger particle, and eventually the emulsion can crack and show 
a separate free lipid layer (III).
It has been suggested that the critical diameter for droplets in lipid emulsions for PN is 6 
pm, and that no more than 0.4% of droplets should be larger than 5pm for the emulsion
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Figure 1.3: Droplet aggregation in lipid emulsions (I = stable; II = creamed; III = cracked emulsion)
1.9. Containers and filters for parenteral nutrition administration
1.9.1. Containers
7Q
Traditionally, PN was administered to patients from multiple containers. Amino acids 
and glucose were available in glass bottles to which other components were added. With 
the development of ethyl-vinyl-acetate (EVA) containers, it was possible to provide 
binary admixtures of glucose and amino acids.80 Currently, various containers are used 
for PN administration, including EVA and multilayered (oxygen barrier) bags. The 
layers of oxygen barrier bags typically consist of EVA and ethyl-vinyl-alcohol. Oxygen
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barrier bags have been shown to reduce oxidation of vitamins during storage.
PN is commercially available in the form of one, two or three compartment bags. One- 
compartment bags contain either TNA or binary solutions. Compartmentalised bags 
have the advantage that glucose and amino acids can be terminally sterilised in one 
container, without the risk of glucose and amino acids undergoing Maillard reaction (as 
mentioned in section 1.8.2). The seal that separates the components is only broken 
prior to administration so that an extended shelf life at room temperature can be 
assigned to these bags. Vitamins and trace elements, however, have to be added 
aseptically prior to administration.
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1.9.2. Filters
In-line filters are used during PN administration to reduce the amount of particles 
infused. They also reduce the risk of infusing potential microbial contaminants. Due to 
the large volumes of fluid given when using PN, it is particularly important to minimise 
the number of particles present in the solution. Filters are also used in the 
compounding process in order to remove possible particles from rubber bungs or glass 
vials. The use of administration filters in paediatrics has recently been recommended.84 
Administration filters typically have a pore size of 1.2 pm for lipid emulsions and 0.2 
pm for clear solutions. Some have negatively charged surfaces in order to retain 
endotoxins and can be left in-situ for several days. Special paediatric PN filters are also 
available.
l.lO.Commercial products for parenteral nutrition
Commercial products for PN range from component mixutres, such as amino acid 
solutions, vitamin lyophilisates, and lipid emulsions, to ready-to-use TNA containing 
glucose, amino acids, lipids, and electrolytes. The list of commercial products presented 
in this section is by no means complete, but shows details of commonly used products 
in the UK, especially with regard to paediatric PN.
Information was derived from manufacturers information.
1.10.1. Individual components
Glucose solutions are available in various concentrations ranging from 5-50 g/100 mL 
and solution volumes ranging from 50 mL to 1000 mL.
The composition of frequently used amino acid solutions is shown in Table 1.4.
Primene and Vaminolact are paediatric formulations; Vamin-9-Glucose is for adult use 
and also contains glucose.
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L-Alanine 8.0 6.3 3.0
L-Arginine 8.4 4.1 3.3
L-Aspartic acid 6.0 4.1 4.1
L-Cysteine 2.5 1.0 1.4
L-Glutamic acid 10.0 7.1 9.0
Glycine 4.0 2.1 2.1
L-Histidine 3.8 2.1 2.4
L-Isoleucine 6.7 3.1 3.9
L-Leucine 10.0 7.0 5.3
L-Lysine 11.0 5.6 3.9
L-Methionine 2.4 1.3 1.9
L-Phenylalanine 4.2 2.7 5.5
L-Proline 3.0 5.6 8.1
L-Serine 4.0 3.8 7.5
Taurine 0.6 0.3 -
L-Threonine 3.7 3.6 3.0
L-Tryptophan 2.0 1.4 1.0
L-Tyrosine 0.5 0.5 0.5
L-Valine 7.6 3.6 4.3
L-Omithine 2.5 - -
Glucose - - 100
Table 1.5: Composition of examples of commercially available amino acid solutions for parenteral 
use
Lipid emulsions typically contain oil, egg phospholipids, glycerol and water. 
Commercial emulsions differ in their source of oil. Some are derived from plants, such 
as soybean oil or olive oil. Others are derived from animals, such as fish oil. Still others 
originate from synthetic oil, such as structured lipids.
An example for a soybean and olive oil based emulsion is ClinOleic from Baxter
Healthcare. ClinOleic is available as 20% oil in water emulsion, containing purified
olive oil and purified soybean oil (80:20). Other ingredients include: glycerol 2.25 g/100
mL, egg phosphatides 1.2 g/100 mL, and sodium oleate 0.03 g/100 mL.
Lipid emulsions, which contain medium-chain triglycerides (MCT) and long-chain
triglycerides (LCT), have been of particular clinical interest.33,52,85 It was found that
MCT/LCT mixtures were more easily oxidised, and were thus more suitable than LCT
alone particular in infants with hyperbilirubinemia. The source for MCT is usually
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capric acid (40%) and caprylic acid (60%).86 LCT is typically used in the form of 
soybean or safflower oil.
The compositions of some vitamin preparations are summarised in Table 1.6. Cemevit 
should be diluted with 5 mL of water for injection, 0.9% sodium chloride, or 5% 
glucose. Adults and children over 11 years of age should receive the entire content of 
one vial. Solivito N should be diluted in 10 mL of Vitlipid N Infant, water for injection, 
or 5% glucose. Infants and children under 10 years of age should receive 1 mL per kg. 
Children over the age of 10 years and adults should receive the entire content of one 
vial. Vitlipid N Infant should be administered at a rate of 1 mL per kg body weight, not 







Vitlipid N Infant 
(Fresenius Kabi) 
In 10 mL
Eh (Thiamine) 3.5 mg 3.2 mg -
B2 (Riboflavin) 4.1 mg 3.6 mg -
Nicotinamide 46.0 mg 40.0 mg -
B6 (Pyridoxine) 4.5 mg 4.0 mg -
Pantothenic acid 17.3 mg 15.0 mg -
Biotin 69 pg 60 pg -
Folic acid 0.4 mg 0.4 mg -
B 12 (Cyanocobalamin) 6 M-g 5Hg -
C (Ascorbic acid) 125 mg 100 mg -
A (Retinol) 3500 IU - 69 mg
D (Ergocalciferol) - - 1.0 mg
D (Cholecalciferol) 220 IU -
E (a-tocopherol) 10.2 mg - 0.64 mg
K (Phytomenadione) - - 0.02 mg
Table 1.6: Composition of commercial vitamin preparations for parenteral use (IU=International 
Unit)
Trace elements for paediatric use are available from Fresenius Kabi (Table 1.7). For 
neonates and paediatric patients, 1 mL of Peditrace should be given. The maximum 
daily dose is 15 mL.
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Table 1.7: Composition of Peditrace
1.10.2. Commercially available admixtures
In more recent years, licensed products have been developed that contain several 
nutrients in one container. Some contain glucose, amino acids, and lipids in one 
compartment, such as KabiMix from Fresenius Kabi. Advances in container technology 
mean that PN products are now available which have separate compartments for 
glucose, amino acids, and lipids. These two- or three- compartment bags do not require 
refrigeration and can be stored for up to 12 months. The components in each 
compartment are mixed only prior to administration. An example of a two-compartment 
product is Clinimix (Baxter Healthcare). Examples of three-compartment bags are 
Clinomel (Baxter Healthcare), and Kabiven (Fresenius Kabi).
Complete admixtures are now available in various volumes, glucose and amino acids 
strength, and electrolyte combinations. Unfortunately, micronutrients are not included 
due to stability limitations. This means that micronutrients have to be added in an 
aseptic environment to provide complete PN.
These commercial admixtures are currently not licensed for neonates and young 
children.
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1.11. Parenteral nutrition, clinical governance and medicines 
management
Clinical governance has been defined as ‘a framework through which National Health 
Service (NHS) organisations in the UK are accountable for continuously improving the 
quality of their services and safeguarding high standards of care by creating an
on
environment in which excellence in clinical care will flourish’.
One aspect of clinical governance is medicines management. This has been defined as 
‘the entire way that medicines are selected, procured, delivered, prescribed 
administered, and reviewed to optimise the contribution that medicines make to 
producing informed and desired outcomes of patient care’.53
PN is part of intravenous medical care within hospitals, and it is therefore important to 
consider the general principles of medicines management applicable to PN.
The ‘desired outcome of patient care’ with regard to PN, as defined by medicines 
management, relates to the provision of optimal nutrition support and minimisation of 
complications, such as metabolic disturbances or sepsis. From a pharmaceutical point of 
view, it also includes the provision of sterile, stable, and accurately prepared PN 
solutions. It is also crucial that this high standard of care can be established and 
maintained in a cost effective way.53
Although these definitions and guidelines have been developed by the Department of 
Health and the Audit Commission in the UK for the management of care in the NHS, 
general recommendations with regard to medicines management can be extrapolated to 
an international environment.
The following sections highlight how medicines management is applied to PN, 
especially with regard to manufacturing and aseptic compounding, standardisation of 
PN in paediatrics, and multidisciplinary approach to PN.
1.11.1. Manufacturing and quality assurance of parenteral nutrition
Medicines legislation requires licensing of individual medicines (Marketing 
Authorisation) and also licensing of the manufacturer (Manufacturer License).
Whenever possible, licensed medicines should be prescribed over unlicensed products 
(“specials”).88 It has been recognised that in some cases licensed products cannot meet 
clinical needs. This is often the case in PN, especially in neonatal and paediatric 
patients. The production of unlicensed medicines is therefore permitted, provided that
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the same quality standards in the manufacturing and quality assurance are met as with 
licensed medicines. Compounding of PN in hospitals pharmacies follows strict
OQ
guidelines, and several computer programs and automated systems have been 
developed and validated to assist with this complex procedure.90'93 
Unfortunately, due to the complexity of the process of compounding PN solutions, the 
occurrence of errors is inevitable. Several reports have investigated errors related to 
intravenous therapy compounding, administration, and compliance with guidelines.94'96 
Implementation of rigorous quality assurance management has been introduced to 
reduce the frequency of errors.88,89
1.11.2. Multidisciplinary approach to parenteral nutrition
In order to provide PN in a safe, nutritionally adequate, and cost effective way, several 
activities, which involve pharmacists, physicians, dieticians and nurses, have to take 
place in a coordinated manner. Typically, pharmacists ensure that appropriate products 
are purchased, that aseptic compounding takes place to the highest standard, and that 
prescriptions are appropriate, in terms of nutritional adequacy and pharmaceutical 
stability.
The decisions to start PN and the prescribing of its components are usually undertaken 
by physicians, although in some hospitals, nutrition support teams have taken over this 
role.97'99 Nutrition support teams are interdisciplinary groups of health-care 
professionals (e.g. nurses, physicians, pharmacists, dieticians, biochemists, or others) 
who meet regularly to decide together which form and amount of nutrition should be 
provided to patients. Gales and colleagues reviewed comparative trials of nutrition 
support teams.100 They found that although these teams were often able to show 
improved nutrition care in the beginning of their practice, their continuing benefits were 
less clear. A recently published report by the British Artificial Nutrition Group shows 
that 38% of 211 hospitals surveyed have nutrition support teams (for enteral and/or 
parenteral nutrition).101 However, it is unclear from this report, if neonatal and 
paediatric PN was included in the teams’ responsibilities.
In some hospitals in the UK, pharmacists have taken over the daily prescribing of 
neonatal and paediatric PN.88 Interestingly, no information about this practice has been 
published and it is unclear if training and competency were properly considered.
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1.11.3. Standardised parenteral nutrition
The term ‘standardisation’ has not yet been defined by any of the European or American 
nutrition societies, yet it has been used inconsistently in publications on both sides of 
the Atlantic.
For the purpose of this work, standard PN solutions (StSol) have been defined as (right- 
hand flow in Figure 1.4):
Pre-compounded, batch-manufactured PN solutions 
administered to patients according to 
individual fluid requirements
PN Prescribing
Individual Prescribing Standard Prescribing
Standard Batch ProductionIndividual Compounding
Figure 1.4: Flow chart o f standardised prescribing and batch production of PN
The opposite of StSol are customised solutions that are prescribed and compounded 
according to the individual patient’s nutritional and fluid needs (left-hand flow).
Several hospitals throughout Europe have published their experiences with StSol in 
national and international journals.102'105 Details about hospitals’ accounts of the use of 
StSol will be further explored in section 3.1.1.
Currently published data regarding standardisation of PN exclusively describe accounts 
of hospitals’ experiences. Little information is available regarding nutritional adequacy 
of standardisation and customisation, economic benefits of one approach versus another, 
or pharmaceutical safety of PN. More details regarding the use of StSol will be 
discussed in Chapter 4.
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1.11.4. International organisations
Several societies have been formed with the aim to promote specialist nutrition support. 
These societies specifically focus on the development of guidelines and standards of 
practice, the promotion of research related to nutrition support, and the provision of a 
forum of interactions for all professions involved. In the UK, the principle society for 
enteral and parenteral nutrition is BAPEN (British Associations of Parenteral and 
Enteral Nutrition). BAPEN was formed by groups representing pharmacists (British 
Pharmaceutical Nutrition Group), physicians (Clinical Nutrition and Metabolism 
Group), nurses (National Nurses Nutrition Group), dieticians (Parenteral and Enteral 
Group of the British Dietetic Association), and patients (Patients on Intravenous and 
Nasogastric Nutrition Therapy).
On a European level, the principle society is ESPEN (European Society of Parenteral 
and Enteral Nutrition). In the USA, ASPEN (American Society of Parenteral and 
Enteral Nutrition) promotes safe and effective nutrition support.
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2. Introduction, aims and objectives
2.1. Introduction
Review of the literature has highlighted several aspects of PN that require careful 
consideration in order to achieve optimal nutrition support:
a) Nutritional assessment / Indications for PN
b) Nutritional requirements and novel components for PN
c) Pharmaceutical quality control / Standardised PN
d) Multidisciplinary approach
e) Cost effectiveness of nutrition support
Appropriate quantities and qualities of nutrition intake have been studied extensively, 
and new components of parenteral feeding are currently being investigated, such as 
optimising amino acid intake and modulating immune function by introducing new lipid 
emulsions. Studies have been undertaken to identify whether different patients have 
different metabolic requirements. Most recently, aggressive nutrition support has also 
been explored in neonates to potentially improve nutritional intake. The term 
‘aggressive nutrition’ has been defined as “practice that ranks towards the upper end of 
the range of established practices, or as practice that goes beyond the established and 
into untested territory”.31 Aggressive nutrition practice will be discussed in more details 
in section 4.1.
International organisations have published detailed guidelines regarding nutrition 
assessment, nutritional requirements in different patients groups, access for the 
administration of nutrition support, and individuals’ responsibilities in multidisciplinary 
teams.1,20,106
Extensive stability studies have been undertaken, especially with regard to lipid 
emulsions stability, vitamin stability, and precipitation in PN solutions.81,107' 111 
Economic investigations have received little attention, and most reports refer to 
experiences in one hospital. As a result, these investigations are difficult to extrapolate 
and generalise.
24
Little information was found in the literature describing how hospitals in the UK, 
continental Europe, and USA manage PN support in neonates and children. Knowledge 
of current practice is vital in order to identify areas for improvement of practice and in 
order to understand how guidelines and recommendations translate into the care of each 
patient.
This research project investigated current paediatric PN practice in detail, and focused 
on the use of StSol in order to identify areas for future improvements. As this project 
was based at a University, the unique opportunity arose to undertake nutrition practice 
research that was not based in one hospital. This allowed for an objective evaluation of 
practice which was not influenced by an investigator’s own practice.
In order to gain a broad understanding of clinical and pharmaceutical research 
methodologies, this project incorporated qualitative research, clinical research, and 
pharmaceutical method validation and applications.
This project was undertaken on a Pan-European level. For budgetary reasons, the USA 
and other parts of the world were excluded from the investigations.
Sufficient analysis of the cost effectiveness of PN was found to be lacking in the 
literature. However, it was beyond the scope of this project to pursue this topic.
2.2. Aims and objectives
The overarching aim of this project was to gain a higher level of understanding of 
current paediatric and neonatal PN practice in order to inform discussions regarding 
safety, efficacy and cost effectiveness of this form of nutrition therapy.
The first objective was to establish how neonatal and paediatric PN is managed within 
hospitals. In order to compare UK practice with other countries, a European wide 
survey was performed. Information was gathered with regard to prescribing, 
compounding, and administration practices. The use of StSol was also investigated.
The second objective was to gain a more detailed understanding of nutrition prescribing 
practice. A study was undertaken comparing PN prescribing practice and nutritional 
intake in several European countries.
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Aims of this part o f the project were to compare prescribed and administered PN, to 
characterise diversity of current prescribing practice, and to compare current PN support 
with recommendations of nutritional intake.
It was realised that detailed monitoring of all paediatric age groups would not be 
feasible. It was therefore decided to perform this study in neonates only.
The third objective was to investigate one element of risk management in PN therapy in 
more detail. Review of the literature had identified that the administration of lipids was 
discussed controversially, especially with regard to the administration of lipids as TNA 
or separately from amino acids and glucose solutions. Peroxidation of lipids had 
previously been investigated, but not with regard to TNA or separate lipid 
administration. It was therefore decided to quantify lipid peroxidation in different 
clinically relevant PN solutions and to focus on the way lipids are administered. For this 
purpose, a novel photometric assay was developed and validated for this application.
A secondary objective throughout the project was to investigate the use of StSol. Many 
reports had been identified which discuss successful introduction of StSol, in particular 
for neonatal patients. Each part of the project was designed to gain a better 
understanding of the use of StSol and to assess the feasibility of introducing StSol. This 
was achieved by enquiring about the use of StSol and potentially useful compositions of 
StSol for different age groups; monitoring neonates to facilitate analysis of the diversity 
of prescribing practice; quantifying lipid peroxides in TNA and lipid emulsions in order 
to potentially inform decision making with regard to the use of StSol as TNA or 
separate lipid infusions.
The author of this thesis performed all data collection and analysis. The only exception 
was that local staff collected data for the neonatal study in international hospitals.
The author of this thesis also executed all laboratory work.
Statistical support was provided by a statistician from the University of Bath and by a 
statistician from the sponsor.
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3. Pan-European survey of paediatric parenteral nutrition 
practice
3.1. Introduction
3.1.1. Neonatal and paediatric parenteral nutrition practice
The literature was reviewed to assess current practice across Europe in the provision of 
PN to neonatal and paediatric patients, especially with regard to prescribing, 
compounding and administration practice. In addition to the literature review, meetings 
with a European discussion group were attended to explore key issues in paediatric PN 
in more detail and to discuss potential future developments.
This discussion group was organised by the sponsor with the aim to explore ways in 
which neonatal and paediatric standardised parenteral nutrition could be introduced in 
Europe, and what the advantages and disadvantages of such practice would be. The 
members had previously worked with the sponsor on other nutrition related research 
projects. Their involvement with the project was related to the following activities: 
Discussing relevant topics for the European survey, supporting the interpretation of 
findings from the survey, supporting methodological aspects of the neonatal study 
(Chapter 4), and discussing findings from the neonatal study. This discussion group also 
provided suggestions for a standard PN for neonatal patient, as discussed in Chapter 4. 
The group consisted of paediatricians, neonatologists, and pharmacists from the UK, 
Germany, Italy, France, Sweden, Belgium, and Finland. Meetings took place on the 3rd 
July 2000, 10th September 2001, and 6th September 2002.
Three principle stages were identified from the literature with regard to the provision of 
PN: prescribing, compounding, and administration.
1. Multidisciplinary input into prescribing was explored in the first chapter of this 
thesis. No publications could be identified in the literature about general prescribing 
practice in Europe or the involvement of different healthcare professionals.
2. The type of compounding facility employed to provide PN depends on the 
availability of pharmacy or commercial aseptic services, economical considerations, and 
availability of trained staff to perform aseptic handling.88 No matter where PN is 
compounded or by whom, the most important factors to consider are quality of the final 
product administered to the patient. The state of current compounding practice
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throughout Europe is not known in terms of options for individual compounding or 
batch preparations of StSol.
3. Various issues arise when considering the administration of PN. The type and 
location of intravenous catheters is of great importance, and several guidelines and 
publication discuss this issue.1,112,113 PN can be given via peripheral or central venous 
catheters, depending on the length of intravenous feeding and the osmolarity of the PN 
solution. Long-term PN feeding (e.g. more than 10 days) or high osmolarity (i.e > 900 
mOsm/L) requires the use of a central catheter.114' 116 The location of the tip of central 
catheters remains controversial (see also section 1.7.3).
Lipids can be administered together with the other nutrients as TNA or administered 
separately. The main reasons why lipids are typically administered separately are related 
to the pharmaceutical instability of lipid emulsions and concerns that TNA would
117 11 Rprovide an excellent growth medium for microbial contaminants. ’ It has since been 
shown that separate lipid emulsions are a better growth medium than TNA.119 
It is also important to conserve the quality of the PN solution during administration and 
to ensure that sterile and particle free solutions are administered. Several reports have 
explored the use of in-line administration filters, and the current recommendation is to
a  a
always filter both binary solutions and lipid emulsions. As mentioned previously, the 
protection of bags and administration tubing from light has been suggested in order to 
protect vitamins and lipids from light induced instabilities and degradation.120,121 Light 
protection of bags is relatively easy, and companies supplying PN components often 
also supply light protective over-wrap bags. However, it is more difficult to protect 
tubing from light, because nursing staff require easy access to the lines to ensure that 
they are free of air and free of particles. Current practice in Europe regarding the use of 
filters and light protection was not known.
Several hospitals in Europe have published their experiences in using StSol. One
199hospital in London introduced their first standard neonatal bags in 1992.
1 A *3
Another report of StSol usage in Belgium goes back to 1993. StSol were introduced 
for neonates in intensive care because it was felt that nutritional requirements are 
relatively stable. The major concern was fluid balance; therefore, it was decided to
design four solutions that contain the same amounts of nutrients in four different fluid
1 0^volumes, allowing the provision of 90 mL/kg/day up to 170 mL/kg/day.
Unfortunately, it was not reported how often each of the solutions was used. A similar 
approach was adopted in a Spanish hospital where one StSol was used to meet daily
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requirements in 100 mL/kg/day. Additionally, this could be diluted to 150 or 190 mL.102 
Interestingly, the 150 mL/kg/day solution was used in 99% of cases. A different system 
of StSol for neonates was developed in Germany.105 Two StSol for the first day of PN 
(5% and 10% glucose) and a ‘basic’ solution providing all required nutrients in 150 
mL/kg/day were available.
In all three cases described, the StSol were used for the majority of neonates. They also 
reported that compounding errors were reduced and that the standardised approach was 
more cost-effective. The German hospital had used their system for eight years, and 
they found that growth and nutritional intake in neonates on standard PN were 
satisfactory'. Despite these positive reports, it has to be pointed out that only hospitals’ 
individual observations were shown, and not results from comparative or randomised 
trials. Thorough investigations of error reduction, economical benefits, and nutritional 
adequacy have not been undertaken. One hospital has reported negative outcomes in 
terms of weight gain and energy intake with StSol after conducting a comparative trial, 
and they recommend that pharmacist-controlled individual prescribing is 
advantageous.123 In a more recent report from the USA, Stettler and colleagues showed 
that parenteral nutrition support of paediatric patients improved after a standardised 
system was changed to a customised system.124 However, improvements were only 
noted with regard to the delivery of lipids and micronutrients.
The published literature only gives a small account of the current situation in European 
hospitals. The actual number of hospitals undertaking standardisation of neonatal and 
paediatric PN is unknown.
Review of the literature revealed that little is known about current European practice in 
paediatric PN. It is not known how some of the recommendations made in the literature 
have translated into actual hospital practice. It was therefore decided to undertake a 
European survey.
3.1.2. Aims and objectives
The overall aims of this survey project were to establish:
a) Current practice of neonatal and paediatric PN treatment in Europe with regard to the 
prescribing, compounding, and administration of PN
b) Prevalence of StSol usage
c) Composition of StSol in five age/weight groups as considered appropriate by 
prescribers in the surveyed hospitals
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3.2. Methods
3.2.1. Selection of the survey tool
The development of an appropriate tool was required to conduct a survey in Europe.
Various techniques can be used to capture information: postal questionnaire survey,
1telephone survey, or focus groups.
Postal questionnaires have the advantage that a large number of people can be reached 
and that this technique is relatively cost effective. The disadvantage is that respondents 
cannot be probed and further explanations cannot be provided. Response rates are also 
usually lower compared with, for example, telephone surveys.125 
As the targets were many hospitals all over Europe, which included many different 
languages, both telephone surveys and focus groups were unsuitable. Focus groups 
would have provided detailed insight from a limited number of individuals, but would 
not have been able to capture a large number of hospitals.
It was decided that a postal questionnaire survey would be most suitable for this 
purpose.
Several stages of development for this questionnaire were identified:
- Exploratory interviews, first in the UK and subsequently in other countries
- Design of questionnaires for the purpose of piloting
- Design and validation of final questionnaires for postal survey.
3.2.2. Selection of hospitals in Europe
Once the decision had been made that a postal questionnaire survey was to be 
conducted, a list of potential contacts was required. It was not feasible to contact all 
hospitals in Europe, due to the large numbers. Additionally, sending questionnaires to
1 9Spersonal contacts rather than anonymously, can increase response rates. A database 
was required, which contained names of hospitals and names of healthcare professional, 
who dealt with neonatal or paediatric parenteral nutrition.
Firstly, international and national specialist nutrition organisations were contacted to
find out if such database already exists. Not surprisingly, their responses were negative.
Secondly, the commercial sponsor was contacted. They were able to provide a database,
which contained the names of physicians and pharmacists in 238 hospitals in the UK,
Germany, France, Italy, and Spain. This database was in place for the company’s
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representatives to maintain contact with customers and non-customers in each country. 
Due to the fact that this was not purely a customer database, it was felt that, although 
not an ideal source, this database was suitable to the purpose of this survey.
3.2.3. Questionnaire development -  Explorative interviews
After it had been decided whom the questionnaire should be sent to, development of the 
survey tool commenced.
Firstly, topics of current interest were identified from the literature.
Secondly, these topics were discussed in face-to-face exploratory interviews with 
pharmacists involved in prescribing and compounding PN in the UK. These interviews 
were informal, one-to-one discussions. Pharmacists in the Bath and Bristol area were 
contacted, and three agreed to participate.
3.2.4. Questionnaire development -  International interviews
In order to get a better understanding of current topics in the five countries, which had 
been identified for the survey, further interviews were conducted.
The initial discussions in the UK had assisted with the development of a first 
questionnaire (Appendix 1), which was used to guide interviews on an international 
level. Twenty-two interviews were conducted in Germany, France, Italy, Spain, and the 
UK. Half of interviewees were pharmacists, and half were physicians, and in each case 
interviewees were nationally recognised experts in the field of neonatal and paediatric 
PN. Interviews were recorded on voice recorders after obtaining permission from the 
interviewees.
The objective was to further explore issues identified in the literature, and to discover 
new aspects that had previously not been considered. An important role of the 
interviews was also to identify cultural differences between countries and to determine 
terminology used.
The interviews revealed areas of interest that had previously not been considered. For
example, the use of filters and light protection during the administration of PN was
important to a number of respondents. Other areas were found to be standard practice in
all centres. As an example, the administration of vitamin K to infants was widely
practised and therefore not included in the subsequent survey. PN given to patients in
their home proved to be a complex legal topic in some countries so these questions were
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subsequently removed. Detailed information about the scope of home PN in the UK was 
available elsewhere.101
Because definitions of the role of various professions within the hospital setting differed 
between countries, this was changed from a closed to an open question in the final 
questionnaire. The use of computer programs for prescribing and compounding was 
found to be widespread. Due to the large number of different programs and internally 
developed systems, it was felt that questions about this subject would not lead to 
meaningful results.
Most hospitals had different policies for neonatal and paediatric care. In order to 
appropriately reflect this, questions in the final questionnaire were split into the two 
patient groups.
One of the objectives of the survey was to investigate the frequency of StSol usage, how 
they are used, and what the composition of those StSol is. The exploratory questionnaire 
proved to be too prescriptive to be able to achieve those aims. A more detailed section 
was subsequently developed for the postal survey.
3.2.5. Questionnaire development -  Piloting
By implementing findings from the exploratory interviews, a postal questionnaire was 
developed for piloting. Native speakers resident at the University of Bath translated into 
this questionnaire French, German, Italian, and Spanish. Translations were validated by 
reverse translation process.
In order to validate reliability of some of the crucial questions, the same topic was 
addressed in two different questions. The question about compounding facilities was 
addressed in question four (‘Is there a unit in your hospital that compounds parenteral 
nutrition?’) and in question fourteen and fifteen (‘Is PN ... prepared on the ward? Are 
ingredients ... added on the ward?’). Information about the source of StSol formulae 
was addressed in questions nineteen (‘Where does the formulation ... come from?’) and 
twenty (‘Are commercially available.. .solutions used... ’).
Firstly, the questionnaire was discussed with the European discussion group.
Secondly, this questionnaire and a cover letter were sent to four hospitals, which were 
randomly chosen from the database described above. Participants were not advised that 
this was a pilot questionnaire, and they were not asked for further comments.
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Ten pilot questionnaires were returned (50%). The returned questionnaires were 
completed satisfactorily and no further changes were made to the questionnaire 
(Appendix 2).
3.2.6. Final postal survey
The questionnaire was sent to 218 hospitals in Germany, France, Italy, Spain, and the 
UK (Germany 45, France 43, Italy 55, Spain 31, and the UK 43). Table 3.1 shows the 







Table 3.1: Proportion of healthcare professional contacted in each country
Several strategies have been suggested to increase response rates from postal 
questionnaires, including the length and appearance of questionnaires, nature of return 
envelopes, conduct of follow-up, and other strategies.125 These suggestions were 
implemented as applicable to this survey: participants were guaranteed confidentiality, 
free return envelopes were included with every questionnaire (freepost reply envelopes 
in the UK and stamped envelopes for other countries), and participants were promised 
to be sent a summary of results.
Follow-up was conducted by telephone in Germany, France, and the UK, and by e-mail 
in Spain and Italy.
The following ethical considerations were made: all participants were informed that a 
commercial sponsor funded the survey, and all information was kept confidential and in 
secure facilities.
Results were analysed using SPSS 10.0 for Windows.
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3.3. Results
3.3.1. Response rates and demographics of responding hospitals
98 hospitals (45%) responded to the questionnaire. Individual countries’ responses 
were: Germany 20 (44%), France 20 (45%), Italy 16 (29%), Spain 11 (36%), and UK 31 
















Figure 3.1: Proportion of healthcare professions who responded in each country







Figure 3.2: Proportions of total responses from each of the five countries (N=98)
Responding hospitals differed greatly in number of neonatal and paediatric beds. 
Number of neonatal beds (mean ± SD) was 29 ± 17, and number of paediatric beds 
(mean ± SD) was 98 ± 94. Figure 3.3 shows how many PN infusions were typically 
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Figure 3.3: Average num ber of PN bags per day for neonates and children in all hospitals (N=98)
3.3.2. Parenteral nutrition prescribing
PN was prescribed by physicians in 81% (N=79) and by pharmacists in 6% (N=6) of 
hospitals. In 13% (N=13) of hospitals either physicians or pharmacists prescribed PN. 
Pharmacist prescribing was found only to occur in the UK.
3.3.3. Parenteral nutrition compounding
There were clear differences in the preparation of PN throughout Europe. 
Compounding units for aseptic PN preparation were present in 35% of hospitals in 
Germany and in 40% of hospitals in France. In Italy, these dedicated PN facilities were 
present in 50% of hospitals, compared to 64% of hospitals in Spain. The largest 
percentage of hospitals with compounding units was in the UK with 87%.
Overall, 21 hospitals (22%) compounded PN on the ward regularly, 10 (10%) rarely, 
and 66 never (68%) (No reply from one hospital). Figure 3.4 shows how often 
additions, such as vitamins, trace elements, electrolytes or drugs were made to the PN 
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3.3.4. Parenteral nutrition practice
Lipids were either administered separately from the binary solutions or in form of TNA. 
Table 3.2 summarises how often lipids were administered separately to neonates and 
children in each country. This data was derived from Question 7 in Appendix 2. The 
following classifications were made: separate lipid emulsion 0% = Never; separate lipid 
emulsion 100% = always; separate lipid emulsion 1-99% = Sometimes.
In the UK and Germany, lipids were always given separately from the binary solution to 
neonates. TNA use was more common for neonates in France, Italy, and Spain. For 
children, there was an increased tendency to give lipids in the form of TNA.
Lipids administered separately from the binary solution
Neonates Children
Always Sometimes Never Always Sometimes Never
n(%) n(%) n(%) n (%) n (%) n(%)
UK 28 (100) 0 (0 ) 0 (0 ) 8(33) 11 (46) 5(21)
Germany 19 (100) 0 (0 ) 0 (0 ) 16 (84) 2(11) 1(5)
France 11 (55) 3(19) 2(13) 7(50) 4(29) 3(21)
Italy 3 (38) 1(13) 4(50) 2(33) 2(33) 2(33)
Spain 6(60) 2(20) 2(20) 3(33) 1(11) 5(56)
Table 3.2: Frequency of separate lipid administration in neonates and children in each country
Vitamins and trace elements were not added to the PN solution every day. Participants 
were asked to indicate when, after commencement of PN, vitamins and trace elements 
are usually initiated. They were also asked to state how many days per week 
micronutrients were provided.
The addition of vitamins to PN for neonates and children is shown for water-soluble 
vitamins in Figure 3.5 and for lipid-soluble vitamins in Figure 3.6 (error bars represent 
95% confidence interval of the mean).
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Figure 3.5: Start of water-soluble vitamins for neonates and children in the five countries
In the UK and Spain, water-soluble vitamins were added from the first day of PN. In the 
other countries, practice was more variable. Hospital in Italy indicated that, on average, 
water-soluble vitamins were added after four days of PN.
Lipid-soluble vitamins were on average added to PN later than water-soluble vitamins. 
This was likely to be related to the fact that lipid-soluble vitamins are usually 
administered concurrently to lipid emulsions. Intravenous lipid administration was, 
however, commenced later than the administration of binary solution.




Figure 3.6: Start of lipid-soluble vitamins for neonates and children in the five countries
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Vitamins were usually added every day of the week once commenced (83 hospitals 
(92%)). The remaining hospitals included vitamins between 6 and 3 days per week (7 
hospitals (8%)) with no reply from a further 8 hospitals.
Trace elements were commenced much later than vitamins, as shown in Figure 3.7. 
(error bars represent 95% confidence interval of the mean). One hospital reported to 
include trace elements after four weeks of PN. Once trace elements were started, they 
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Figure 3.7: Start of trace elements for neonates and children in the five countries
The use of in-line filters has been recommended in order to prevent infusion of 
microbial contaminants and to reduce the number of particles infused.84 
Figure 3.8 shows that in-line filters were frequently used in the UK, Germany, and in 
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Figure 3.8: Frequency of use of in-line administration filters in each country
Light protection has also been recommended to protect vitamins from light-induced 
degradation and to reduce peroxidation.64,126 Table 3.3 summarises how often PN 
containers and administration tubing were protected from light.
Light protection during administration
Container Administration tubing
Always Sometimes Never Always Sometimes Never
n (%) n (%) n (%) n (%) n (%) n (%)
UK 20 (65) 9 (29) 2 (7 ) 3(10) 2 (7 ) 25 (83)
Germany 6(30) 8(40) 6 (30) 3 (17) 11 (61) 4(22)
France 6 (30) 3(15) 11 (55) 1(5) 2(11) 16(84)
Italy 10(63) 2(13) 4 (25 ) 5(31) 4 (25 ) 7(44)
Spain 5(50) 1(10) 4 (40 ) 2(22) 3(33) 4(44)
Table 3.3: Frequency of light protection of PN containers and administration tubing during PN 
administration
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3.3.5. Use of standard solutions
Amongst 98 responding hospitals, 79 provided information on the use of StSol. For 
neonates, 19 hospitals (24%) used StSol. Of those hospitals utilising StSol, 57% used 
StSol that had been developed and compounded internally, yet some also used StSol in 
conjunction with other hospitals (21%) or through commercial suppliers (21%). With 
children, 14 hospitals (18%) reported using StSol. On the other hand, only one hospital 
had developed internal standard PN specifically for paediatric patients. All other 
hospitals used products from commercial suppliers.
Open questions were asked to find out more about the reasons why hospitals chose to 
individualise or standardise PN. Some of the answers are listed below.
Reasons fo r  individualisation:
• ‘It is better for the patient to have each bag individualised’
• ‘There is a lack of suitable standard products’
• ‘Our existing system works well, there is no need to change it’
• ‘Our patients are not standard, that is why the nutrition cannot be standard’
Reasons fo r  standardisation:
• ‘To allow continuation of supplies during shutdowns’
• ‘To start new patients on PN over the weekend’
• ‘Better treatment for neonates from day to day’
• ‘Better data on stability and sterility’
• ‘Our physicians agreed that there was no need to individualise regimens’
Participants of the survey were also invited to supply detailed descriptions about StSol 
used in their hospital. In regard to internally prepared StSol, five hospitals returned 
information (two from the UK, two from Germany and one from France), which are 
summarised in Table 3.4.
In 100 mL Hospital A Hospital B Hospital C Hospital D Hospital E
Amino acids (g) 1.7 1.5 1.7 1.3 1.2
Glucose (g) 12.5 10.0 10.0 10.0 11.0
Sodium (mmol) 2.5 3.0 1.5 2.0 1.6
Potassium (mmol) 1.7 2.0 2.0 2.0 1.3
Table 3.4: Neonatal standard solutions used in participating hospitals
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Lipids were given separately, and they are not included as part of the standard solutions. 
One hospital also returned a floppy disc containing an internally developed computer 
program that facilitated their prescribing of neonatal and paediatric PN.
3.3.6. Suggested standard intake
All participants were invited to suggest potentially suitable StSol based either on their 
experience with StSol or based on their prescribing practice. Suggestions did not have to 
be based on current practice, but should have reflected ‘ideal’ practice. Information was 
collected for premature neonates, neonates, children <10 kg, children 10-20 kg, and 
children 21-30 kg body weight. Nutritional information included: volume of PN 
(mlVkg/day), amino acids (g/kg/day), glucose (g/kg/day), lipids (g/kg/day), sodium 
(mmol/kg/day), and potassium (mmol/kg/day).
The following figures (Figure 3.9-Figure 3.14) summarise the overall responses in the 
form of boxplots (the horizontal dotted line represents the median, the boxes represents 
the quartiles, and the whiskers include all values). Outliers are not shown.
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3.10: Suggested amino acids (g/kg/day) for five age/weight groups
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3.12: Suggested lipids (g/kg/day) for five age/weight groups
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Figure 3.14: Suggested potassium (mmol/kg/day) for five age/weight groups
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3.3.7. Grouping responses (Cluster analysis)
Data shown in section 3.3.6 represents responses overall. Due to the diversity of the 
overall data, responses were grouped according to similarity. This was done using 
hierarchal cluster analysis. Hierarchal cluster analysis attempts to identify relatively 
homogeneous groups of cases based on selected characteristics. In this case, the 
following groups were used: amino acids (g), glucose (g), lipids (g), sodium (mmol), 
and potassium (mmol). This way it was possible to identify groups of respondents who 
considered similar StSol suitable for use. Data were standardized by Z score and 
squared Euclidean distance was used.
Using the suggested PN volume per kg per day, macronutrients and electrolytes were 
calculated as components per 100 mL (Table 3.5.).








Amino acid (g) 1.8 1.8 2.1 2.3 2.5
(1.7-2) (1.6-2) (1.8-2.6) (1.9-2.7) (2.2-3.1)
Glucose (g) 9.7 10.0 11.6 12 12.5
(8-10.6) (8.6-11.3) (10.0-14) (10.0-14.3) (10.0-15.0)
Lipids (g) 1.8 2.0 2.1 2.5 2.8
(1.4-2) (1.5-2.3) (2.0-2.9) (2.1-2.9) (2.3-3.3)
Sodium (mmol) 1.5 2.0 2.5 3.0 3.8
(1.2-1.8) (1.9-2.3) (2.1-3) (2.5-3.8) (2.9-4.3)
Potassium (mmol) 1.5 1.7 2.0 2.2 2.6
(1.2-1.8) (1.3-2.0) (1.5-2.5) (1.9-2.9) (2.0-3.3)
Table 3.5: Median (Interquartile range) for all respondents
Hierarchal cluster analysis was then used to identify sub-populations of PN solutions by 
taking all components of the suggested StSol into consideration. Several sub­
populations were also identified. The two largest clusters (Ni; N2) in each age group are 
shown below and include the following number of cases:
Premature neonates: Ni=37 (47%); N2=17 (22%)
Neonates: Ni=29 (36%); N2=18 (22%)
Child <10 kg: Ni=30 (47%); N2=18 (28%)
Child 10-20 kg: Ni=24 (38%); N2=22 (35%)
Child 21-30 kg: Ni=24 (40%); N2=l 1 (18%)
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The median and interquartile range for the five components is summarised for the 
largest cluster in Table 3.6. and then again for the second largest cluster in Table 3.7.








Amino acid (g) 1.8 1.8 1.8 2.5 2.5
(1-7-2) (1.6-2) (1.6-2) (2.1-2.6) (2.3-2.9)
Glucose (g) 10.0 10.0 10.0 12 11.7
(9.3-10) (10.0-10.0) (8.3-10.0) (11.5-12.5) (11.3-12.5)
Lipids (g) 1.7 2.0 2 2.6 2.7
(1.3-2) (1.7-2.3) (1.7-2.1) (2.5-3.1) (2.5-2.9)
Sodium (mmol) 2.0 2.0 2.5 3.3 4.0
(1.9-2.7) (2-2.5) (2.1-3) (2.9-3.8) (3.4-4.3)
Potassium (mmol) 1.5 1.3 1.8 2.2 2.6
(1.3-1.7) (1.3-1.7) (1.5-2.1) (1.9-3.1) (2.2-2.9)
Table 3.6: Median (Interquartile range) for the largest cluster (Nx) in each age group
In 100 mL Premature Neonate Child Child Child
Neonate <10 kg 10-20 kg 21-30 kg
Amino acid (g) 1.7 1.7 2.2 2.0 2.5
(1.5-1.8) (1.4-1.8) (2-2.5) (1.7-2.2) (2.1-3.1)
Glucose (g) 7.4 8.2 12 9.5 15
(6.7-8) (8-8.6) (11.6-12.5) (8.1-10) (14.3-15.6)
Lipid (g) 1.7 2.0 2.3 2.1 2.9
(1.5-2) (1.7-2.3) (2-2.6) (1.9-2.5) (2.5-3.1)
Sodium (mmol) 2.0 2.0 2.5 3.0 3.8
(1.5-2) (1.8-2.3) (2.5-3) (2.5-3.3) (3.1-3.8)
Potassium (mmol) 1.3 1.3 2.1 2.0 2.9
(1-1.7) (1.1-1.8) (1.9-2.4) (1.8-2.5) (2.5-3.3)
Table 3.7: Median (Interquartile range) for the second largest cluster (N2) in each age group
Further analysis of the cluster groups showed that they could not be grouped by country 
or size of hospital. This means that each cluster represented respondents from any 
country and from any type of hospital.
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3.4. Discussion -  Methodology
Because of the relatively low response rate, results cannot be easily generalised.
One reason for non-responding, as investigated during follow-up, was the low 
frequency of PN used in some of the hospitals contacted. Unfortunately, follow-up 
results were not recorded in details. It is therefore not known which percentage of 
hospitals contacted did not use PN frequently.
Also, since the response rate in the UK was high, the overall results might be biased 
towards this country.
An improved response rate could have been achieved by:
a) Contacting all centres prior to sending questionnaire, in order to find out if substantial 
amounts of neonatal and paediatric PN were used and to find out if there was sufficient 
interest in the subject
b) Employing native speakers to conduct telephone follow-up in Italy and Spain
Another possible interference could have arisen from selective response: hospitals might 
have been more likely to respond to the questionnaire because they had a special interest 
in PN and in standard PN. As a result, this could have lead to an overestimation of, for 
example, the percentage of hospitals using StSol.
The questionnaire used for this survey was also relatively long and complex. Some 
hospitals who had returned the questionnaire indicated, that they had completed the 
questionnaire jointly between pharmacists and physicians (for example, if prescribing 
and compounding was handled completely separately). This had not been envisaged 
during the development phase and added to the complexity.
During follow-up, some physicians and pharmacists stated that they did not have the 
time to participate, although they were interested in the subject. This difficulty could 
have been overcome by splitting the survey into two separate parts. As an example, a 
postal survey could have been conducted that examined general aspects of PN practice 
only. Then, a second survey could then have focused on StSol by targeting respondents 
who had shown an interest in this subject in the first survey.
Despite these concerns, the response rate in this survey was similar to other published 
European questionnaire surveys where responses ranged from 36% to 42%.127,128
Several problems were also detected that can be attributed to the piloting process.
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Questions that appeared to perform well during piloting provided inconsistent 
responses. Responses to the quality control questions, for example, were meaningless, 
because it became evident that no distinction had been made between end-control and 
process validation. Another difficulty, which had not been apparent during 
interviewing, was related to the specification of manufacturers products used. Different 
companies in each country supplied products. Consequently, answers to this question 
were inconsistent and were not presented.
Piloting in five languages and countries proved to be a complex task. Focusing on the 
UK only for a first study and subsequently expanding the survey overseas might have 
achieved more successful and complete validation of the survey tool.
The opportunity had been missed to asked hospitals contacted for piloting purpose to 
comment on the questionnaire. This would have been useful to detect inconsistencies 
and topics that had been missed during interviewing.
It has to be concluded that postal piloting was unsatisfactory, and that results from this 
survey have to be interpreted in the light of these shortcomings.
It is also important to highlight the fact that a commercial database was used to contact 
participants. This was the only identifiable database in Europe, and was not customer 
database. Nevertheless, results have to be interpreted taking this source of information 
into consideration.
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3.5. Discussion -  Survey results
This survey of PN practice in five European countries has investigated prescribing, 
compounding, and administration of PN. The use of StSol and the composition of StSol 
in the view of prescribers have also been studied.
The results of this survey show that physicians are mainly responsible for prescribing of 
PN, although in some hospitals in the UK pharmacists are prescribing. The current legal 
situation requires the physician to sign PN prescriptions, but some hospitals have 
introduced policies that allow pharmacists to prescribe PN, or allow nutrition support 
teams take over a joint prescribing role.100
Compounding practice differed greatly throughout Europe. In the UK, most hospitals 
prepared PN in hospital pharmacy aseptic compounding units, and additions were rarely 
made to PN bags on the ward (Figure 3.4). Hospitals in Europe that did not have an 
internal compounding unit either received PN from another hospital, or from 
commercial contractors, or compounded PN on the ward. In a fifth of surveyed hospitals 
PN was compounded directly on the ward.
Unfortunately, the opportunity was missed to enquire about hospitals’ infection rates as 
part of the survey. It is therefore not know whether the type of compounding practice 
had a direct effect on infection rates in each hospital. Discussions about the advantages 
or disadvantages of compounding PN in pharmacy departments thus remain purely 
speculative in the context of this survey. Further work is required in order to make 
recommendations about the optimal location and environment for aseptic compounding 
of PN.
With regard to the infusion of lipids, results from this survey show that they were 
mostly given separately, especially in neonatal PN (Table 3.2). Separate infusion of 
lipids was widespread in neonates in comparison to practice in adults for whom most 
PN is given as TNA. This may have been surprising, as there is no evidence in the 
literature that TNA would not be feasible or clinically inappropriate in neonates. Giving 
lipids as TNA can potentially lead to a more consistent provision of lipids, and doing so
1 90might also have economic advantages. Further aspects of separate lipid 
administration or TNA will be explored in Chapter 5 of this thesis.
Commercially available micronutrient solutions are designed to meet recommended 
daily intakes. This survey has shown that a substantial number of hospitals did not start 
micronutrients on the first day of PN, and some did not include it each day of the week
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(Figure 3.5-Figure 3.7). Particularly in Germany and Italy, micronutrient addition was 
frequently delayed until several days after PN commencement.
If micronutrients are not given every day from the first day, a risk of deficiency can 
occur. During piloting of the questionnaire, it became clear that some hospitals did not 
include micronutrients due to concerns of their stability or concerns of the effect that 
micronutrients might have on the stability of other PN components. Regarding the 
stability of micronutrients in PN, clearer guidance might be required from 
manufacturers and international organisations, in order to ensure that micronutrients are 
provided in appropriate concentrations.
Many hospitals filtered PN solutions during administration (Figure 3.8). It has been 
shown that particles contaminate PN solutions, and recent guidelines have highlighted 
the importance of filtration of all PN solutions.17,130
PN bags were often light protected, but light protection of the administration tubing is 
currently rare (Table 3.3). This is possibly due to a lack of suitable or affordable 
materials. Light, especially phototherapy light, can affect the stability of PN is two 
ways. Light sensitive vitamins are more likely to degrade, and lipid peroxidation is 
potentially increased.81,126 More research is needed to show clear benefits of light 
protection, especially the importance of protecting the administration tubing from light. 
This topic was further explored as described in chapter five of this thesis.
One of the objectives of this survey was to find out more about current practice with 
regard to the use of StSol. The results show that StSol had been mainly developed for 
neonatal patients. Five hospitals have returned information with the questionnaire about 
the exact composition of their neonatal StSol. The solutions shown in Table 3.4 are 
comparable to some of the StSol described in the literature.105 If these solutions were 
administered at a rate of 150 mL/kg/day, between 1.8 and 2.6 g/kg/day amino acids, 
then 15 and 18.8 g/kg/day glucose would be provided. Current recommendations of 
amino acids intake are 3.5-3.85g/kg/day for premature neonates and 2-3 g/kg/day for 
term neonates.1 StSol used in some of the surveyed hospitals might provide insufficient 
amounts of amino acids, especially if used for premature infants.
The second part of the questionnaire asked participants to suggest StSol that they felt 
would be suitable to use in five age/weight groups. The overall data summarised in 
Figure 3.9-Figure 3.14 shows that standard concentrations fell steadily with increasing 
maturity and weight. Only sodium and potassium levels are suggested to remain at 
approximately 3 and 2 mmol/kg/day respectively. The large variability, especially in 
terms of proposed amounts fluids and amino acids, suggests that current practice and the
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perception of best PN practice is diverse across Europe. Another reason for variability 
might have been that different hospitals treat different patient populations. This factor 
was, however, not investigated.
Overall results (Table 3.5) showed a steady increase in all components of PN from 
premature neonates to older children and interquartile ranges showed that responses 
were very variable. As a result, cluster analysis was employed to identify homogenous 
groups of respondents, based on similar responses to all five PN components.
Table 3.6 shows that suggested concentrations of nutrients for premature neonates and 
term neonates in the largest cluster differed only slightly. Table 3.7 however, shows that 
a lower glucose concentration might be required in some patients, and this is an 
approach already used in some hospitals for very premature neonates.105 Recommended 
amino acids intake differs for premature and term neonates as described above,1 but this 
was not reflected in the results of this survey.
In the three groups of children, concentrations of all components increased steadily, 
with the exception of sodium. Cluster analysis discriminates two different groups of 
responses with regard to the glucose concentration, especially for older children where 
suggestions vary between 11.7% and 15% glucose.
These results have revealed the diversity of current practice, and have highlighted the 
fact that more guidance is needed regarding controversial issues. Importantly, the use of 
StSol requires further investigation and guidance.
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4. Pan-European study of neonatal nutrition prescribing 
practice and nutritional intake
4.1. Introduction
4.1.1. Neonatal enteral and parenteral nutrition
Neonates require special nutritional support if bom prematurely (before 38 weeks of
111gestation) or if satisfactory nutrient intake cannot be achieved by oral feeding. The 
natural food for neonates is maternal breast milk. It has been shown that breast milk 
intake is advantageous for physical and mental development of neonates and should be 
the nutrition of choice.47 If breast milk is unavailable, various specially formulated 
products can be used for bottle-feeding. Specialist nutrition support is required if 
neonates are too premature or weak to suck or swallow. These conditions are common 
in neonates below 32-34 weeks of gestation. In these cases, a nasogastric or transpyloric 
tube can be inserted to provide either breast milk or formula milk. If enteral feeding is 
not possible or insufficient to meet energy and nutrient requirement, parenteral nutrition 
is indicated.131
Adequate nutrition for neonates and specifically premature neonates is crucial for their 
growth and development.132 In some cases, nutritional intake must be increased above 
normal requirement to promote catch-up growth if in-utero development was 
impaired. Nutritional requirements have been estimated using various approaches
00including: extrapolation from healthy neonates and from in-uterus nutrient accretion, 
and estimation of requirements by measuring energy expenditure.134,135 Studies have 
been undertaken which distinguish between requirements for premature and surgical
1 1 'IQinfants. ' Current recommendations for macronutrient and energy intake for 
neonates are summarised in Table 4.1.
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Premature infants Surgical infants
Amino acids (g/kg/day) 3.5-3.85" 2.5-3°
Glucose (g/kg/day) 14.4-18.7" <18°
Lipids (g/kg/day) 3" 3-4*
Total energy (kcal/kg/day) 100-120" 90-100*
Table 4.1: Recommended macronutrient/energy intake in neonates (a1; n139; • 138)
In recent years, studies comparing conventional treatment with more aggressive
nutrition support have been undertaken.31’140,141 The term ‘aggressive nutrition’ has been
defined as “practice that ranks towards the upper end of the range of established
practices, or as practice that goes beyond the established and into untested territory”.142
Wilson and colleagues randomised two groups of sick very low birth weight infants.
One group received nutritional support according to internal protocols, while the other
received nutritional support according to a more aggressive protocol.31 This more
aggressive protocol included an earlier start of enteral feeds, administration of insulin in
hyperglycaemia, administration of amino acids at amounts of up to 3 g/kg/day, and
administration of more glucose and lipids. They found that total energy intake was
significantly increased in the intervention group, but clinical outcome did not differ.
Although growth did improve in the intervention group, it remained a problem in both
groups. Porcelli and colleagues focused on the administration of amino acids for infants
below 1000 g birth weight.141 They compared nutritional intake and clinical outcomes in
infants who received 3 g/kg/day with infants who received 4 g/kg/day amino acids. The
study was designed as a temporal cohort study after a change in nutrition policy on their
neonatal ward. Increased amino acid intake was largely from parenteral nutrition, and
the increased intake was not found to cause metabolic disturbances. Thureen and
colleagues investigated the safety of increased amino acid intake in the same patient
group and found that intake of up to 3 g/kg/day was safe.140 It is important to note in
Porcelli’s study that low amino acid intake was equivalent to the ‘aggressive’
intervention in the studies by Wilson and Thureen. Consequently, comparison of these
studies is difficult and must be undertaken with caution. Both reports, however,
concluded that an increase in nutritional intake was safe and that there is considerable
potential for improving long-term outcome by such changes in nutrition policy.
Review of the literature has shown that nutritional guidelines are available for neonates,
and recommendations have been made to guide prescribers in choosing the appropriate
amount and type of special nutrition care. A more recent focus has been the topic of
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aggressive nutrition support, during which nutrition is increased more quickly than 
during more traditional regimens. A clear lack of information in the literature was 
identified regarding current prescribing practice and differences between prescribed and 
administered PN in neonatal patients.
It is therefore not known how recommendations made by international organisations are 
translated into practice. Additionally, the level of diversity within prescribing practice 
and the degree to which clinical factors might influence prescribing decisions is not 
known.
Understanding current practice is advantages as it informs prescribers about how their 
own practice compares to others in their field. It also enables assessment of quality of 
nutrition support.
Investigation of clinical practice can also highlight areas for improvement, especially 
with regard to the implementation of guidelines into practice.
4.1.2. Aims and objectives
The aim of this study was to characterise current UK and continental European nutrition 
support for neonates receiving PN, and thereby to evaluate the quality of neonatal 
specialist nutrition support. This was done in the form of external auditing.
In order to achieve this, the following parameters were measured: prescribed PN, 
differences between prescribed and administered PN, and total nutritional intake. The 
aim was also to assess diversity of prescribing practice within different types of 
hospitals in the UK in comparison to European centres.
This study was also designed to expand on previously explored use of standard 
solutions (StSol), as discussed in Chapter 3. The frequency of StSol use was recorded, 
and composition of prescribed PN was compared with StSol described in the literature, 
StSol used in previously surveyed hospitals, and StSol suggested by surveyed hospitals. 
This comparison allowed an analysis of feasibility of StSol in the light of current 
practice.
Beecroft and colleagues investigated StSol for neonates in a similar way, by analysing 
the number of times prescribers deviated from recommendations made by prescribing 
software.143 They concluded that up to two-thirds of feeds could be administered as 
StSol. The conception of this study was partly related to the work undertaken by 
Beecroft and colleagues.
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The focus of this study was neonates receiving PN, even though enteral nutrition intake 
was also investigated. It is important to note that results from this study are not 
representative for the entire neonatal special care population, but only for neonates 
receiving most of their nutrition from PN.
This study was conducted in neonates only, as it was estimated that, in order to have 
sufficient numbers of patients for group comparison, a relatively homogenous group of 
patients was required. Paediatric patients are very diverse in terms of age and 
indications for PN, so large numbers of patients would have to have been recruited to 
compare PN prescribing practice. It was decided that data collection in all paediatric age 
groups was not feasible and that the focus should be on neonates only.
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4.2. Methods
4.2.1. Study centres (UK)
For this study, 145 hospitals in England, Wales, Scotland, and Northern Ireland were 
invited to participate, which represented all hospitals treating a minimum of 300 
neonates per year listed in the ‘Neonatal Nurses Association Yearbook 2001 This was 
the only identifiable and reliable source of information about all neonatal care units in 
the UK. The booklet was also very useful for this purpose as it contained detailed 
information about the names and contacts number of the staff in each of the neonatal 
wards. This meant it was possible to send the invitations to a specific person in each 
hospital.
The cut-off point of 300 neonates per year was chosen, because it was predicted that a 
sufficient amount of PN would be prescribed in these hospitals to make data collection 
feasible.
Two options had been identified in order to collect data from a random sample of 5-8 
hospitals in the UK. Firstly, 5-8 contacts could have been randomly chosen from all the 
contacts. They could have then been invited to participate. The decision was made that 
this process would be too lengthy, as many of the contacted hospitals were likely not to 
participate. The second option was to send the invitation to all contacts, and to then 
randomly choose participants from the interested contacts. This second option was 
chosen.
Invitations were sent to the medical director, ward manager or paediatric consultants on 
neonatal intensive or special care wards as available from the Yearbook (Appendix 4). 
Forty-nine hospitals initially replied to the invitation. They were sent a confidentiality 
agreement (for the purpose of protecting the intellectual property of the study design, 
data collection form, and proposal for statistical analysis) in order to view detailed study 
documentation (Appendix 5). Of the forty-nine initial respondents, twenty returned the 
confidentiality agreement. Ten hospitals agreed to participate within the given deadline, 
eight in England and two in Scotland. Although this original plan had been to include 5- 
8 hospitals, this number was increased to 10, due to the unexpected large interest.
Due to the delay in the responses, it was not possible to actually randomise participants, 
as suggested above. Hospitals were included as soon as they agreed to participate. This 
meant that it was not a true random selection.
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Of the participating hospitals, six were teaching hospitals (TH) and four were general 
district hospitals (GH). The study protocol and plan of data analysis are presented in 
Appendix 6.
4.2.2. Study centres (Belgium, Germany, Finland, France, Sweden, UK)
International teaching hospitals (ITH) were recruited as the comparison group. The 
hospitals where the members of the European discussion group practised (as described 
in section 3.1.1 of this thesis) were invited to take part in the study. Six agreed to 
participate. One of the members of the discussion group was from a UK hospital, 
consequently one of the ITH was in the UK.
This comparison group was recruited, as it was deemed important to maintain an 
international scope to the project, but it was not feasible to conduct data collection by 
the same monitor in other European countries. Data from this group were analysed 
separately, and differences in data collection were considered in the discussion of the 
results as appropriate.
4.2.3. Data collection
Retrospective data collection took place in the UK between May and July 2002 by the 
author. It was not feasible to collect data prospectively, due to time constraints on the 
data collector, as the author of this thesis personally collected all data. Prospective data 
collection would have meant that the data collected had to spend 20 weeks in 10 
different hospitals. In some cases more than two weeks per hospital would have been 
required, due to the small amount of PN used. Retrospective data collection meant that 
all data were collected in each hospital in 2-3 days, i.e. 25 days in total. The drawback 
of retrospective data collection was that all information collected had to be available 
from medical records or pharmacy compounding records.
In ITH centres, local monitors (as appointed by the members of the European discussion 
group) collected data prospectively over a two-week period during June and July 2002. 
Prospective data collection was feasible in ITH, as data collectors were based at the 
hospitals.
Hospitals were characterised by number of neonatal beds, number of neonatal intensive
care beds, number of surgical neonates per year, and number of neonates treated per
year with a birth weight below 1500 g. Information was collected about neonates’
gender, birth weight, gestation, Apgar scores at one and five minutes, and about the
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following medical problems or interventions: sepsis, surgery, metabolic disorder, 
congenital malformation of the gastrointestinal tract, fluid restriction, and organ failure. 
Discussions with members of the European discussion group had identified that these 
conditions would be the most relevant. These data were extracted from medical records. 
Information about prescribed PN was either available from the compounding pharmacy 
department or from medical records, and prescribed volume of binary solution (amino 
acids and glucose solution) (mL), lipid emulsion (mL), amino acids (g), glucose (g), 
sodium (mmol), and potassium (mmol) per day were recorded. Amounts of 
administered PN were extracted from fluid charts. The type of intravenous line used to 
administer PN was available either from medical records or fluid charts. Details were 
also recorded about the type and amounts of enteral feeding administered concurrently 
with PN, and amounts of additional non-nutritional fluids (e.g. medication, flushes, or 
clear fluids) given, excluding blood products. It was estimated that the collection of the 
exact type of additional non-nutritional fluids, especially regarding glucose, sodium, 
and potassium content, would be too complex and inaccurate, and would mostly be 
negligible compared to the amounts derived from nutrition. It was therefore decided that 
only the amount, not the exact composition, of additional fluids would be recorded.
Data collection forms are attached in Appendix 7.
4.2.4. Electronic data capture tool
Investigators in ITH centres were given the option to use the same data collection forms 
as used in the UK or to electronically collect and transfer data. Because six different 
countries were involved, electronic storage and submission of data saved time and 
resources, provided data collectors with an easy to use interface, and potentially 
increased accuracy of data transfer into the final database, by reducing transcription 
errors. A Microsoft Access data capture tool was developed, details about which are 
available from the CD and examples in Appendix 8.
4.2.5. Patient population
Neonates less than twenty-eight days of age were included, independent of gestation,
birth weight, or indication for PN. In the UK, data were collected retrospectively from
neonates who had received PN in the two weeks prior to data collection, but in some
hospitals this period had to be extended to up to five weeks due to the small number of
neonates treated. In ITH centres, data were collected prospectively over a two-week
59
period. At least five neonates were included per hospital, and a minimum of fifteen 
nutrition days amongst all patients was collected per hospital. The maximum number of 
PN days per neonate was fourteen, in order to prevent data from being biased towards a 
small number of patients. Although this meant that long-term PN in neonates was not 
studied, the majority of patients were expected to have relatively short term PN (e.g. 5- 
10 days). It was envisaged that if data collection was allowed to take place for 28 days 
for any patient, the overall number of PN days would have been weighted towards a 
small number of patients (e.g 10 neonates could have accounted for 280 nutrition days). 
Data collection stopped if  greater than half of nutrition volume was provided enterally 
or if the neonate reached the age of twenty-eight days.
4.2.6. Ethical considerations
The protocol and data collection forms for the UK part of the study were submitted as a 
research project to the South West Multicentre Ethics Committee for ethical 
consideration. The committee decided that this was an audit and would not require 
formal approval, as it was non-interventional and anonymous. The terminology of the 
documentation was therefore changed to ‘Audit’ (Appendix 3). It is important to point 
out that, although this project has characteristics of an audit, it cannot be classified as a 
traditional medical audit, especially as data were collected externally. To clarify this, 
the term audit was subsequently changed to ‘study’.
It was pointed out that individual centres should receive feedback regarding their 
performance. This recommendation was followed, and a summary of results was sent to 
each hospital in confidence in October 2002. The letter from the Ethics committee is 
attached in the appendix. As the data collector was not an NHS employee, and access 
was required to patients’ notes and fluid charts, honorary contract were singed with 8 of 
the 10 hospitals, the other two hospitals only required an agreements of confidentiality. 
International centres dealt with their local ethical committees as required. No special 
confidentiality considerations were necessary in international centres, as data collectors 
were employees of the hospital.
4.2.7. Data analysis
Data were analysed using the software SPSS 10.0 for Windows. Populations were
compared by non-parametric Kruskal-Wallis H procedure. A maximum P  value of 0.05
was chosen to represent statistical significance. Figures show means unless otherwise
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stated, and error bars represent 95% confidence intervals. A one-way analysis of 
variance was applied to detect any interaction between ‘Day of PN’ and ‘Body weight’. 
Unless otherwise stated, data were analysed separately for the three types of hospitals: 
GH, TH, and ITH. Data were shown as mean and standard deviation, if  they were 
normally distributed. If data were skewed, median and interquartile ranges were shown.
Concentrations of prescribed macronutrients were compared to an empirically derived 
standard formula. The suggestion for this formula for comparison had been the result of 
the analysis of clinical and pharmaceutical requirements by the discussion group (as 
highlighted in Chapter 3). The standard solutions suggested contained 2.5 % amino 
acids, 12 % glucose, and 2 % lipids. The numbers of days were calculated when these 
standard concentrations would have fit the prescription (this method is closely related to 
the work by Beecroft and colleagues).143
4.2.8. Estimation of energy intake
Data collected allowed an estimation of energy intake. Due to the way in which data 
were collected (e.g. mL of nutrition volume), some assumption of caloric contents had 
to be made. It was assumed that breast milk contained on average 67 kcal/100 mL (1.2 g 
amino acids, 7.0 g glucose, 3.8 g lipids) . Enteral formulae were calculated according to 
manufacturers’ information as shown in Table 4.2.
In 100 mL Nutriprem Enfalac Premature Pepti-Junior SMA Gold
Amino acids (g) 2.4 2.3 2.0 1.5
Glucose (g) 7.9 8.3 7.2 7.2
Lipids (g) 4.4 3.8 3.7 3.6
Energy (kcal) 80 75 66.4 67
Table 4.2: Macronutrient and energy content o f commercial enteral formulae
The caloric content of macronutrients was defined as 4 kcal/g for amino acids, 4 kcal/g 
for glucose, and 9 kcal/g for lipids.[Hackl, 1994 #378] Additional glucose administered 
with non-nutritional fluids was not recorded, as previously highlighted, this was 
considered insignificant. Consequently, the macronutrient and energy intake shown only 
relates to parenteral and enteral nutrition intake.
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Information was only recorded regarding quantities of nutrition. Proprietary brands of 
amino acid solutions or lipid emulsions were not recorded.
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4.3. Results
4.3.1. Demographics of participating hospitals
Hospitals were characterised by number of neonatal beds and the number of surgical 
and low-birth-weight neonates they typically treat in one year. Table 4.3 summarises 
hospital characteristics in the three types of hospitals.
Hospitals GH (N=4) TH (N=6) ITH (N=6)
Mean SD Mean SD Mean SD
Neonatal beds 20.0 5.2 34.8 7.7 22.2 14.4
Intensive care beds 5.3 3.3 10.0 2.5 14.4 9.2
Surgical neonates per year 1.0 2.0 57.0 97.5 61.3 22.5
Neonates <1500 g birth 
weight per year
49.0 19.3 118.6 23.9 98.5 50.2
Table 4.3: Demographics of participating hospitals
4.3.2. Patient demographics
A total of 142 neonates were included in this study, 30 in GH, 60 in TH, and 52 in ITH. 
They were segmented by birth-weight, gestation, and Apgar scores at one and five 
minutes. The age at which PN was first prescribed was also recorded. Among all 
neonates, mean birth weight was 1459 ± 814 g and mean gestational age was 30.3 ± 4.3 
weeks; 81 neonates (57%) were male and 61 (43%) were female. Most of the neonates 
(94%) were bom prematurely (before 38 weeks of gestation). Additional or underlying 
problems were usually sepsis (GH 3 patients, TH 19 patients, ITH 9 patients) and 
surgery (GH 1 patient, TH 12 patients, ITH 13 patients). Also present were congenital 
malformations of the gastrointestinal tract (TH 1 patient, ITH 9 patients) and metabolic 
disorders (GH 1 patient, ITH 2 patients). In ITH, 2 patients were fluid restricted and 2 
had organ failure. No additional or underlying problems other than prematurity were 
noted in 25 patients in GH (83%), 34 patients in TH (57%), and 26 patients in ITH 
(50%). Table 4.4 summarises data for each of the three types of hospitals.
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GH (N=30) TH (N=60) ITH (N=52)
Mean ± SD Mean ± SD Mean ± SD
Birth weight (g) 1375 ± 699 1309 ±696 1682 ± 954
Gestation (weeks) 30.0 ± 3 .6 29.5 ± 3 .9 31.5 ± 4.8
Gestation surgical neonates (weeks) N/A 32.4 ±4.1 32.4 ± 6 .2
Gestation non-surgical neonates (weeks) N/A 28.8 ± 3 .6 31.2 ± 4.3
Apgar 1 min 6.6 ± 2 .3 6.6 ± 2 .2 6.2 ± 2 .5
Apgar 5 min 8.5 ± 1.1 8.4 ± 1.9 7.8 ± 1.8
Age at first PN (days) 3.4 ± 1.8 2.5 ± 1.4 2.9 ± 4 .6
Table 4.4: Patient demographics (N/A: not applicable)
There were apparent differences between the birth weight and gestation of neonates in 
GH, TH and ITH, but these were not statistically significant (birth weight P=0.099; 
gestation P=0.083). Surgical neonates were bom significantly later in gestation than 



















■  Small for gestation  
HID Appropriate for gestation  
H  Large for gestation
ITH
Figure 4.1: Appropriateness of weight for gestation in three birth weight groups
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Birth weight and gestation data have been further analysed to identify neonates who are 
small, appropriate, and large for gestational age.
Small or large for gestational age was defined as values more than two standard 
deviations below or above the mean. Standard weight curves were used from Helsinki 
University Central Hospital, and the calculations were performed with the help of 
software at this hospital. Standard curve had been identified in the literature, but manual 
calculation was considered to be unnecessarily complex and time consuming.
The results showed that 62% percent of neonates were appropriate for gestation, 35% 
were small, and two percent were large for gestation. Appropriateness for gestation 
related to birth weight is shown in Figure 4.1.
Figure 4.2 shows the relationship between the age at the start of PN and the neonate’s 
birth weight. PN was mostly started between the ages of two and three days, and there 






1 Day 2-3 Days 4-6 Days 7-9 Days >9 Days 
Age (days) at start of PN
Figure 4.2: Age (days) when PN was First started in neonates depending on birth weight in all 
hospitals
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4.3.3. Prescribed parenteral nutrition
One of the main objectives of the study was to investigate PN prescribing practice and a 
total of 752 nutrition days were collected (GH 118, TH 395, ITH 239). One patient in 
TH had been transferred between hospitals, and the starting date of PN was therefore 
not available. The five nutrition days related to this patient are therefore missing when 
the ‘Day of PN’ is shown.
Sub-population: D avofPN
Data were split into different days of PN (1st Day; 2nd-3rd Day; 4th-6th Day; 7th-9th Day; 
>9 Day) to take into account that PN was introduced slowly over several days. This 
was a slight deviation from the plan of analysis, but it was realised during data 
collection and preliminary data analysis that PN was sometimes advanced over more 
than a week. Table 4.5 summarises prescribed PN for GH, Table 4.6 for TH, and Table 
4.7 for ITH. The values shown for lipids only relate to days when lipids were 
prescribed, i.e. zero values were treated as missing data.
GH
(per kg/day)
Day 1 Days 2-3 Days 4-6 Days 7-9 Days >9
N=26 N=45 N=29 N=8 N=10
Binary solution (mL) 84.8 ± 33 .6 103.9 ± 34 .8 116.6 ±30 .3 130.4 ±44.3 116.1 ± 29 .6
Amino acids (g) 0.9 ± 0.5 1.5 ±0 .5 2.0 ± 0 .5 1.6 ±0 .5 1.8 ± 0 .5
Glucose (g) 9.6 ± 3 .4 12.0 ± 3 .5 14.5 ± 2.2 14.2 ±4.3 14.1 ± 3 .2
Sodium (mmol) 1.2 ±1.3 1.5 ± 1.5 2.4 ± 1.7 2.6 ± 1.7 4.2 ± 1.3
Potassium (mmol) 1.5 ± 1.0 1.7 ± 0 .9 1.9 ± 0 .6 1.9 ±0 .5 2.0 ± 0 .6
N=6 N=26 N=20 N=7 N=9
Lipids (g) 1.2 ± 0 .6 1.3 ± 0 .6 2.3 ± 0 .8 1.5 ± 1.0 2.2 ± 0.9
Table 4.5: Prescribed PN in GH at different days of PN (mean ± SD)
In GH, volumes of binary solutions were increased to an average of 130 mL/kg/day 
over a week and showed large variability. Macronutrient prescriptions were also very 
variable, and they reached highest levels after four to six days of PN.
Prescribed amounts of binary solution were observed at lower levels in TH than in GH 
(128 mL/kg/day), but they were equally variable. Macronutrients increased over more 
than nine days of PN and amino acids were prescribed in much larger amounts.
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Day 1 Days 2-3 Days 4-6 Days 7-9 Days >9
N=37 N=95 N=107 N=82 N=69
Binary solution (mL) 81.5 ±28.1 100.5 ± 32.5 110.3 ±35.5 108.4 ± 33 .7 107.3 ± 33 .7
Amino acids (g) 1.3 ± 0 .8 1.9 ± 0 .8 2.3 ± 0 .8 2.5 ± 0.8 2.8 ± 0.9
Glucose (g) 9.4 ± 3.2 10.8 ±3 .1 13.1 ± 2 .9 13.6 ± 3 .2 13.8 ± 3 .0
Sodium (mmol) 2.5 ± 1.2 2.5 ± 1 .1 3.2 ± 1.5 3.6 ± 1.7 3.6 ± 1.4
Potassium (mmol) 1.6 ± 0 .8 1.7 ± 0 .7 2.1 ± 0 .7 2.1 ± 0 .6 2.0 ± 0.6
N=20 N=76 N=103 N=82 N=69
Lipids (g) 0.9 ± 0.4 1.4 ± 0 .8 2.0 ± 1.0 2.5 ± 1.2 2.6 ± 0.9
Table 4.6: Prescribed PN in TH at different days of PN (mean ± SD)




Day 1 Days 2-3 Days 4-6 Days 7-9 Days >9
N=33 N=66 N=66 N=38 N=36
Binary solution (mL) 58.2 ± 34 .0 70.9 ± 33.9 94.6 ± 38.2 113.8 ±45 .5 113.5 ±34 .3
Amino acids (g) 0.9 ± 0.6 1.5 ± 0 .6 2.1 ± 0 .6 2.6 ± 0.6 2.7 ± 0.4
Glucose (g) 7.3 ± 2 .8 9.1 ± 3 .4 12.1 ± 4 .0 14.6 ±4.1 14.7 ± 5 .3
Sodium (mmol) 1.2 ± 1.6 1.6 ± 1.5 2.3 ± 1.2 2.6 ± 1.1 1.8 ± 1.7
Potassium (mmol) 0.7 ± 0.7 1.1 ± 0 .7 1.8 ± 0 .9 2.1 ± 0 .5 2.0 ± 1.0
N=8 N=28 N=35 N=30 N=30
Lipids (g) 0.7 ± 0.4 1.1 ± 0 .7 1.8 ± 1.0 1.9 ± 1.0 2.3 ± 0 .7
Table 4.7: Prescribed PN in ITH at different days of PN (mean ± SD)
Differences in prescribed PN were significant between the three types of hospitals on 
the following days (Table 4.8):
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Day o f PN Binary volume Amino acids Glucose Lipids Sodium Potassium
(mL/kg) (g/kg) (g/kg) (g/kg) (mmol/kg) (mmol/kg)
1 3C2 14.0 13.3 8.7 3.8 20.2 20.1
P 0.001 0.001 0.013 0.143 0.000 0.000
2-3 %2 35.9 11.7 20.1 1.4 28.6 23.7
P 0.000 0.003 0.000 0.474 0.000 0.000
4-6 %2 11.6 6.3 12.3 5.9 26.9 10.2
P 0.003 0.042 0.002 0.050 0.000 0.006
7-9 %2 2.0 12.7 1.4 9.9 13.3 0.4
P 0.361 0.002 0.484 0.007 0.001 0.791
>9 %2 .9 12.0 0.0 9.6 34.6 0.1
P 0.611 0.002 0.969 0.008 0.000 0.960
Table 4.8: Analysis o f statistical significance in PN prescribing practice between the three types of 
hospitals
Sub-population: Body weight
Amino acids and glucose prescriptions were analysed separately for three body weight 
groups: <1000 g; 1000 -  1500 g; >1500 g. These body weight groupings were designed 
in order to help identify if  weight played a significant role in prescribing decisions. Data 
are shown in Table 4.9 for GH, in Table 4.10 for TH, and in Table 4.11 for ITH.
Body weight < 1 0 0 0 g 1000 -  1500g > 1 5 0 0 g
X2 P
GH N Mean ± SD N Mean ± SD N Mean ± SD




Days 2-3 18 1.4 ± 0 .5 15 1.6 ±0 .5 12 1.6 ± 0 .6 1.8 0.412
Days 4-6 15 1.8 ± 0 .4 5 2.2 ± 0.2 9 2.3 ±0 .5 10.1 0.006
cd
Oc
Days 7-9 6 1.7 ± 0 .0 2 1.3 ± 1.1 0 - 0.0 1.000
Days >9 5 1.7 ± 0 .0 5 2.0 ± 0 .7 0 - 0.3 0.577
Day 1 9 9.9 ± 3 .2 11 9.5 ± 3 .9 6 9.5 ±3 .5 0.0 0.988
td
'5b
Days 2-3 18 13.0 ±3.1 15 10.9 ± 3 .6 12 11.6 ± 3 .6 2.2 0.333
$ Days 4-6 15 14.4 ± 2 .7 5 14.2 ±0 .8 9 14.7 ± 2 .2 0.3 0.893
<DC/3oO3
Days 7-9 6 15.0 ± 4 .7 2 11.8 ±2.5 0 - 0.4 0.505
o Days >9 5 16.3 ± 1.0 5 11.9 ± 3.1 0 - 6.8 0.009
Table 4.9: Glucose and amino acids prescribed for infants of different body weight in GH
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Amino acid prescriptions in GH did not show differences for neonates of different 
weight. Although it reached statistical significance on days four to six, there was no 
general pattern of amino acid prescriptions for smaller or larger neonates. In TH, the 
tendency was to prescribe more amino acids for smaller neonates, but this only reached 
significance after nine days. The trend was, however, to prescribe more glucose, and 
this was significant on days four to nine. In ITH, less amino acid and more glucose were 
prescribed for smaller neonates.
The overall picture was that prescription did not differ greatly for smaller or larger 
infants. There was a slight tendency for smaller infants to be prescribed more amino 
acids and less glucose in TH and ITH.
Body weight < 1000 g 1000 -  1500 g > 1 5 0 0 g
X2 P
TH N Mean ± SD N Mean ± SD N Mean ± SD
Day 1 13 1.6 ± 0 .9 11 1.3 ± 0 .9 13 1.1 ± 0 .3 1.8 0.407
1
I
Days 2-3 40 2.1 ± 0 .9 31 1.9 ± 0 .9 24 1.7 ± 0 .6 3.9 0.140
Days 4-6 54 2.4 ± 0.9 33 2.3 ± 0 .8 20 2.2 ± 0.6 0.2 0.883
'oa
oc
Days 7-9 48 2.6 ± 0.9 21 2.4 ± 0.9 13 2.3 ± 0.4 0.8 0.666
Days >9 39 2.8 ± 1.1 23 2.9 ± 0 .6 7 2.0 ± 0 .3 6.2 0.046
Day 1 13 9.1 ± 4 .0 11 10.3 ±3 .3 13 9.1 ± 2 .4 1.1 0.581
Days 2-3 40 10.4 ± 3 .3 31 11.5 ± 3.0 24 10.5 ± 2 .7 2.6 0.271
~Hfo1 Days 4-6 54 12.8 ± 2 .6 33 12.9 ± 2 .2 20 14.2 ± 4 .2 6.0 0.045
a>
C /3O Days 7-9 48 13.1 ± 2 .8 21 13.4 ± 3 .0 13 15.9 ±4 .3 12.1 0.002
a Days >9 39 13.8 ± 3 .0 23 14.5 ± 2 .2 7 11.8 ± 4 .6 3.1 0.218
Table 4.10: Glucose and amino acids prescribed for infants of different body weight in TH
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Body weight < 1 0 0 0 g 1000 -  1500g > 1500g
x2 P
ITH N Mean ± SD N Mean ± SD N Mean ± SD
a





Days 2-3 21 1.8 ± 0 .8 16 1.7 ± 0 .6 29 1.3 ± 0 .4 8.1 0.017
Days 4-6 17 2.6 ± 0.7 20 2.0 ± 0 .5 29 1.9 ± 0 .5 11.8 0.003
o(9
OG
Days 7-9 15 2.8 ± 0 .6 9 2.2 ± 0.5 14 2.5 ± 0.4 5.9 0.052
Days >9 8 2.7 ± 0.4 18 2.7 ± 0 .5 10 2.7 ± 0 .5 0.7 0.691
Day 1 9 7.2 ± 2 .7 9 8.2 ± 3 .5 15 6.9 ± 2.4 0.9 0.641
cd
i
Days 2-3 21 9.1 ± 3 .3 16 11.0 ± 3.8 29 8.2 ± 2.8 7.5 0.024
Days 4-6 17 11.5 ± 4 .0 20 12.5 ± 4 .5 29 12.1 ± 3 .7 0.6 0.728
<D
c /3OOG
Days 7-9 15 14.3 ± 3 .8 9 13.1 ± 5 .5 14 15.9 ± 3 .5 2.1 0.355
o Days >9 8 12.0 ± 3 .9 18 12.9 ± 4 .6 10 19.9 ± 3 .9 12.0 0.002
Table 4.11: Glucose and amino acids prescribed for infants o f different body weight in ITH
Sub-population: Type of PN
PN was either given as sole means of feeding or concurrently with EN. Data have been 
analysed separately for days when neonates received full PN and partial PN, in order to 
examine if concurrent enteral feeding affected PN prescribing. Full PN referred to days 
when at least 90 % of feeding volume was PN; partial PN refers to days when between 
50% and 90% of feeding volume was PN. The plan of analysis had set out to refer to 
full PN if 80-100 % of nutrition volume was from PN. This had been based on the 
assumption that enteral feeding would be given on the majority of PN days. This was 
subsequently changed to 90-100 %, as EN was not administered on a large number of 
days, in order to achieve a more equal distribution in the two groups.
Table 4.12 shows prescribed amounts of macronutrients in GH. There was a tendency 
for higher amounts of amino acids in partial PN that was only significant after nine days 
of PN. The overall trend, however, was that concurrent enteral feeding did not influence 
PN prescriptions.
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GH Full PN Partial PN Kruskal-Wallis
N Mean ± SD N Mean ± SD I 1 P
Day 1 19 1.0 ± 0 .6 7 0.6 ± 0.2 2.2 0.138










1.9 ± 0 .4  









Days >9 6 1.6 ± 0 .3 4 2.3 ± 0.6 5.2 0.023
Day 1 19 9.6 ± 3 .5 7 9.7 ± 3 .5 0.0 0.977











13.6 ± 5 .7  
16.1 ± 4 .3
16
4
12.8 ± 3 .8  





Days >9 6 14.2 ± 4 .2 4 13.9 ± 0 .6 0.7 0.394
Day 1 6 1.2 ± 0 .6 0 - - -



















Days >9 6 1.9 ± 0 .7 3 2.9 ± 0 .8 2.0 0.154
Table 4.12: Prescribed amounts of macronutrients depending on type of PN in GH
Prescriptions in TH are summarised in Table 4.13. As reported for GH, there was no 
clear tendency for higher or lower prescribed amounts of macronutrients in full or 
partial PN.
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TH Full PN Partial PN Kruskal-Wallis
N Mean ± SD N Mean ± SD X2 P
Day 1 31 1.3 ± 0 .7 6 1.7 ± 1.1 1.1 0.303










2.3 ± 0 .7  









Days >9 40 2.9 ± 0.9 29 2.6 ± 0.9 2.3 0.127
Day 1 31 8.7 ± 2 .4 6 13.4 ± 4 .4 5.7 0.017










13.3 ± 3 .0  
13.6 ± 3 .3
42
29






Days >9 40 14.1 ± 2 .9 29 13.3 ±3.1 0.6 0.426
Day 1 18 0.9 ± 0.4 2 0.8 ± 0.4 0.0 0.900



















Days >9 40 2.6 ± 0.9 29 2.6 ±0.1 0.1 0.784
Table 4.13: Prescribed amounts of macronutrients depending on type of PN in TH
In ITH, however, significantly less amino acids and glucose were prescribed if neonates 
received substantial amounts of concurrent EN (Table 4.14), although these differences 
were not reflected in the prescribed lipid.
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ITH Full PN Partial PN Kruskal-Wallis
N Mean ± SD N Mean ± SD X2 P
Day 1 23 1.0 ± 0 .6 10 0.5 ± 0.2 5.0 0.026









2.3 ± 0.6 
2.8 ± 0 .5
31
15
1.9 ± 0 .5  





Days >9 27 2.7 ± 0.4 9 2.7 ±0.4 0.3 0.596
Day 1 23 7.8 ± 3 .0 10 6.2 ± 1.8 2.2 0.137








12.9 ± 3 .2  
16.6 ± 3 .5
31
15
11.2 ± 4 .7  





Days >9 27 15.2 ± 5 .3 9 13.0 ± 5 .5 0.9 0.351
Day 1 7 0.8 ± 0 .3 1 0.2 ± 1.2 1.2 0.272
























Days >9 21 2.3 ± 2 .3 9 2.2 ± 1.8 1.8 0.182
Table 4.14: Prescribed amounts of macronutrients depending on type of PN in ITH
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Sub-population: Surgical neonates
Twenty percent of neonates in TH and twenty-five percent of neonates in ITH 
underwent surgery. Table 4.15 compares prescribed amounts of amino acids, glucose, 
and lipids in surgical and non-surgical neonates in both TH and ITH. There was a small 
tendency to prescribe more macronutrients to surgical patients, especially amino acids 
and lipids. GH are not included, as only one patient underwent surgery in this group.
TH and ITH Surgical Non-surgical Kruskal-Wallis
N Mean ± SD N Mean ± SD I 2 P
Day 1 15 1.3 ± 0 .6 55 1.1 ± 0 .7 2.3 0.127





















Days >9 50 2.9 ± 0.7 55 2.6 ± 0 .8 3.4 0.066
Day 1 15 8.1 ± 0 .7 55 8.6 ± 3.4 0.0 0.869











13.1 ± 3 .5  
15.7 ± 3 .5
118
75
12.5 ±3 .3  





Days >9 50 13.5 ± 3 .9 55 14.6 ± 4 .0 0.9 0.357
Day 1 8 0.8 ± 0.3 20 0.9 ± 0.4 0.6 0.460
























Days >9 49 2.7 ± 0 .7 50 2.4 ± 1.0 0.9 0.357
Table 4.15: Prescribed amounts of macronutrients to surgical and non-surgical neonates in TH and 
ITH
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4.3.4. Interactions between ‘Day of parenteral nutrition9 and ‘Body weight9
It has been established that prescriptions were significantly different depending on the 
day of PN and, in some instances, for neonates of different weight. By using one-way 
analysis of variance, this section will examine potential interactions between the two 
groups ‘Day of PN’ and ‘Body weight’ to establish if these reached levels of 
significance. Data are only shown for TH and ITH, because the amount of data available 
from GH is insufficient for this analysis.
The following figures show data for amino acids, glucose, lipid prescriptions, and the 
level of significance of difference between day of PN and body weight. The three 
separate lines represent different body weight groups. The horizontal axis represents 
different days of PN, and the vertical axis shows increasing amounts of prescribed 
macronutrient. The level of parallelism of the three lines defines the level of interaction, 
i.e. the more parallel they are the least do the factors interact.
Amino acid prescriptions in TH are shown in Figure 4.3. Larger neonates were 
prescribed less amino acid than smaller neonates after nine days of PN, but the 
interaction was not significant.
Figure 4.4 shows the same data for ITH. Again, there was no significant interaction, but 
smaller neonates tended to be prescribed more amino acids. The main difference 
between TH and ITH was that after nine days of PN larger neonates were prescribed 









2-3 4-6 7-9 >9
Day of PN
Figure 4.3: Prescribed amino acids (mean) in TH; significant differences for ‘Day of PN’ (P=0.000) 









2-3 >91 4-6 7-9
Day of PN
Figure 4.4: Prescribed amino acids (mean) in ITH; significant differences for ‘Day of PN’ (P=0.000) 
and ‘Body weight’ (P=0.005); interaction not significant (^Q.060)
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The slopes for glucose prescriptions in TH are not parallel, and there is an interaction 
between day of PN and weight (Figure 4.5). Neonates over 1000 g were prescribed 
similar amounts, but smaller neonates were prescribed more glucose between the fourth 
and ninth day of PN and less after the ninth day.
There was also an interaction in ITH, but, unlike TH, neonates weighing over 1500 g 
received constantly increasing amounts of glucose, whereas glucose prescriptions for 









2-3 4-6 7-9 >91
Day of PN
Figure 4.5: Prescribed glucose (mean) in TH; significant differences for ‘Day of PN’ (P=0.000) and 










2-3 4-6 7-9 >91
Day of PN
Figure 4.6: Prescribed glucose (mean) in ITH; significant differences for ‘Day of PN’ (P=0.000) and 
‘Body weight’ (P=0.016); significant interaction (/^O.OOO)
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Prescribed amounts of lipids were similar in both TH and ITH, and there was no 














2-3 7-9 >91 4-6
Day of PN
Figure 4.7: Prescribed lipids (mean) in TH; significant differences for ‘Day of PN’ (/^O.OOO) and 





.5 - Body weight group
-o < 1000 :
1000-1500g
>1500g
2-3 4-6 7-9 >9
Day o f PN
Figure 4.8: Prescribed lipids (mean) in ITH; significant differences for ‘Day of PN’ (P=0.000) and 
‘Body weight’ (P=0.839); interaction not significant (P=0.799)
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Lipids were increased steadily over nine days until reaching just over 2.5 g/kg/day in 
TH, and 2 g/kg/day in ITH. In TH, neonates weighing more than 1500 g were 
prescribed fewer lipids after nine days of PN, but this was not significant.
4.3.5. Concentrations of prescribed parenteral nutrition
Chapter 3 of this thesis focused on the use of StSol and potential concentrations of 
nutrients in PN. In order to analyse results of this study with regard to StSol, prescribed 
amounts of macronutrients were converted into concentrations. As lipids were usually 
given separately (in 98% of cases), only the binary solution has been used for these 
calculations.
Table 4.16 summarises concentrations of amino acids and glucose in prescribed 
amounts of binary solution in three different weight groups in GH. None of the weight 
groups showed a statistically significant difference, and mean values were very 
consistent throughout the increasing days of PN. Mean amino acid concentration were 
1.2 % and mean glucose concentration 10 %.
Body weight < 1000 g 1000 -  1500g > 1 5 0 0 g
X2 P
GH N Mean ± SD N Mean ± SD N Mean ± SD
?
oo
1st Day 9 1.2 ± 0 .8 11 1.2 ± 0 .7 6 0.7 ± 0.7 2.8 0.252
2nd-3rd Day 18 1.1 ±0.5 15 1.5 ± 0 .5 12 1.4 ± 0 .7 4.5 0.107
w
t/3 4th-6*h Day 15 1.3 ± 0 .4 5 1.9 ± 0 .6 9 1.6 ± 0 .4 3.6 0.168
oce
O 7th-9th Day 6 1.2 ±0 .5 2 1.0 ± 0 .8 0 - 0.1 0.733
>9th Day 5 1.0 ±0.1 5 1.4 ± 0 .6 0 - 2.3 0.130
1st Day 9 10.0 ± 0 .7 11 9.9 ± 0.7 6 9.7 ± 0 .8 0.8 0.672
i 2nd-3rd Day 18 9.8 ± 0 .7 15 10.1 ±3.1 12 9.7 ±2.1 0.3 0.852
©o
4th-6th Day 15 10.1 ± 0 .6 5 12.4 ± 3 .6 9 10.0 ± 1.0 3.0 0.222
u1/3oo3
O
7th-9th Day 6 9.9 ± 2.7 2 8.4 ± 2 .3 0 - 0.8 0.375
>9th Day 5 10.0 ± 0 .0 5 8.5 ± 2 .3 0 - 2.8 0.095
Table 4.16: Concentration of amino acids and glucose in prescribed binary solution (GH)
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The variability of concentrations was much larger in TH, especially for glucose (Table 
4.17). Mean amino acid concentrations increased with increasing days of PN, but 
differences between weight groups were mainly non-significant. Glucose concentrations 
were different between weight groups with solutions for neonates below 1000 g 
containing 10 g/100 mL glucose and solutions for neonates above 1500 g containing 
15g/l 00 mL glucose after nine days of PN. At earlier stages of PN, glucose 
concentrations were almost independent of body weight at around 10 g/100 mL.
Body weight <1000 g 1000 -  1500 g > 1 5 0 0 g
X2 P
TH N Mean ± SD N Mean ± SD N Mean ± SD
i
©o
1st Day 13 1.6 ± 0 .7 11 1.3 ± 0 .7 13 1.2 ± 0 .5 2.4 0.301
2nd-3rd Day 40 1.9 ±0 .5 31 1.6 ±0 .5 24 1.6 ± 0 .5 9.7 0.008
'Sfo
C /3
4th-6th Day 54 1.9 ± 0 .5 33 1.8 ± 0 .6 20 1.9 ± 0 .7 0.4 0.811
’5cd
o 7th-9th Day 48 2.0 ± 0.6 21 1.9 ± 0 .6 13 2.2 ± 0 .7 1.4 0.490
>9th Day 39 2.1 ± 0 .5 32 2.3 ± 0 .6 7 2 .7 ±  1.1 2.9 0.231




2nd-3rd Day 40 9.4 ± 1.3 31 9.7 ± 1.2 24 10.2 ± 0 .9 10.0 0.007




7th-9th Day 48 10.1 ± 1.9 21 10.8 ± 1.5 13 14.1 ± 2 .5 27.8 0.000
>9th Day 39 10.3 ± 0 .9 32 11.5 ± 2.6 7 15.0 ± 3 .3 19.2 0.000
Table 4.17: Concentration of amino acids and glucose in prescribed binary solution (TH)
Concentrations of amino acids were very variable in ITH (Table 4.18). With the 
exception of the first day of PN, differences were significant between the weight 
groups. Reaching 3.1 g/100 mL after nine days of PN, amino acid concentrations were 
highest for smaller neonates. Glucose concentrations also tended to be higher for 
smaller neonates, although this was less consistent.
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Body weight < 1000 g 1000 -  1500g > 1 5 0 0 g
X2 P
ITH N Mean ± SD N Mean ± SD N Mean ± SD
?
o©
1st Day 9 1.3 ± 0 .6 9 1.4 ± 0 .5 15 1.4 ± 0 .5 1.0 0.621
2nd-3rd Day 21 2.5 ± 1.3 16 2.4 ± 2 .2 29 1.8 ± 0 .4 9.7 0.008
W
c/a
4th-6th Day 17 3.2 ± 1.0 20 2.2 ± 0.7 29 1.8 ± 0 .5 20.3 0.000
'5CG
O 7th-9th Day 15 2.7 ± 0 .6 9 2.0 ± 0.6 14 2.0 ± 0 .5 9.7 0.009
>9th Day 8 3.1 ± 0 .6 18 2.3 ± 0 .3 10 2.0 ± 0.3 16.3 0.000










14.5 ± 5 .8
16
20




11.9 ± 2.9 








7th-9th Day 15 13.6 ± 3 .6 9 11.1 ± 3 .4 14 12.3 ± 1.7 3.7 0.160
>9th Day 8 14.1 ± 5 .3 18 10.5 ±2.1 10 14.3 ± 1.2 11.4 0.003
Table 4.18: Concentration of amino acids and glucose in prescribed binary solution (ITH)
Concentrations of prescribed binary solution were further compared to an empirical 
standard, as described in the methods section. Prescriptions were considered to fit the 
proposed standard, if it was within 20% of the proposed concentration (i.e. 2-3g amino 
acids, 9.6-14.4g glucose, and 1.6-2.4 g lipids in 100 mL). Results were split into the 
different days of PN. Further analyses of 30% deviation from the suggested standard as 
described in the plan of analysis (Appendix 6) was not performed, because the 20% 
deviation exhibited a poor overall fit.
Most prescriptions on the first day of PN were below the empirical standard, but 










GH Amino acids (g) 25 96
' 1 4 0 0
Glucose (g) 6 23 20 77 0 0
Lipids (g) 23 89 , . ; . :. . 3 / v 11 0 0
TH Amino acids (g) 29 78 V/.;'.8;.' 2 2 / ' , : 0 0
Glucose (g) 20 54 ■ 17 46 0 0
Lipids (g) 37 100 : vQ ’v \C :'o 0 0
ITH Amino acids (g) 30 91 3 ■ 9 0 0
Glucose (g) 8 24 18 7 21
Lipids (g) 33 100 0 0 0
Table 4.19: Number of first days o f PN, where prescribed macronutrients fit the empirical standard










GH Amino acids (g) 43 96 2 4 0 0
Glucose (g) 22 49 22 49 1 2
Lipids (g) 39 87 4 9 2 4
TH Amino acids (g) 74 78 21 22 0 0
Glucose (g) 57 60 38 40 0 0
Lipids (g) 80 84 13 14 2 2
ITH Amino acids (g) 36 55 24 36 6 9
Glucose (g) 16 24 25 38 25 38
Lipids (g) 56 85 ; 8 . 12 ■' 2 3
Table 4.20: Number of days between 2nd and 3rd day of PN, where prescribed macronutrients fit the 
empirical standard
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GH Amino acids (g) 28 97 /..• 1;'.'■ v ,3 ■ 0 0
Glucose (g) 15 52 13 45 1 3
Lipids (g) 18 62 i 10 35 1 3
TH Amino acids (g) 79 74 26 : ;v: 24;; 2 2
Glucose (g) 61 57 46 43 0 0
Lipids (g) 62 58 32 30 ': 13 12
ITH Amino acids (g) 32 49 : 24 36 10 15
Glucose (g) 20 30 j 23 3 5 23 35
Lipids (g) 50 76 10 15 6 9
Table 4.21: Number of days between 4th and 6th day of PN, where prescribed macronutrients fit th
empirical standard
As more amino acids were prescribed in TH and ITH, more amino acid values fit the
standard (Table 4.22). In GH, amino acid concentrations were always below the
suggested standard, but glucose concentrations exhibited a better fit.
7th-9th Day Below Fit Above
N % N % N %
GH Amino acids (g) 8 100 0 0 0 0
Glucose (g) 3 38 5 63 0 0
Lipids (g) 6 7 5  ; i 12 1 12
TH Amino acids (g) 55 67 27 33 0 0
Glucose (g) 42 51 39 48 1 1
Lipids (g) 31 38 35 43 16 20
ITH Amino acids (g) 18 47 I8 47 2 5
Glucose (g) 10 26 18 47 10 26
Lipids (g) 23 61 8 21 7 18
Table 4.22: Number of days between 7th and 9th day of PN, where prescribed macronutrients fit the 
empirical standard
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Finally, after nine days of PN, more prescriptions were within the standard range, but 






% /j  N
Above
%
GH Amino acids (g) 9 90 1 10 0 0
Glucose (g) 5 50 : 5 50 0 0
Lipids (g) 7 70 2.'- ’■■'•20 1 10
TH Amino acids (g) 30 43 37 54 ; 2 3
Glucose (g) 40 58 22 32 7 10
Lipids (g) 21 30 30 44 18 26
ITH Amino acids (g) 21 58 12 33 3 8
Glucose (g) 11 31 18 50 " 7 19
Lipids (g) 15 42 16 44 5 14
Table 4.23: Number of days after 9th day of PN, where prescribed macronutrients fit the empirical 
standard
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4.3.6. Intravenous lipid emulsions
Intravenous lipids were administered on 68 days (58%) in GH, on 355 days (90%) in 
TH, and on 132 days (55%) in ITH. Lipid emulsions were usually infused separately 
from the binary solutions (97.3% of 555 days when lipids were given). All cases of lipid 
administration as TNA occurred in one particular ITH (fifteen cases). Number of days 
when lipids were administered to neonates are shown in detail in Figure 4.9 for GH, 
Figure 4.10 for TH, and Figure 4.11 for ITH. The left hand chart represents 
prescriptions for days when less than 10% of concurrent enteral feeding was given (Full 
PN); the right hand chart represents prescriptions for days when between 10 and 50% of 
concurrent enteral feeding was given (Partial PN). The scale of the y-axis was not 
standardised in each graph due to the large differences of data collected in each type of 
hospital.
Figure 4.9 shows that lipids were more likely to be started on the first day in GH, if full 
PN was given.
Full PN GH Partia l PN GH
Lipid n o t g iv en  
Lipid g iven
2-3 4-6 7-9 >9
D ay of PN
2-3 4-6 7-9 >9
Day of PN
Figure 4.9: Number of days when lipids were administered in GH depending on concurrent enteral 
feeding
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In TH, lipids were administered on most days of PN, regardless of enteral intake (Figure 
4.10).





1 2-3 4-6 7-9 >9
Day of PN
E Lipid n o ! g iv en  
B  Lipid g iv en
1 2-3 4-6 7-9 >9
Day of PN
Figure 4.10: Number of days when lipids were administered in TH depending on concurrent 
enteral feeding
Figure 4.11 shows that in ITH, intravenous lipids were provided independently of 
enteral intake, and they were more likely to be provided at later stages of PN.
Full PN ITH Partia l PN ITH
2-3 4-6 7-9
Day of PN
I L ip ids n o t g iv en  
I L ip ids g iven
1 2-3 4-6 7-9
Day of PN




The volumes of enteral feeding given concurrently to PN was recorded. Enteral feeding 
was administered on 99 days (84%) in GH, on 227 days (57%) in TH, and on 113 days 
(47%) in ITH. In GH, enteral feeding was given as maternal breast milk on 93 days 
(94%), compared to TH where maternal breast milk was given on 178 days (78%). In 
ITH, enteral feeding was given as maternal breast milk on 90 days (80%). The use of 
enteral nutrition was analysed in more detail in surgical patients in TH and ITH.
Table 4.24 shows that significantly less enteral feeding was given to surgical patients. 
Values shown refer to the full course of PN, not just days before and after a surgical 
procedure.
kcal/kg/day Enteral nutrition intake
30 P








Table 4.24: Energy from enteral feeding administered in TH and ITH depending on surgery
4.3.8. Prescribed versus administered parenteral nutrition
In order to fully discuss nutritional intake, it is important to know how much of 
prescribed PN was actually administered to the patient. Disruption to intravenous 
infusion of PN had various clinical causes, e.g. blockage of lines, surgical procedures, 
deterioration of clinical condition, or the requirement to use more of the available 
amount of fluid for medication. Specific reasons were not researched for each day when 
the amount administered differed from the amount prescribed. Sometimes more than the 
prescribed amount of PN was administered (up to 178% on one occasion). Figure 4.12 
shows that, on average, more than 80% of prescribed amounts were administered.
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Figure 4.12: Percentage of administered amounts of binary solution versus prescribed amounts
Table 4.2 shows a more detailed breakdown of the number of days when different 
percentages of binary solution were administered, and it shows that on a substantial 





GH (N= 118) TH (N==395) ITH (N==239)
N % N % N %
>105% 4 3.4 27 6.8 3 1.3
95-105% 33 28.0 137 34.7 169 70.7
80-95% 40 33.9 111 28.1 34 14.2
50-80% 34 28.8 101 25.6 21 8.8
<50% 7 5.9 19 4.8 12 5.0
Table 4.25: Volumes of binary solution administered versus prescribed
In ITH, the compliance to the prescription is much greater with over 70% of days falling 
into the 95-105% group. The picture is very similar for the administration of lipid 





GH (N=68) TH (N=355) ITH (N=132)
N % N % N %
>105% 16 23.5 57 16.1 8 6.1
95-105% 19 27.9 136 38.3 93 70.5
80-95% 19 27.9 102 28.7 14 10.6
50-80% 11 16.2 43 12.1 12 9.1
<50% 3 4.4 17 4.8 5 3.8
Table 4.26: Volumes of lipid emulsion administered versus prescribed
4.3.9. Fluid intake
PN and EN were only one part of total amounts of fluids administered. Other intake 
included medication and clear fluids. In order to find out more about the role of PN in 
neonatal fluid management, total daily intake was recorded. It has to be pointed out that 
data collection only took place if neonates received more than half of nutrition from PN; 
therefore data will be biased towards a higher level of nutrition from PN compared to 
the overall neonatal population. Average amounts of fluids administered in GH are 
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Figure 4.13: Mean fluid intake in GH from binary solution, lipid emulsion, enteral feeds, and other 
fluids
Fluid intake in TH is shown in Figure 4.14. There was not a great difference between 
the weight groups regarding total fluids administered, but there was a small tendency to 
higher non-nutritional fluid intake.
Fluid intake was different in ITH compared to the UK (Figure 4.15). Non-nutritional 
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4.14: Mean fluid intake in TH from binary solution, lipid emulsion, enteral feeds, and other
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4.3.10. Total macronutrient intake
In Table 4.27, Table 4.28, and Table 4.29, daily amounts of macronutrient administered 
from both enteral and parenteral feeding were combined for GH, TH, and ITH 
respectively. Estimations of breast milk and enteral formulae contents are discussed in 
the methods section. Although both enteral and parenteral feeding were taken into 
consideration, intake of macronutrients in GH was lower than prescribed amounts of PN 
alone (Table 4.27). The average amino acid intake was below 2 g/kg/day, but average 
lipid intake was reached 3 g/kg/day after nine days of PN.
GH 1st Day 2nd-3rd Day 4*-6ih Day 7th-9th Day >9th Day
(per kg/day) N=26 N=45 N=29 N=8 N=10
Amino acids (g) 0.9 ± 0.5 1.5 ±0 .5 1.9 ± 0 .4 1.6 ±0.5 1.7 ± 0 .6
Glucose (g) 9.3 ± 3.4 12.0 ± 3 .7 13.7 ± 2 .8 15.0 ±4.1 12.6 ± 2 .7
Lipids (g) 0.8 ± 0.9 1.4 ± 1.2 2.1 ± 1.4 2.5 ± 1.8 3.0 ± 1.6
Table 4.27: Total macronutrient intake in GH (enteral and parenteral feeding)
In TH, amino acid intake reached 2.6 g/kg/day after 
Intake was overall very variable.
nine days of PN (Table 4.28).
TH 1st Day 2nd-3rd Day 4th-6th Day 7th-9th Day >9th Day
(per kg/day) N=37 N=95 N=107 N=82 N=69
Amino acids (g) 1.2 ± 0 .6 1.9 ± 0 .7 2.2 ± 0 .8 2.3 ± 0.6 2.6 ± 0 .8
Glucose (g) 8.2 ±3 .3 10.6 ± 3 .2 12.6 ± 3 .8 13.2 ±4 .3 13.4 ± 3 .6
Lipids (g) 0.6 ± 0.7 1.5 ± 1.0 2.3 ± 1.2 3.0 ± 1.3 3.2 ± 1.1
Table 4.28: Total macronutrient intake in TH (enteral and parenteral feeding)
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Results were similar in ITH, but fewer lipids were given than in TH (Table 4.29).
ITH
(per kg/day)
1st Day 2nd-3rd Day 4 m-6th Day 7th-9th Day >9m Day
r*~iIIZ N=66 N=66 N=38 N=36
Amino acids (g) 0.9 ± 0.5 1.6 ± 0 .7 2.3 ± 0.8 2.7 ± 0 .7 2.7 ± 0 .5
Glucose (g) 6.6 ± 2 .9 9.8 ± 3 .9 13.4 ± 4 .8 15.3 ± 4 .2 15.1 ± 5 .4
Lipids (g) 0.3 ± 0 .4 0.9 ± 0 .9 1.6 ± 1.5 1.9 ± 1.2 2.0 ± 1 .3
Table 4.29: Total macronutrient intake in ITH (enteral and parenteral feeding)
4.3.11. Energy intake
Total energy intake can be estimated from enteral and parenteral macronutrient intake 
using the conversion factors described in the methods section (4.2.8). Figure 4.16 shows 
how much energy was given to neonates in the three types of hospitals in the form of 
amino acids, glucose, and lipids. Intake was lower in ITH than in GH and TH during the 
first few days of PN. The average energy intake at later stages of PN is very similar in 
all three types of hospitals at around 80-90 kcal/kg/day.
100 .00 -
H  Amino acids (kcal/kg/day) 
DU Glucose (kcal/kg/day)
§3 Lipids (kcal/kg/day)
Figure 4.16: Total energy administered from parenteral and enteral feeding
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Figure 4.19: Total energy intake from EN and PN in neonates > 1500 g body weight
4.3.12. Comparison of energy intake with recommended intake
Total daily intake of energy was compared with recommended intake for each neonate. 
As true measurement of energy requirements (i.e. measurement of energy expenditure at 
the bedside) had not been undertaken, several estimations and simplifications had to be 
made:
1) Calculations were based on body weight only
2) Gestational age was not taken into consideration for the calculation
3) Other clinical factors, such as sepsis, surgery, ventilation or critical illness, were not 
adjusted for
4) Enteral and parenteral requirement were not considered separately (parenteral 
requirement are slightly lower, as energy is not required for digestion)3
Nearly all neonates were premature (94%) and calculations of energy requirements were 
based on published recommendations for premature infants.1 These recommendations 
state that stable premature infants should be given 100-120 kcal/kg/day to. The lower 
end of this guideline was used (i.e. 100 kcal/kg/day), to show ‘worst case scenario’.
It is important to point out that the following figures have to be considered taking the 
simplifications above into consideration.
Data are shown as energy deficits per kg per day (Figure 4.20-Figure 4.22).
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Figure 4.20 shows how the deficit in energy intake decreases with increasing age in 
neonates weighing less than 1000 g. After ten days of life, the daily energy deficit 
ranges from 20 kcal/kg in GH to less than 10 kcal/kg in ITH.
<1000g
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Figure 4.20: Energy deficit (kcal/kg/day) in neonates <1000 g body weight
Neonates weighing between 1000 and 1500 g showed a similar pattern of reduction in 
energy deficits, but it is interesting to note that in GH and ITH the deficit increased 
again after the first week of life (Figure 4.21).
1000 - 1500g
75 .0 0
■ =  50.00
> ,2 5 .0 0 Age 
■  1 d a y  
□  2-3  d a y s  
IS  4-6  d a y s  
E3 7-9 d a y s  
0  <9 d a y s
Figure 4.21: Energy deficit (kcal/kg/day) in neonates 1000-1500 g body weight
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For neonates weighing more than 1500 g a similar development in energy balance can 
be seen (Figure 4.22). Data were not available for the first day of life and after nine days 
of life in GH.
> 1 5 0 0 g
7 5 .0 0 ^
GH TH ITH
Figure 4.22: Energy deficit (kcal/kg/day) in neonates >1500 g body weight 
4.3.13. Weight gain during the course of the study
The last section showed that, on most days of PN, neonates were given less than the 
recommended energy. In order to find out if this had an effect on overall weight gain, 
the body weight of neonates was analysed over the course of the study. Figure 4.23 
shows how the average weight change was distributed in the three different weight 
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Figure 4.23: Changes in average body weight (g) in the three types of hospitals and for three 
different birth weight groups
In GH, no weight change was on average observed. Neonates weighing less then lOOOg 
showed a trend of weight loss of 80-120g. In TH and ITH, infants >1500g showed a 
weight loss trend. Weight change for infants <1500g was minimal in both TH. In ITH 
on the other hand, infants < l500g showed a relatively wide distribution of both weight 
gain and weight loss.
Although this comparison of weight gain is a useful indicator of trends, this data has to 
be viewed with caution. Neonates were enrolled into the study at different points in their 
first month of life, and data for each neonate were collected for any length of time (from 
one to fourteen days). The medians and interquartile ranges in the figure above thus do 
not represent weight change on a homogenous time scale. Additionally, neonates were 
not weighed every day. As a result, a lack of weight change in some cases might be 
related to a lack of up-to-date information.
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4.3.14. Ratio of amino acids and energy intake
Amino acids can only be utilised efficiently by the body if adequate energy is provided 
in the form of carbohydrates or lipids.22 Non-protein energy intake for neonates in this 
study was always above the recommended ratio (Figure 4.24).
Figure 4.24: Non-protein energy and amino acid ratio (reference line represents minimum 
recommended ratio)
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4.3.15. Use of standard solutions
Standard PN was used in half of the centres included in this study. Of those, four centres 
exclusively used StSol, whereas the other hospitals use StSol in combination with 
individualised PN.
StSol were used on 42% of all PN days studied. In the three types of hospitals, the use 
of StSol was distributed as follows: GH 39 of 118 PN days (33%), TH 212 of 395 days 
(54%), and ITH 63 of 239 days (26%). Standard PN and non-standard PN were 
compared in terms of prescribed amounts of macronutrients and total energy intake 
(Table 4.30).
Prescribed macronutrients per Non-standard Standard Kruskal-Wallis
kg per day N Mean ± SD N Mean ± SD X2 P
Amino acids (g) 438 2.0 ± 0 .8 314 2.1 ±1.0 0.0 0.853
Glucose (g) 438 12.4 ± 4 .2 314 11.6 ± 3 .4 6.4 0.011
Lipid (g) 315 2.0 ± 1.1 239 1.7 ± 1.0 10.7 0.001
Table 4.30: Comparison of prescribed macronutrients and total energy intake between standard 
PN and non-standard PN in all hospitals
Amino acid prescriptions did not differ significantly between the two groups, whereas 
glucose and lipid prescriptions were significantly lower in the standard group.
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4.3.16. Intravenous lines
As part of the study the types of intravenous line used to administer the binary solution 
was investigated. Lines were classified as either having the tip in a central vessel or in a 
peripheral vessel. The location of line entry into the body was not recorded.
Type of line GH (N=118) TH (N=395) ITH (N=239)
N % N % N %
Central line 59 64 141 78 140 59
Peripheral line 33 36 39 22 99 41
No information 26 - 215 - 0 -
Table 4.31: Frequency of central and peripheral catheter use for PN administration
It is evident from Table 4.31 that central lines were used most frequently. It is important 
to note that many data are missing from UK hospitals. The nature of data collection was 
retrospective and medical records and fluid charts did not always provide information 
about the type and location of lines used to administer PN. In ITH, data collection was 
prospective, and no data are missing. Peripherally located lines were more often used in 
ITH.
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4.4. Discussion - Methodology
This study allowed a comparison of prescribing practice in ten UK hospitals and six 
European hospitals by means of an audit. It offered insight into nutrition management 
for neonatal patients in the UK and in Europe.
The following critical considerations of the methodology have to be highlighted:
1) Hospitals in the UK were included based on their response to an initial invitation.
This inclusion method can have the disadvantage of response bias. Responding hospitals 
might have been more likely to have a special interest in neonatal nutrition. It is 
therefore possible that results from these hospitals might reflect better than average 
practice.
2) Within the UK, one monitor collected data retrospectively, whereas in Europe 
prospective data collection took place by monitors in each centre. In order to minimise 
potential diversification of collected data, standard protocols and data collection forms 
were used, and monitors were personally instructed in the use of the study 
documentation. An electronic data collection tool was also used to minimise data 
transcription errors.
Although these measured have been implemented, the comparison between 
retrospectively and prospectively collected data has to be undertaken with care. 
Prospective data collection had the advantage that the data collectors did not have to 
rely on medical notes, but were able to check prescribed and administered nutrition at 
the bedside. On the other hand, prospective data collection could have introduce bias 
into the way PN was prescribed and administered, as medical, nursing, and pharmacy 
staff was aware that the audit was taking place.
Retrospective data collection had the advantage that practice was unbiased, and that 
data collection time was greatly reduced. On the other hand, all information had to be 
extracted from notes, which meant that clarification of, for example catheter locations, 
was not possible. This was particularly true in cases were neonates had already been 
discharged by the time data were collected.
In conclusion, differences between GH/TH and ITH have to be interpreted taking these 
limitations into consideration.
In order to reduce differences between UK and ITH data collection, it would have been 
advisable to choose either retrospective or prospective data collection and not both.
3) Data were collected for a maximum of 15 days per neonates, in order to reduce the 
risk of weighing data towards a small number of patients. This meant that the study was 
not able to investigate long-term PN practice in neonates. In order to capture long-term
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PN, a separate study needs to be undertaken, which focuses only on neonates receiving 
PN for more than a fortnight.
4) This study evaluated PN practice for 142 neonates, and 752 nutrition days were 
analysed. Many subgroups had to be analysed, for example for differing weight, 
nutrition days, or clinical conditions. This meant that in some subgroups only one or 
two patients were represented. In conclusion, the overall number of nutrition days was 
large, but taking the subgroups into consideration, the sample size was relatively small. 
Extrapolation of results has to take this limitation into consideration.
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4.5. Discussion - Results
This study has investigated prescribed PN, administered PN, EN, total fluids, and StSol 
in neonatal patients. Different types of hospitals in the UK and Europe were included in 
order to obtain information from a large population of patients. Between centres, 
neonates did not differ significantly in birth weight, gestation, or Apgar scores; 
therefore differences in prescribed nutrition and nutritional intake were likely to reflect 
true differences in prescribing practice. Most neonates were bom prematurely and many 
were small for gestation (Figure 4.1). Surgical neonates in TH and ITH were analysed 
separately.
PN was usually initiated on the second or third day of life, independent of birth weight. 
It has been recommended that, if clinically possible and indicated, PN should be started 
on the first day of life in preterm infants.1 Several explanations are possible for the 
slight delay in commencing PN found in this study (Figure 4.2). Due to the way in 
which data were collected, the next day of life commenced at midnight. Neonates bom 
in the evening, who received PN the next morning, were classified as having received 
PN on the second day of life, even though PN was given within 24 hours of birth. In 
many cases, PN might not have been indicated immediately after birth, for example if 
difficulties in enteral feeding only became apparent after several days.
One of the objectives of this study was to explore the diversity of prescribing practice. 
Volumes of binary solution prescribed were variable, but there was a steady increase 
over the first six days, ranging from around 80 mL/kg/day on the first day of PN to 130 
mL/kg/day at later stages of PN (Table 4.5-Table 4.7). Overall, prescribed volumes 
were lower in ITH, reaching only 114 mL/kg/day after nine days of PN.
A decrease in the volume of binary solution was observed at seven to nine days of PN in 
TH. This was most likely related to an increased volume of concurrent enteral feeding. 
Table 4.8 shows that differences between the three types of hospitals were significant on 
the majority of days. In ITH prescribed volumes of binary solution were significantly 
lower compared with GH and TH until day seven of PN. Prescribed amounts of amino 
acids in TH were significantly higher in TH compared with GH and ITH.
Volumes of binary solution prescribed depended on the patients’ fluid balance, on 
enteral feeds, and on other fluids administered, for example as diluents for intravenous 
medication. Fluid balance depends on the infant’s maturity, medication, and external
1 9factors such as phototherapy or incubators. It is therefore not surprising that prescribed 
volumes of binary solutions were variable. Differences seen between the three types of
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hospitals are probably related to differences in the way fluid balance was managed. The 
largest difference in prescribing practice can be seen in amounts of amino acids 
prescribed. Current recommendations for amino acid intake for term infants is 2.5 
g/kg/day and up to 3.9 g/kg/day for infants weighing less than 1500 g.1 Mean birth 
weight of infants in this study was 1459 g, and many of them could have been expected 
to have amino acid requirements of up to 3.9 g/kg/day, especially those who were small 
for gestation. The highest average amount of amino acids prescribed in GH was 2 
g/kg/day. Additional amino acids were administered via the enteral route, but analyses 
of total intake shows that this reached a highest average 1.9 g/kg/day. A recent review 
of nutrition support of very-low-birth weight infants recommends that 2.5 to 3 g of 
amino acids should be administered from the first day of PN.142 Although more than this 
level of amino acids were prescribed and administered in TH and ITH, the levels were 
still below current recommendations. The relatively low amounts of prescribed amino 
acids in this study might be a result of earlier concerns that high amino acid intake by 
infants might cause metabolic disturbances.144 Recent studies have however shown that 
intakes of 3.5-4 g/kg/day are safe even in extremely low-birth-weight infants
(<1000g).31’141
Prescribed and administered amounts of glucose were similar across all hospital types. 
Recommended intake for premature infants is 14-18 g/kg/day, but it depended on 
metabolic tolerance. Insulin can be used to control hyperglycaemia in infants in order to 
ensure sufficient energy intake.1,32 The use of insulin has not been recorded in this 
study, but it appears that prescribed amounts of glucose were within current 
recommendations and were typically given in sufficient amounts to allow effective 
nitrogen retention.
Lipids form an important part of PN, especially if enteral feeds are not provided. Lipids 
are not only a highly caloric source of energy; they also provide essential fatty acids.
The recommended intake for infants is 0.5-1.0 g/kg/day on the first day, followed by 
progressive increase to 3 g/kg/day. Essential fatty acid deficiency can be avoided with 
0.5 g/kg/day.145 Highest amounts of lipids prescribed were 2.2 - 2.6 g/kg/day, but on 
many days no lipids were prescribed at all, especially during the first three days of PN. 
Lipids were prescribed most readily in TH, and lipids were part of the prescription on 
the first day of PN on twenty out of thirty-seven days. Highest total intake of lipids 
could also be seen in TH, where average intake reached 3.2 g/kg/day after nine days of 
PN.
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Data were further analysed to take into account that prescriptions might have differed 
for different groups of infants (Table 4.9-Table 4.11). Literature recommendations 
differentiate between amino acid needs of infants < 1500 g and term infants (3.5 versus
2.5 g/kg/day),1 whereas recommended intake for glucose and lipids are similar for both 
groups. In this study, body weight did not appear to be a reason for differences in PN 
prescriptions. Only a slight tendency to prescribe more amino acids to smaller infants 
could be identified in TH and ITH.
The effect of body weight on prescribing practice was further analysed by one-way 
analysis of variance (Figure 4.3-Figure 4.8). In the previous section (4.3.3), body weight 
and day of PN had been considered separately. Analysis of variance enabled the 
comparison of both factors at the same time, i.e. are neonates of different body weight 
prescribed nutrients differently during the progression of PN? Analysis of variance 
could, for example, detect, whether smaller neonates are first prescribed less 
macronutrients, but then, after several days of PN, are prescribed more than neonates 
weighing more then 1500g. This analysis gave a graphical display of the relationship 
and also an analysis of statistical significance.
Amino acid and lipid prescriptions did not change significantly with body weight. There 
was, however, a significant interaction between day of PN and body weight in both TH 
and ITH for glucose prescriptions. In TH, neonates weighing more than 1500 g were 
prescribed more glucose than smaller neonates between days four and nine, but less on 
days one to three and after nine days. In ITH, neonates below 1500 g were prescribed 
similar amounts of glucose, but neonates weighing more than 1500 g were initially 
prescribed less, and then, after four to six days, more glucose than smaller neonates.
It is possible that this was related to an accelerated glucose tolerance in more mature 
neonates.
It had been estimated that macronutrients in PN prescriptions would be increased if no 
concurrent enteral feeding were given. In GH and TH, prescriptions did not differ for 
neonates on full or partial PN (Table 4.12 and Table 4.13). In ITH, however, 
significantly more amino acids were prescribed to neonates on full PN until nine days of 
PN (Table 4.14). On some days, more glucose was prescribed, but lipid prescriptions 
were not affected by enteral feeding.
A fifth of neonates in TH and a quarter of neonates in ITH had undergone surgery. 
Separate analyses of PN prescriptions in this group of patients showed consistently
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higher amounts of prescribed macronutrients, particularly lipids (Table 4.15). These 
results are not surprising, as metabolic studies have found that increased lipid provision 
reduce the CO2 load compared to equivalent amounts of energy from glucose.146 This 
might be particularly important in infants suffering from respiratory problems. Overall 
energy requirements have not been found to be increased in surgical infants.138 In TH, 
surgical infants were significantly more mature at birth than non-surgical infants. 
Differences in prescribed amounts of macronutrients might therefore be related to the 
increased maturity and not to the surgical procedure itself. However, this is unlikely, as 
this study has shown that prescriptions did not differ greatly for neonates of different 
weight.
It is important to note that overall neonates were grouped as surgical patients, and all 
their nutrition days were analysed as surgical days, i.e. pre- and post surgical days. It is 
possible that small nutritional differences between surgical and non-surgical neonates 
can only be detected if  post-surgical days are specifically investigated.
Prescribed macronutrients and total energy intake were compared for neonates who 
received StSol and then compared to those who received individually prescribed and 
compounded solutions. Amino acid prescriptions did not differ significantly, but 
amounts of glucose and lipids were lower in the group receiving StSol. This is an 
important finding that highlights the fact that the use of StSol must be investigated 
thoroughly in order to ensure that nutritional intake in not compromised.
Prescribed amino acids and glucose were also converted into concentrations in order to 
compare findings in this study with an empirically derived StSol, with literature reports, 
and with results from earlier work during this project.
Comparison of prescribed macronutrients with a theoretical standard showed that 
agreements between the two were very low (Table 4.19-Table 4.23).
As previously mentioned, comparison of actual prescribing practice with an empirical 
StSol was based on a pilot study undertaken by Beecroft and colleagues.143 They 
investigated how often prescribers deviated from computer software recommendations. 
Results showed that 82% of prescription deviated from computer recommendations. 
Changes were most frequently made to amounts of glucose, sodium, and phosphate. 
Beecroft and colleagues conclude, however, that, with suitable adjustments to the 
computer recommendations, up to two-third of all prescriptions could be met by a 
limited range of StSol. These adjustments were mainly related to increased 
carbohydrate, sodium, and phosphate prescription, which indicates that the original
108
computer guidance were not suitable. Computer recommendations for phosphate were, 
for example lmmol/kg/day, which frequently lead to hypophosphataemia.
In contrast to Beecroft and colleagues findings, this present study found that 
macronutrient prescriptions deviated greatly from an empirically derived StSol. 
Prescriptions were usually for lower amounts of macronutrients compared to the StSol. 
This disagreement requires further investigation, especially with regard to the clinical 
feasibility of using the higher concentrated formula.
This study has also shown that prescribed PN volumes were variable and differed 
greatly between the three types of hospitals. Hospitals previously surveyed (chapter 3 of 
this thesis) reported that their StSol contained 1.2-1.7 g/100 mL amino acids and 10-
12.5 g/100 mL glucose. Suggestions for potentially suitable neonatal StSol were on 
average higher for both amino acids (2.5 g/100 mL) and glucose (14 g/100 mL). 
Literature reports show that neonatal StSol often contained 10 g/100 mL glucose and 
amino acid concentrations that ranged from 1.8 g/100 mL to 2.6 g/100 mL.102,105
This study has shown that, in GH, mean amino acid concentrations were very similar to 
those reported in the literature, ranging from 1.2-1.6 g/100 mL. Average concentrations 
in TH reached 2.7 g/100 mL and in ITH 3.1 g/100 mL. Similarly, mean glucose 
concentrations in GH were 8.4-12.4 g/100 mL in GH, 9.3-15 g/100 mL in TH, and 10.5-
14.5 g/100 mL in ITH. Higher concentrations of amino acids in ITH are related both to 
larger amounts of amino acids and reduced volumes of binary solution prescribed.
This comparison of results from the survey (chapter 3 of this thesis) with prescribed 
amounts of macronutrients and PN volumes highlights the fact that the introduction of 
StSol needs to take individual hospitals’ prescribing practice and fluid management into 
consideration in order to ensure that sufficient amounts of nutrients are provided.
This first part of the study investigated prescribed PN and compared prescriptions for 
neonates of different weight or clinical situation. Prescriptions were also compared for 
neonates on partial and full PN. In order to obtain a more detailed picture of neonatal 
clinical nutrition, other factors had to be considered, for example the amount and type of 
concurrent enteral feeding. It was also considered important to investigate how much 
total energy and nutrients were administered each day. This was calculated from 
amounts and type of enteral feeding given and from the amounts of PN administered. 
Subsequently, this calculation allowed an accurate comparison of nutritional intake with 
currently recommended intake in the literature.
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Enteral feeding was given concurrently with PN on the majority of days in GH and on 
about half of PN days in TH and ITH. The lower prevalence of enteral feeding in TH 
and ITH could be explained by the fact that surgical neonates who received less EN 
were treated in these two types of hospitals. It has been recommended that enteral feeds 
should be administered concurrently to PN as soon as clinically possible, and as little as 
0.5 mL/kg/day has been shown to be beneficial.1
In order to measure total PN intake, the difference between prescribed and administered 
PN was recorded. Previous studies of administered amounts of enteral feeds in adults 
showed that 61% of patients received more than 75% of prescribed volumes.147 It is 
difficult to extrapolate these results to PN in neonatal intensive or special care, but they 
give an indication that this is an important problem that needs to be recognised when 
providing special nutrition support. Others investigated adherence to prescriptions in 
adult intensive care and found that low amounts of initially prescribed nutrition were 
reduced further by the fact that ten percent were on average not administered.148 They 
discovered, however, that insufficiently prescribed amounts of nutrition played a more 
important role in underfeeding than the discrepancy between administered and 
prescribed amounts. This study found that in some cases less than 50% of prescribed PN 
was administered (Table 4.25 and Table 4.26). In those cases, discrepancies between 
prescribed and administered PN can potentially lead to significant underfeeding.
Results from this study show that PN was in most cases administered in satisfactory 
amounts, i.e. more than 80% of prescribed volume. It is, however, important to note that 
neonates in the UK received less than 80% of prescribed PN on approximately 30% of 
nutrition days studied. This discrepancy, together with initially low amounts of 
prescribed macronutrients, might have contributed to a significant under-provision of 
nutrients in some instances. Although these results can give an indication of the extent 
of deviation from the prescription, reasons for this have not been investigated. In order 
to develop recommendations for potential improvements in this area, more detailed 
prospective studies have to be undertaken.
Total energy intake was very similar in the three types of hospitals (Figure 4.16). 
Interestingly, energy intake from lipids was lower in ITH than in TH and GH. This was 
most likely related to the fact that intravenous lipids and enteral feeds were given on 
fewer days in ITH.
110
Amino acids can only be utilised efficiently by the body if adequate energy is provided
99in the form of carbohydrates or lipids. Data extrapolated from animal studies and adult 
PN patients suggests that 20 non-protein kcal/g amino acids are sufficient for amino 
acid utilisation.22 This study found that non-protein energy intake for neonates was 
always above the recommended ratio (Figure 4.24).
PN can be given through a central or peripheral line. The choice of line depends on the 
availability of venous access, osmolarity of the solution for infusion, and estimated 
length of time of line use.149 Central venous access was mainly used in the population in 
this study (Table 4.31). A surprising finding during the course of this study was the 
difficulty in retrospective identification of the type of venous access used in the UK. 
Neonates’ fluid charts did not always specify the type of line used for binary solutions 
or lipid emulsions. This problem did not arise in ITH, because data collection was 
prospective. It would appear that the recording of the catheter location forms an 
important part of documentation in neonatal care, and that this would be important for 
reasons of accountability and clinical governance.
This means that a comparison between ITH and the other hospitals in the UK is not 
possible. Furthermore, no detailed definition of ‘central catheter’ was offered in the 
study protocol. Hospitals’ own interpretation of central and peripheral lines was 
adopted, as it was not known at the time that differences in interpretation exist. As a 
result it is, for example, not known whether femoral groin access was considered to be 
central or peripheral.
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5. Optimising intravenous lipid administration for neonatal 
and paediatric patients
5.1. Introduction
The administration of fatty acids in the form of lipid emulsions is essential in order to 
provide essential nutrients and high-density calories.1 Lipid emulsions are typically 
given in the form of TNA to adult patients. This has been shown to be cost effective and 
safe, and the stability of these complex emulsions has been thoroughly studied.56,118,150 
In paediatric patients, however, lipid emulsions are usually given in the form of separate 
infusions, as highlighted in the preceding two chapters. The reasons for this have been 
multifactorial including: emulsion stability concerns related to high concentrations of 
calcium and magnesium,18 and the historical assumption that TNA would provide an
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excellent growth medium for microbial contaminants. It has since been shown that 
TNA supports microbial growth no more than glucose 5% solutions for most 
nosocomial pathogens.119 Rollins and colleagues have also shown that TNA can be used 
safely in infants and that it provides a more cost effective way of administering lipids. 
Another reason to give lipids separately has been the concern that calcium phosphate 
precipitates would not be visible in TNA. Precipitation of calcium phosphate has been 
of major stability problem in paediatric PN. This issue lead to a safety alert by the Food 
and Drug Administration, after several death in 1994 were linked to infusion of calcium 
phosphate particles.151 Since then, organic phosphates (e.g. glucose-1-phosphate, 
glycerol phosphate, fructore-1,6-phosphate) have become available that allow safe 
provision of calcium and phosphate in one solutions with a greatly reduced risk of 
precipitation.46 It appears that this problem has now been largely addressed.
A more recent concern has been the formation of lipid peroxides in PN. Their detection 
is discussed controversially, as shown later in section 5.1.4.
This laboratory study was conducted to test whether or not TNA contain less 
peroxidised lipids than lipid emulsions alone and to thereby provide a new aspect in the 
discussion surrounding the administration practice of lipids in neonatal and paediatric 
patients.
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5.1.1. Reactive oxygen species
Aerobic organisms derive their energy from the reduction of oxygen, and, in the 
process, highly reactive oxygen intermediates are formed, e.g. O’ { (superoxide), OH* 
(hydroxyl radical) and H2O2 (hydrogen peroxide). These species, together with unstable 
intermediates in the peroxidation of lipids, are referred to as reactive oxygen species 
(ROS).152 Although O’ {  and H2O2 are able to cause cellular damage, they are weak 
oxidants in aqueous solutions. Their importance with regard to the pathophysiologic 
role of ROS is that they are substrates in the formation of hydroxyl radicals (OH* ).153 
Hydroxyl radicals are formed when superoxide and hydrogen peroxide react to generate 
oxygen and hydroxyl radicals:154
Fe2+ + H2O2 -> Fe3+ + OH* + OH' (Fenton Reaction).
In 1934, Haber and Weiss proposed that superoxide and hydrogen peroxide could react 
to form the hydroxyl radical:154
O* 2 + H2O2 ->02  + OH’ (Haber-Weiss reaction).
It has since been shown that this reaction is only likely to occur in-vivo if transition 
metals are present to act as catalysts.154
The hydroxyl radical is highly reactive and able to react with many organic molecules; 
thus it plays a pivotal role in causing oxidative damage to in-vivo systems.154
ROS are part of normal aerobic life, and systems are in place to scavenge those highly 
reactive substances. Hydrogen peroxide has been shown to play an important part in the 
formation of hydroxyl radicals. As a result, it is advantageous for in-vivo systems to 
control the amount of hydrogen peroxides present.154 There are two specific enzymes 
designed to remove hydrogen peroxides: catalases and peroxidases.154 Catalase is 
present in most aerobic cells and inactivates hydrogen peroxides by the following 
reaction:
2 H20 2 > 2 H 20  + 0 2.
Glutathione peroxidase is the most abundant of the various peroxidases. The substrate 
glutathione (GSH) is a simple tripeptide (glutamic acid -  cysteine -  glycine) that is
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present in its oxidised from as a GSH dimer joined with a disulphide bridge (GSSH). 
Once GSH has been oxidised to GSSH, glutathione reductase catalyses the reaction to 
reduce GSSH back to GSH.154
Another important ROS is superoxide. This species is inactivated by superoxide 
dismutase. Superoxide is the specific substrate for superoxide dismutase, and the 
dismutase is most abundant as copper-zinc containing enzyme. Superoxide is 
inactivated by the following reaction:154
O' i  + O' 2 + 2H+ -> H20 2 + 0 2.
Other non-enzymatic molecules are able to protect in-vivo structures from damage by 
ROS. Ascorbic acid is a potent electron donor and plays a role in various anti-oxidative 
pathways. Its key roles include keeping metal ions in hydroxylase enzymes in the 
reduced form, detoxifying organic radicals in-vivo, and reacting readily with ROS 
(including superoxide and hydroxyl radicals).154
When reduced, ascorbic acid forms semi-dehydro-ascorbic acid and dehydro-ascorbic 
acid (DHA) (Figure 5.1). Further breakdown of DHA eventually produces oxalic acid.
HO OH 0 2




Ascorbic acid Dehydro-Ascorbic acid (DHA)
Figure 5.1: Reversible oxidation of ascorbic acid to dehydro-ascorbic acid
In order to prevent the formation of toxic oxalic acid, organisms have evolved systems 
to revert DHA back into ascorbic acid. The enzyme involved in this process is DHA 
reductase. Despite these important anti-oxidative properties, ascorbic acid has also been 
linked to pro-oxidative reactions, such as the formation of hydroxyl radicals via the 
Fenton reaction.154 This occurrence is dependent on the concentration of ascorbic acid. 
Another non-enzymatic scavenger is GSH. GSH is not only a substrate for glutathione 
peroxidase, but also a direct scavenger of hydroxyl radicals.154
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5.1.2. Lipid peroxidation
Lipid peroxidation has been defined as the ‘oxidative deterioration of polyunsaturated 
lipids’.154 This event can be initiated by hydrogen extraction from a methylene group by 
hydroxyl radicals.

















Figure 5.2: Formation of peroxyl radicals from unsaturated fatty acids
This process is called ‘first-chain initiation’. Peroxy radicals can then react further by 
extracting hydroxyl radicals from methylene groups of other fatty acid chains. This 
chain reaction is called the ‘propagation stage’ of lipid peroxidation. The process of 
lipid peroxidation occurs not only in biological membranes, but also in food lipids.154 
The most important antioxidant in the peroxidation of lipids is the chain breaking a- 
tocopherol (Figure 5.3) (although p, y and 8-tocopherol also have some antioxidant 
activity).
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Figure 5.3: Chemical structure of a-tocopherol
Tocopherols are lipophilic substances that are embedded into the structure of biological 
membranes. They are able to react with lipid peroxy radicals by donating their labile 
hydrogen and forming the relatively stable tocopheryl radical. In order to reduce the 
radical back into tocopherol, a synergistic activity by ascorbic acid has been 
suggested.154
5.1.3. Oxidative stress and parenteral nutrition
In-vivo, an imbalance between pro-oxidant and anti-oxidants in favour of the pro-
1 Ooxidant sometimes occurs. This imbalance is called oxidative stress.
A number of clinical conditions have been linked to oxidative stress including 
atherosclerosis, multiple sclerosis, solar radiation injury, and rheumatoid arthritis. It has 
been questioned whether the increased levels of ROS measured in such conditions are 
primary causes of the disease or if they are secondary effects of cellular damage.154 
In paediatrics, a number of pathologies have been linked to oxidative stress including
1 SInecrotizing enterocolitis and retinopathy of prematurity. Premature infants were
found to have insufficient levels of superoxide dismutase and vitamin E. As a result, the
i s*!infants were more susceptible to biological damage from radicals and peroxides.
Wispe and colleagues first examined the role of intravenous lipid emulsions in 
contributing to oxidative stress in neonates in 1985.155 These investigators measured 
exhaled ethane and pentane in newborn infants receiving lipids intravenously and they 
found that the infusion of lipids increased the amount of expired pentane significantly. 
Subsequently, they suggested that one possibility for the increase in lipid peroxidation 
markers could be an increased level of LPO in the lipid emulsion in-vitro.
Hammerman and colleagues investigated the effect of lipid emulsions on outcome in 
premature infants in a randomised trial comparing infants receiving lipids with infants 
not receiving lipids.156 They found an increased incidence of retinopathy of prematurity 
in the lipid group. As a result of this work, they proposed that lipids should be given
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with caution during the first week of life. Additionally, they proposed that the increase 
of pathological events could have been related to prostaglandin-mediated events.
PN can contribute to oxidative stress either due to the peroxides present in-vitro, or due 
to in-vivo reactions to the intravenous administration of nutrients. Although it has not 
been shown directly that the administration of peroxidised PN poses a problem, it is 
considered undesirable.
Several groups have investigated in-vitro formation of peroxides, but it is currently not 
known which concentrations of peroxides are potentially damaging, nor how easily
/rr i cn i co
infused peroxides are scavenged in-vivo. ’ ’ It is also not known how effectively
different types of peroxides, i.e. lipid and hydrogen peroxides, are scavenged. Although, 
it has been suggested that hydrogen peroxides are more easily scavenged than lipid 
peroxides.66
In-vivo contribution of PN to oxidative stress is more complex. PN solutions are 
exposed to an oxygen-rich environment when entering the bloodstream, and as a result 
susceptible molecules, such as riboflavin and polyunsaturated fatty acids, could 
potentially be oxidised. Basu and colleagues found that oxidative stress generated by 
PN in infants could be reduced, by maximising the utilisation of infused lipids through 
concurrent reduction of glucose intake.159 Lipid peroxidation is not only important with 
regard to clinical and toxicological implications, but also with regard to pharmaceutical 
stability. Peroxidation leads to rancidity of lipids; therefore it is undesirable in terms of 
overall product quality.154
5.1.4. Quantification of peroxides
It is advantageous to know the level of contamination of intravenous lipid emulsions 
with LPO for several reasons. This knowledge allows assessment of pharmaceutical 
product quality, enables evaluation of strategies to reduce their formation, and supports 
the interpretation of in-vivo studies of oxidative stress related to PN.
Although the European Pharmacopoeia sets a limit for peroxides in intravenous lipids 
(see below),74 the clinical implications of peroxide administration from pharmaceuticals 
are less clear. Because PN is usually infused in large amounts and sometimes for very 
long periods of time, it is desirable that the concentration of in-vitro LPO is as low as 
possible.
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Various methods have been employed to quantify peroxides in-vitro. The European 
Pharmacopoeia’s method of choice to determine the peroxide value (milliequivalents of 
active oxygen in 1000 g of the substance) is by iodometric titration.74 The limit for LPO 
in Soybean oil for intravenous use is 5 mmol/kg oil. This is equivalent to 1 mmol LPO 
per litre of 20% lipid emulsion. Steger and colleagues adopted this method to determine 
in-vitro oxidation of intravenous lipid emulsions.160 The main disadvantages of this 
method were related to the large amounts of solvents required for each sample 
extraction (50 mL of chloroform and methanol mixture) and susceptibility of iodine to 
the presence of oxygen. The recovery of extracted LPO was 78% and the detection limit 
was 20 pM in 20% lipid emulsion. The standard used for comparison was cumene 
hydroperoxide. Lipid emulsions were stored for four weeks in EVA or 
polypropylene/polyamide containers for TNA, and LPO values of up to 3 mmol/L lipid 
emulsions were detected.
Others used the ferrous oxidation -  xylenol orange (FOX) method.66,161 This method 
measures the absorbance of a complex of ferric ions (which are formed from ferrous 
ions after oxidation with peroxides) with xylenol orange.
1 0f\Laborie and colleagues measured peroxides in TNA without prior extraction of lipids. 
As a consequence, this method did not distinguish between hydrogen and lipid 
peroxides. Silvers and colleagues have critically evaluated this approach, and they 
found that the FOX method is susceptible to the presence of ascorbate.161 The authors 
concluded that results showing that multivitamin solutions were a major contributor to 
the peroxide load in intravenous lipid emulsion were questionable. It has also been 
suggested that reliability of the FOX method is impaired by the fact that molar 
absorptivity of the ferric-xylenol orange complex vary with different makes of the 
dye.163
Other researchers have used high performance liquid chromatography (HPLC) to
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quantify LPO. Peroxides oxidise isoluminol in the presence of heme. Isoluminol is 
then quantified using post-column chemiluminescence. Method validation included the 
use of triphenylphosphine (TPP), a strong reducing agent, which quantitatively reduced 
LPO. The authors concluded that the response generated was specific to peroxides. 
Helbock and colleagues investigated LPO concentrations in freshly opened bottles of 
20% lipid emulsions, and found that they contained between 214 and 655 pM LPO. 
Silvers and colleagues also used this HPLC method to quantify LPO in lipid emulsions
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and found that in newly opened bottles LPO levels varied substantially, but were usually 
below 100 pM.66
Various factors, which can potentially influence the formation of peroxides in lipid 
emulsions, have been investigated in the literature, including natural light and 
phototherapy light, oxygen exposure, length of storage, different TNA formulae, and 
different types of lipid emulsions. 120’126,160’161,164‘166 Some researchers have also 
investigated peroxide formation during simulated infusion of lipid emulsions and 
TNA 66>126’165’166
After finding that addition of vitamins reduces the amount of total peroxides and LPO 
formed, Silvers and colleagues recommended that lipid emulsions should be mixed with 
multivitamins and administered via dark delivery tubing.66 In administration tubing 
exposed to phototherapy, LPO concentration ranged from 20 pM in light protected 
tubing to 50 pM in light exposed tubing.66 Total peroxides measured by the FOX 
method ranged from 120 to 270 pM.
Laborie and colleagues investigated the influence of light protection in more detail, 
especially with regard to the use of coloured administration tubing.126 They found that 
orange and yellow tubing provided suitable protection whilst allowing monitoring of air 
bubbles.
Lipid peroxidation has been investigated in great detail in biological materials, such as
1 ^ 9plasma and cell-cultures. Basu and colleagues measured plasma malondialdehyde 
(MDA) in surgical infants receiving PN.159 MDA is one degradation product of lipid 
peroxidation. Basu and colleagues compared plasma MDA concentration generated by 
two different PN regimens. Firstly, infants were given 3 g/kg/day of lipids and glucose 
infusion was reduced from 18 g/kg/day to 10 g/kg/day. Secondly, infants received 
constant amounts of glucose (18 g/kg/day), but lipid infusion of 3 g/kg/day was stopped. 
Results showed that the first PN regimen promoted lipid metabolism. The authors 
concluded that reducing glucose lipid ratio reduced reduces free radical formation in- 
vivo.
Other measurement techniques for biological samples include photometric 
quantification of conjugated dienes or thiobarbituric acid reactive materials and 
measurement of loss of fatty acids by HPLC.152 It is also possible to measure LPO in- 
vivo by quantifying exhaled hydrocarbon gases (using gas chromatography) that have 
formed during the decomposition of LPO.155
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5.1.5. Evaluation of the ferric thiocyanate assay
Shortcomings were discovered in the methods described in the literature for the 
quantification of LPO in PN solutions. These methods were either based on complex 
techniques, such as HPLC with post column chemiluminescence detection,164 or, in the 
case of the FOX method, have been criticised for being prone to interferences.66 
Measurement of LPO separately from hydrogen peroxides was also not common 
practice and required either special HPLC equipment or large quantities of solvents for 
iodine titration.
It was therefore decided to explore the literature further for novel methods of LPO 
detection. Measurement of LPO is common practice in investigations related to the in- 
vivo role of free radical damage. The ferric thiocyanate assay was one method chosen to 
this purpose. This assay is based on the redox properties of LPO, and it measures 
absorbance of ferric thiocyanate. Mihajevic and colleagues have evaluated this method 
with regard to the specificity of the response and the choice of standard for 
comparison. They found that hydrogen peroxides that are often used for calibration of 
analytical methods, such as tert-butyl hydroperoxide (TBH), cumene hydroperoxide, 
and H2O2, might lead to the overestimation of LPO due to the differences in response. 
No differences were found in the response between different LPO standards. They 
concluded that the ferrous thiocyanate method gave a rapid and complete measurement 
of peroxides of mono-, di-, and polyunsaturated acids in biological and food samples.
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5.1.6. Aims and objectives
The primary aim of this laboratory study was to contribute a novel aspect to the 
discussion of optimal intravenous lipid administration in paediatric patients. The 
question about whether to give intravenous lipids separately from the binary solutions or 
give them in the form of TNA has primarily focused on sterility issues.119 Other 
researchers have investigated the use of TNA in infants and children and found that 
TNA provided a safe, cost effective way of delivering lipids.119,129 
Various research groups have quantified both in lipid emulsions and in TNA lipid 
peroxidation. LPO generation was, however, never compared directly by the same 
analytical method in the same experimental setting.
In direct response to the unexplored territory, this study aimed to directly compare the 
two approaches to lipid administration in order to inform the discussion about whether 
to give lipids separately or as TNA in neonates or children.
Secondary aims of this study were related to laboratory method validation and to the 
application of a peroxide assay to PN solutions for the first time.
This pilot study aimed to validate a rapid and specific method for detecting in-vitro 
formation of LPO in lipid emulsions for PN. Interestingly, this method had previously 
only been applied to biological and food samples, and had not been applied to PN 
solutions.163 Method development and validation have been based on a report by
1 ATMihaljevic and colleagues.
This assay measures LPO after extraction into chloroform; therefore it is specific for 
lipid hydrogen peroxides. The standard used for comparison is the peroxide of linoleic 
acid, 13-(S)-HpODE (9,11- Octadecadienoic acid, 13- hydroperoxy [S-(E,Z)]) (Figure
5.4).
OOH
Figure 5.4: Chemical structure of linoleic acid peroxide (13-(S)-HpODE)
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After successful validation, the aim was to compare two commercially available lipid 
emulsions, currently in use for paediatric patients. These lipid emulsions were chosen, 
as the sponsor was able to provide the emulsions free of charge and the sponsor had 
previously undertaken work comparing these two emulsions.
Ivelip is made from soybean oil and contains 17% saturated fatty acids, 23% 
monounsaturated fatty acids, and 60% polyunsaturated fatty acids. ClinOleic is made 
from 80% olive oil and 20% soybean oil and contains 15% saturated fatty acids, 65% 
monounsaturated fatty acids, and 20% polyunsaturated fatty acids. Ivelip contains 11 
mg a-tocopherol per litre; ClinOleic contains 30 mg a-tocopherol per litre (details 
extracted from manufacturer’s product information).
Two chemical properties of lipid emulsions are important when considering their 
susceptibility to peroxidation: a-tocopherol content and concentrations of 
polyunsaturated fatty acids. By breaking the reaction chain, a-tocopherol reduces 
generation LPO.154 Polyunsaturated fatty acids are the most likely source for 
peroxidation.167 A high concentration of polyunsaturated fatty acids therefore 
potentially increases susceptibility for peroxidation.
Due to the differences in concentrations of polyunsaturated fatty acids (mainly as 
linoleic acid) and the differences in a-tocopherol concentrations, it was hypothesised 
that ClinOleic would generate fewer LPO than Ivelip.
The aim was also to apply this assay to clinically relevant PN solutions. This included 
measurement of LPO in lipid emulsions and TNA, assessment of the influence of 
administration procedures on the formation of LPO, and comparison of various 
environmental factors. Environmental factors of interest were also identified in the 
literature, and included type of container,160 storage time,160 light126 and oxygen160 
exposure.
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5.2. Materials and equipment
Materials and equipment used for this study are listed below.
5.2.1. Parenteral nutrition components
Baxter Healthcare, Compton, UK:
Batch Number Expiry
ClinOleic 20%, 100 mL 0201138 03/04
Ivelip 20%, 100 mL 0201137 03/04
Glucose 20% 500 mL 02J31BR 09/04
Primene 10% 100 mL 0201266 09/04
Primene 10% 250 mL 0201251 09/04
Sterile Water 1000 mL 02407B27 05/06
Fresenius Kabi, Runcorn, UK:
Batch Number Expiry
Peditrace 10 mL 021V23 09/05
Vitlipid N Infant 1006990AZ 04/04
Solivito N Lyophilisate JE0908 09/04
5.2.2. Compounding equipment
Baxter Healthcare, Compton, UK:
Batch Number Expiry
3-lead transfer set for PN 00K25030687 11/05
Beckton Dickinson, Oxford, UK:
Batch Number Expiry
Microlance 3 Needles 7602C03 03/07
5.2.3. Consumables
Beckton Dickinson, Oxford, UK:
Batch Number Expiry
Plastipak, Syringes 50 mL 7602C03 03/07
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BBraun Carex, Mirandola, Italy:
Batch Number Expiry
Evarex EVA (ethyl-vinly-acetate) 021460 10/07
bags 500 mL
Evarex barrier (layers of EVA and 021661 12/07
ethyl-vinly-alcohol) bags 500 mL
BBraun, Melsungen, Germany:
Batch Number Expiry
Discofix, 3-way tap 02K099204 10/05
Baxter Healthcare, Compton, UK:
Batch Number Expiry
Administration sets RMC9608 02K18V54DG 10/05
Fisher, Loughborough, UK: 
Eppendorf vials 1.5 mL 
1 mL pipette tips, certified 
200 pL pipette tips, certified
Anachem, UK:
Gilson certified pipettes 20, 100, 200, 1000 pL 
(Calibration certificates are enclosed in Appendix 10)
Elkay, UK: 





13(S)-HpODE 100 pg 188674
Polyphosphoric acid 18520a
4.5 mM ferrous sulphate




Fisher Chemicals, Loughborough, UK:
Batch Number
Chloroform, analytical grade 0253404
Methanol, HPLC grade 0270438
5.2.5. Equipment
Biomat AC class 2 sseptic cabinet, MAT, Manchester, UK 
(Validation certificate is enclosed in Appendix 9)
Astec Sensair Fume Hood, Astec Microflow, Andover, UK 
Laboratory fridge, LEC, UK
Vip series -86 Celcius Freezer, Sanyo Scientific, USA
Juan BR 41 Centrifuge
Vortex Mixer, Fisher, Loughborough, UK
SS 40-D Shaking bath, Grant, Cambridge, UK
Dynatec MR 500 Plate reader, Filter 490 nm, Dynatec, USA
BioLink 2.10 Plate reader software, Datatech Laboratories, Virginia, USA
Colleague Infusion pumps, Baxter Healthcare, Compton, UK
96-well plate, Zeiss, Jena, Germany
BOC Gases Nitrogen (Oxygen free), EEC 2317839
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5.3. Lipid peroxide assay
5.3.1. Synopsis
Lipid peroxides were quantified by redox reaction with ferrous ions. The resulting ferric 
ions were detected using thiocyanate ion as the chromogen:
ROOH + Fe2+ RO’ +Fe3+
RO' + Fe2+ + H+ -> ROH + Fe3+
Fe3++ 5SCN' -> Fe(SCN)52'
Ferric thiocyanate absorbs light at a wavelength of 490 nm and colour development was 
photometrically measured at this wavelength. Interferences from hydrogen peroxides 
were circumvented by performing the assay after extraction of lipids into chloroform. 
This assay is available from Cayman Chemicals as a kit for measurement of lipid 
peroxidation containing 13-(S)-HpODE, polyphosphoric acid, 4.5 mM ferrous sulphate 
in 0.2 M hydrochloric acid, 3% ammonium thiocyanate in methanol, and TPP.
5.3.2. Preparation
Solvents used were deoxygenated by bubbling with nitrogen for 30 minutes 
immediately prior to use. The analytical standard, 13-HpODE, was commercially 
available as a solution of 100 pg in approximately 100 pL ethanol. In order to obtain the 
appropriate concentration of standard, this solution was diluted by first removing the 
carrier solvent under a stream of nitrogen and then adding exactly 6.0 mL of ethanol. 
This diluted standard was stored at -80° Celsius. Samples were diluted with sterile water 
to a final lipid concentration of 2 mg/mL, i.e. lipid 20% solutions were diluted 1:10 and 
TNA solutions were diluted 1:100. Explorative experiments had shown that higher 
concentrations of lipids adversely affected the repeatability of the analytical response.
5.3.3. Extraction process
To begin, 500 pL of appropriately diluted sample were transferred into 2 mL plastic 
vials in triplicate. Next, 500 pL of a 6.7% solution of polyphosphoric acid in methanol 
were added. To this, 1 mL of cold chloroform was added. After thorough mixing by 
vortex, the mixture was centrifuged at 0° Celsius for 5 min at 4000 rpm.
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The upper aqueous and protein layers were removed and discarded from the vial, and 
approximately 800 pL of the bottom chloroform layer was transferred into a fresh 1.5 
mL vial. Exactly 500 pL of this extract was transferred into a fresh vial. To this, 450 pL 
of a 2:1 chloroform -  methanol mixture was added. Finally, 50 pL of chromogen was 
added to give a final volume of 1 mL in each vial.
5.3.4. Sample measurement
After leaving the samples for a minimum of 5 minutes (and no longer than 30 min) at
room temperature, 300 pL of each sample was transferred onto a 96-well glass plate.
Each sample reading was accompanied by a standard reading to take into account 
potential fluctuations in colour development due to temperature or residual oxygen 
content of solvents. Absorbance of samples and standards were read at 490 nm using the 
plate reader.
5.4. Results - Method validation
Method validation was achieved by measuring the following parameters:
a. Linearity of standard response
b. Repeatability of sample measurements
c. Specificity and accuracy
d. Recovery of added standard
e. Linearity of standard addition
f. Effect of matrices on response
5.4.1. Linearity of standard response
The standard response was evaluated by measuring 13-HpODE in eight different 
concentrations including a blank. Concentrations were 0, 0.5, 1,1.5, 2, 3, 4, and 5 
nmol/mL. These measurements were preformed by adding chloroform/methanol 
mixture to 0,10, 20, 30, 40, 60, 80, and 100 pL of 13-HpODE. Final volume in each 
vial was 1 mL. Figure 5.5 shows that the standard response was linear (R =0.996; 
y=0.0338 x + 0.140) over a range of 0-5 nmol/mL. The correlation coefficient of the 
least square regression line was 0.996, indicating significant dependence of absorption
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Figure 5.5: Linearity of 13-HpODE standard response 
5.4.2. Repeatability of sample measurements
In order to assess repeatability, each sample was measured ten times. Repeatability was 
to be considered satisfactory, if the coefficient of variance (CV) was below 10%. Table 
5.1 summarises the results and shows that repeatability was satisfactory for each 
sample. The following samples were tested:
Sample A: ClinOleic 20%
Sample B: Ivelip 20%
Sample C: ClinOleic in TNA 2% (without micronutrients)
Sample D: Ivelip in TNA 2% (without micronutrients)
Sample E: ClinOleic in TNA 2% (with micronutrients)
Sample F: Ivelip in TNA 2% (with micronutrients)
TNA contained water, glucose, and amino acids (see Table 5.4 for details). Sodium, 
potassium, calcium, magnesium, and phosphate were not added to any of the samples.
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Mean absorbance Standard deviation CV (%)
Sample A 0.168 0.012 7.5
Sample B 0.177 0.013 7.2
Sample C 0.178 0.011 8.0
Sample D 0.172 0.014 7.0
Sample E 0.179 0.007 4.4
Sample F 0.177 0.010 5.9
Table 5.1: Sample repeatability for samples A-F
5.4.3. Specificity
It was important to ensure that absorbance was due to peroxides and not due to 
interferences. This aspect was validated using triphenylphosphine (TPP), a potent 
reducing agent. TPP quantitatively eliminate all peroxides from the sample.158,168 Any 
remaining sample absorbance can then be attributed to interferences. If no remaining 
sample absorbance is measured, interferences can be ruled out.
One of two lipid emulsion samples was treated by adding 10 pL of a 10 mM solution of 
TPP; the second sample was not treated. If the treated sample had shown a reading close 
to the blank, interferences could have been ruled out. In order to further validate the use 
of TPP, another sample was spiked with 2 nmol/mL of 13-HpODE. TPP could be 
considered a useful tool, if added peroxides were quantitatively reduced.
The following measurement were performed in triplicate:
a. Sample A
b. Sample A + TPP
c. Sample A + 2 nmol 13-HpODE
d. Sample A + 2 nmol 13-HpODE + TPP
Table 5.2 shows that samples treated with TPP had a reduced absorbance below or on 
the limit of detection (limit of detection was specified in the technical information of the 
assay kit as 0.025 nmol/mL).
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Absorbance CV (%) nmol/mL LPO
Blank 0.284 4.5 -
Sample A 0.306 3.1 0.61
Sample A + TPP 0.285 6.4 0.04
Sample A + 2 nmol 13-HpODE 0.343 2.2 1.61
Sample A + 2 nmol 13-HpODE + TPP 0.293 7.0 0.26
Table 5.2: Absorbance o f samples with and without treatment with triphenylphosphine
These results show that measurements obtained with this assay are due to peroxides and 
not interferences.
5.4.4. Recovery of added standard
Using the data described in section 5.4.3, it was also possible to calculate the 
completeness of recovery of 13-HpODE during the extraction process.
Because half of extracted volume was used for measurement, it was expected that if  1 
nmol of the added 2 nmol of 13-HpODE were measured, then this measurement would 
signify that recovery was 100%.
Sample A contained 0.61 nmol/mL of LPO. The actual recovery of LPO from 13- 
HpODE was 1.61 nmol/mL. Of those, 0.61 were from the Sample A, and 1.0 was from 
13-HpODE, which successfully indicated that recovery was 100%.
5.4.5. Linearity of standard addition
Recovery of 13-HpODE was previously established for one concentration (section
5.4.4). It was also important to ensure that peroxides were recovered equally if present 
in differing concentrations. This was achieved by adding varying amounts of 13- 
HpODE to three different lipid emulsion samples (A, C, and E). As previously 
described above, half of the extracted solutions were used for measurement; 
concentrations were therefore doubled for the purpose of this analysis. Linearity of 
response is shown in Figure 5.6.
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Figure 5.6: Standard response of 13-HpODE without extraction process (yellow) and recovery of 
13-HpODE added to samples A (blue), C (red), and E (green)
Linearity of recovered standard (least square regression) as shown in Figure 5.6 was: 
13-HpODE (yellow square): y=0.035 x + 0.129; Sample A (blue circle): y=0.030 x +
0.194; Sample C (red triangle): y=0.027 x + 0.206; Sample E (green diamond): y=0.032 
x + 0.215. Recover of added 13-HpODE was considered satisfactory for each TNA 
matrix.
5.4.6. Effect of matrix on response
In order to validate the use of the assay for TNA samples (with a complex matrix), 
different concentrations of the matrix were prepared (Table 5.1). Different amounts of 
13-HpODE were then added to the three matrix concentrations.
50% Matrix 100% Matrix 150% Matrix
Primene 10% 12.5 mL Primene 10% 25 mL Primene 10% 37.5 mL
Glucose 20% 30 mL Glucose 20% 60 mL Glucose 50% 36 mL
Lipid 20% 5 mL Lipid 20% 10 mL Lipid 20% 15 mL
Water 52.5 mL Water 5 mL Water 11.5 mL
Table 5.3: Composition of matrices for matrix validation
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Results are shown in Figure 5.7. The response to the three different matrix 
concentrations varied by less than 5% across a matrix concentration of 50-150%. It can 
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Figure 5.7: Analytical response depending on concentration of nutrients in matrix (100% 
represents typical neonatal formula) (Addition of 0.5 nmol 13-HpODE (green triangle); addition of 
1.5 nmol 13-HpODE (blue square))
After consideration of all validation procedures, this method was considered fully 
validated for measurement of lipid peroxides in PN solutions and lipid emulsions for 
PN.
5.5. Experimental
Lipid peroxides were to be quantified in six different samples:
A. ClinOleic 20%
B. Ivelip 20%
C. ClinOleic in TNA 2% (without micronutrients)
D. Ivelip in TNA 2% (without micronutrients)
E. ClinOleic in TNA 2% (with micronutrients)
F. Ivelip in TNA 2% (with micronutrients)
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5.5.1. Peroxides in parenteral nutrition
Lipid peroxides were quantified in 20% lipid emulsions (samples A and B) and in TNA 
(samples E-F) as supplied by the manufacturer. The composition of samples C-F is 
shown in Table 5.4. TNA and lipid syringes were prepared in a Biomat Class A aseptic 
cabinet.
In 500 mL Sample C Sample D Sample E Sample F
Glucose 20% 300 300 300 300
Primene 10% 125 125 125 125
Water 25 25 20 20
ClinOleic 20% 50 - 45 -
Ivelip 20% - 50 - 45
Peditrace - - 5 5
Vitalipid in Soluvito - - 5 5
Table 5.4: Composition of PN solutions for lipid peroxide quantification
Samples A and B were stored in 60 mL polypropylene syringes; TNA were stored either 
in EVA or in oxygen barrier bags. The layers of oxygen barrier bags typically consist of 
EVA and ethyl-vinyl-alcohol (EVA/Ethyl-vinyl-alcohol/EVA).
Lipid syringes and TNA bags were stored at 25° Celsius for 48 hours (storage details 
shown below). Samples were measured for peroxides at 0, 6,12, 24, and 48 hours. 
Syringes were also stored at 8° Celsius for six days, followed by 48 hours at 25°
Celsius. This experiment was performed, as it is common practice in hospitals to store 
lipid emulsion syringes for several days.169
Samples were measured at four and six days; after removal from refrigeration after six 
days, samples were measured and at 0, 6, 12, 24, and 48 hours. Half of the TNA 
samples were wrapped in foil for light protection, and all samples were measured in 
duplicate (light exposure details shown below).
Details of sampling procedures are shown in Table 5.5 -  Table 5.7 (each cross 
represents one measurement).
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Sample A Sample B
Sampling time Temp 48 hrs 6 days 48 hrs 6 days
0 hrs XX XX XX XX
6 hrs 25 °C XX XX
12 hrs 25 °C XX XX
24 hrs 25 °C XX XX
48 hrs 25 °C XX XX
4 days 8 °C XX XX
6 days 8 °C XX XX
+6 hrs 25°C XX XX
+12 hrs 25°C XX XX
+24 hrs 25°C XX XX
+48 hrs 25°C XX XX
Table 5.5: Sampling schedule for lipid emulsion in syringes
Sampling time Temp C
Sample C
C* [C] [C*] F
Sample F
F* [F] [F*l
0 hrs XX XX XX XX XX XX XX XX
6 hrs 25 °C XX XX XX XX XX XX XX XX
12 hrs 25 °C XX XX XX XX XX XX XX XX
24 hrs 25 °C XX XX XX XX XX XX XX XX
48 hrs 25 °C XX XX XX XX XX XX XX XX
Table 5.6: Sampling schedule for TNA with ClinOleic; []=Oxygen-barrier; *=light protection
Sample D Sample E
Sampling time Temp D D* [D] [D*] E E* [E] [E*]
0 hrs XX XX XX XX XX XX XX XX
6 hrs 25 °C XX XX XX XX XX XX XX XX
12 hrs 25 °C XX XX XX XX XX XX XX XX
24 hrs 25 °C XX XX XX XX XX XX XX XX
48 hrs 25 °C XX XX XX XX XX XX XX XX
Table 5.7: Sampling schedule for TNA with Ivelip; []=Oxygen-barrier; *=light protection
In order to achieve a constant temperature of 25° Celsius and exposure to light, all TNA 
bags and syringes were positioned in a water bath near a large southeast-facing window. 
Containers were floated on the water to allow for adequate light exposure and oxygen
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permeation. Inserting an electronic thermometer into a PN bag and into a 60 mL 
syringe validated the effectiveness of the water bath in providing the appropriate 
temperature. The water bath was set at a temperature of 25° Celsius. Maximum 
temperature was reached after 30 minutes in the syringe and after 45 minutes in the PN 
bag as shown in Table 5.8.







Table 5.8: Temperature validation of water bath
The refrigeration unit holding the samples was regularly monitored in order to ensure 
that the syringes were maintained at 8° Celsius. Lowest temperature measured was 5.8; 
highest temperature measured was 8.1° Celsius.
5.5.2. Peroxide generation in lipid emulsions and TNA during simulated 
administration
In order to estimate total peroxide exposure of patients receiving parenteral lipid 
therapy, generation of peroxides during the administration process was assessed. 
Samples were prepared in duplicate in oxygen barrier bags. For this experiment, the 
same containers were chosen for all samples in order to eliminate the effect of the 
container on the generation of peroxides.
Samples A-F were prepared in duplicate in oxygen barrier bags. Administration sets and 
infusion pumps were then fitted to each container. The tubing was placed into the 25° 
Celsius water bath. Another PN bag was fitted to the opposing end of each 
administration set to capture the sample. Samples were taken from the beginning and 
the end of the administration set. Pumps were set at 0.4 mL/hour for lipid emulsions and 
6.3 mL/hour for TNA (simulating an infusion of 15 mL/day of 20% lipid emulsion and 
150 mL/day of TNA).
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LPO generation during administration was measured during the course of 48 hours for 
the lipid emulsions. TNA administration was simulated for a shorter duration of six 
hours, because the infusion rate of 6.4 mL/hour meant that the emulsion would pass 
through the administration set in less than four hours. LPO generation was assumed to 
remain constant after six hours.
To enable sampling without disrupting the simulated administration, 3-way taps were 
fitted to both ends of the administration set. Aseptic compounding and sampling took 
place in a Biomat Class 2 aseptic cabinet. Sampling details are shown in Table 5.9 and 
Table 5.10.
Sampling time Rate Temp
Sample 
A B
0 hrs 0.6 mL/hr XX XX
6 hrs 0.6 mL/hr 25 °C XX XX
12 hrs 0.6 mL/hr 25 °C XX XX
24 hrs 0.6 mL/hr 25 °C XX XX
48 hrs 0.6 mL/hr 25 °C XX XX
Table 5.9: Sampling schedule for lipid emulsion administration
Sample
Sampling time Rate Temp c D E F
0 hrs 6.3 mL/hr XX XX XX XX
3 hrs 6.3 mL/hr 25 °C XX XX XX XX
6 hrs 6.3 mL/hr 25 °C XX XX XX XX
Table 5.10: Sampling schedule for TNA administration
5.5.3. Data analysis
Data were analysed using SPSS 10.0 for Windows. This software was chosen, as it was 
a familiar tool and allowed the generation of complex figures.
In the following series of figures, bars represent the mean of two sample means; error 
bars represent +/-1 standard error of the mean. Samples were prepared in duplicate, and 
measurements were performed in triplicate. Reference lines in graphs that relate to 
results for lipid emulsions 20% represent the limit of peroxides in lipid emulsions for 
intravenous use as defined in the European Pharmacopoeia (i.e. 1000 pM).74 Reference 
lines in graphs that relate to results for TNA represent the limit for peroxides in the 1:10 
dilution (i.e. 100 pM).
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5.6. Results -  Sample measurements
5.6.1. Lipid hydrogen peroxides in lipid emulsions stored in syringes
Lipid emulsions stored at 25° Celsius in polypropylene syringes for 48 hours were 
tested for peroxide. Figure 5.8 shows that only minimal amounts of LPO were formed. 
No difference between the two types of emulsions was detected. All measurements were 
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Figure 5.8: LPO concentrations in 20% lipid emulsions stored at 25° Celsius for 48 hours in 
syringes
Additionally, syringes were stored for six days at 8° Celsius, followed by 48 hours at 
25° Celsius. Figure 5.9 shows that LPO increased during the four days of storage. After 
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Figure 5.9: LPO concentrations in 20% lipid emulsion stored at 25° Celsius for 6 days in syringes
5.6.2. Lipid hydrogen peroxides in total nutrient admixtures
Four different types of TNA were tested for levels of LPO. These admixtures were then 
stored under four different conditions with regard to oxygen and light exposure. Figure 
5.10 shows that LPO were generated in TNA containing ClinOleic immediately after 
compounding. Notably, concentrations of LPO did not increase with time. Storage 
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Figure 5.10: LPO concentration in TNA (Sample C - ClinOleic) stored at 25° Celsius for 48 hours
TNA containing Ivelip showed no measurable LPO formation for the first six hours 
after compounding, as shown in Figure 5.11. After 12 hours, LPO increased to 50 
pM/L.
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Figure 5.11: LPO concentration in TNA (Sample D - Ivelip) stored at 25° Celsius for 48 hours
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The effect of micronutrients on LPO formation was investigated. Vitamins and trace 
elements were added to TNA containing either ClinOleic or Ivelip. Figure 5.12 and 
Figure 5.13 show the amounts of LPO formed in TNA containing micronutrients. Light 
and oxygen protection did not affect LPO levels. After six hours, TNA containing 
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Figure 5.12: LPO concentration in TNA (Sample E -  ClinOleic + Micronutrients) stored at 25° 
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Figure 5.13: LPO concentration in TNA (Sample F -  Ivelip + Micronutrients) stored at 25° Celsius 
for 48 hours
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5.6.3. Peroxide generation during administration
In order to estimate the total amount of LPO administered to patients, peroxide 
formation was investigated during the administration process. Table 5.11 summarises 
the additional amount of LPO formed during administration in 20% lipid emulsions.
pmol/L 0 hrs 6 hrs 12 hrs 24 hrs 48 hrs
Sample A 0.0 ± 0.0 54.6 ± 54.6 43.8 ± 43 .7 137.5 ± 50 .0 5.9 ± 5 .9
Sample B 0.0 ± 0.0 91.0 ± 18.2 75.0 ± 50 .0 81.3 ± 18.8 147.0 ± 5 .9
Table 5.11; LPO generation during simulated administration of 20% lipid emulsions
In the TNA samples, additional LPO generated during administration was also 
measured. Results are shown in Table 5.12.
jxmol/L 0 hrs 3 hrs 6 hrs
Sample C 4.7 ± 3 .6 0.0 ± 0.0 1.7 ± 0 .6
Sample D 3.5 ± 1.2 12.0 ± 5 .2 7.5 ± 1.7
Sample E 3.0 ± 1.8 2.9 ± 1.8 5.2 ± 1.8
Sample F 0.6 ± 0.6 7.5 ± 0 .6 2.3 ±2 .3
Table 5.12: LPO generation during simulated administration of TNA
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5.6.4. Estimated intake of lipid peroxides during parenteral nutrition
LPO concentrations measured in this study facilitate an estimation of daily LPO intake 
from PN in neonates.
The assumption was made that lipid intake for a typical neonate is 3 g/kg/day (i.e. 150 
mL of TNA and 15 mL of lipid emulsion 20%). Light protection or oxygen barrier bags 
were not taken into consideration (i.e. calculations were based on the means), because 
their effect on LPO concentrations was negligible.
Cumulative LPO intake over 48 hours was calculated using the results shown in 
sections 5.6.1-5.6.3 (Table 5.13).
6 hrs 12 hrs 24 hrs 48 hrs
pmol/kg
ClinOleic 20% 0.16 0.79 1.12 6.80
ClinOleic 20% (after 6 days storage) 1.99 4.58 6.66 20.92
Ivelip 20% 0.00 0.43 0.99 6.36
Ivelip 20% (after 6 days storage) 2.06 4.93 6.94 19.36
TNA ClinOleic (Sample C) 3.04 5.88 11.64 20.13
TNA Ivelip (Sample D) 0.21 0.50 4.09 14.42
TNA ClinOleic (Sample E) 2.24 5.97 6.36 11.42
TNA Ivelip (Sample F) 0.86 1.32 1.49 3.64
Table 5.13: Estimated cumulative intake of LPO per kg body weight over 48 hours in neonates
Highest exposure to LPO occurred if  ClinOleic 20% was stored for six days prior to 




This photometric quantification method for LPO to PN solutions was utilised for the 
first time in these study experiments for a new application. Various validation steps 
were performed showing that the method was specific for LPO and that the nutrition 
matrix did not interfere with the assay response.
The ferric thiocyanate assay was selected for this purpose because it had previously 
been suggested that this method provided an easy, rapid, and sensitive measurement of 
LPO in biological samples. A lipid peroxide {i.e. 13-(S)-HpODE) was chosen as the 
standard for comparison, rather than inorganic hydrogen peroxides as used in the FOX 
and iodine titration method. It has previously been shown that these inorganic peroxides
1 ATshow a lower analytical response than LPO. Previously published results that have 
used inorganic peroxides for comparison might have overestimated the level of 
contamination in PN solutions.165
This method also proved to be a rapid method for quantifying LPO in PN solutions; 
extraction and measurement of eight samples in triplicate took less than two hours. The 
amount of solvents used was 1 mL of chloroform and 0.5 mL of methanol for each 
sample extraction. This can be compared to 50 mL of solvent required for iodometric 
titration.65 A majority of the chemicals and equipments used would be standard in most 
laboratories. This method might potentially be a useful tool for measurement of LPO in 
hospital pharmacies as part of routine quality control monitoring. The only equipment 
that might not be standard in every laboratory was the -80° C freezer; this freezer was 
required for storage of the linoleic acid peroxide standard.
Although this method allowed measurements of as little as 0.5 nmol LPO in 1 mL of 
extracted samples, the sensitivity was reduced due to the fact that samples had to be 
diluted prior to the extraction of LPO. Lipid emulsions were diluted 1:100 and TNA 
was diluted 1:10. This was necessary to achieve good reproducibility, but meant that 
sensitivity was reduced to 50 pM in 20% lipid emulsions and 5 pM in TNA. As values 
reported in the literature were found to be much higher than 5 or 50 pM, it was 
considered that the sensitivity of this method was sufficient to detect changes in LPO 
concentrations.160,164 In order to further validate the use of this assay, future work 
should compare this method to previously validated HPLC methods.165
After validating this assay for use in parenteral lipid emulsions, various clinically 
relevant PN solutions were tested for LPO levels.
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Firstly, lipid emulsions were tested as supplied by the manufacturer. These 20% 
emulsions are usually infused in paediatric patients using syringe drivers, and they are 
aseptically transferred into syringes prior to administration. The typical duration of 
infusion is 24 hours, but sometimes syringes are left in-situ for 48 hours. In some 
hospitals, syringes are prepared by hospital pharmacy staff in advance and stored for
oo
several days in a refrigerator until use. The experimental design included storage 20% 
lipid emulsions in syringes at an elevated room temperature of 25° C (as would be 
expected to be the case on neonatal wards) for 48 hours and storage syringes in a 
refrigerated environment for 6 days, followed by 48 hours at 25° C.
Results from this experiment showed that LPO formation in syringes stored 
immediately at 25° C was minimal (Figure 5.8). No differences between ClinOleic and 
Ivelip were detected. Syringes first stored at 8° C for six days however showed a 
considerable increase in LPO, especially after 48 hours at 25° C (Figure 5.9). After six 
days in refrigerated conditions and 48 hours at 25° C, LPO levels exceeded the 
European Pharmacopoeia maximum recommended levels 1.7 times.74 
Steger and colleagues stored various 20% lipid emulsions in containers for PN at room 
temperature for up to 30 days and found that levels of LPO rose to 3 mM (measured by 
iodometric titration).160 Although these levels were very high, it must be pointed out 
that this experimental design was not relevant in clinical practice because lipid 
emulsions are unlikely to be stored at room temperature for such long periods in actual 
clinical practice. The increased levels of LPO measured in syringes in this study suggest 
that syringes might not be an ideal storage medium for lipid emulsions that are not used 
immediately. Syringes stored at 25° C for 48 hours directly after their preparation did 
not show an increase in LPO levels. This practice might not contribute significantly to 
the oxidative load infused in patients receiving PN.
Secondly, TNA solutions were tested for LPO. TNA contained either ClinOleic or 
Ivelip 2g/100 mL. Results showed that LPO concentrations were lower in TNA 
containing Ivelip compared with ClinOleic (Figure 5.10-Figure 5.13). As Ivelip contains 
more unsaturated fatty acids, it had been expected to show higher levels of LPO. A 
possible explanation for the increased concentration of LPO in ClinOleic could be 
related to the way in which ClinOleic is manufactured. Unfortunately, this has not been 
further explored and remains a speculation.
Solutions were tested with and without added micronutrients to determine whether 
micronutrients affect the amounts of LPO generated. Conflicting reports regarding the
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role of micronutrients have been published. Some suggest that multivitamin solutions
1 Oficontribute significantly to the total peroxide load of PN, whereas others suggest 
adding micronutrients to lipid emulsions for protection from LPO.66 
TNA were either stored in EVA or oxygen barrier bags to test the influence of oxygen 
diffusion during storage on peroxidation. Half of the samples were also light protected, 
in response to reports, which have shown that light protection reduces LPO 
concentrations.66,120’126 It was hypothesised that LPO generation would be reduced in 
oxygen barrier and light protected containers.
Results showed that LPO concentrations were lowest in TNA containing micronutrients 
and Ivelip, and highest in micronutrient-free TNA containing ClinOleic (Figure 5.10 
and Figure 5.13). Highest levels reached were 100 pM. Storage conditions did not 
appear to affect LPO generation significantly. This was surprising as previous reports 
had always shown significant differences between light exposed and light protected 
solutions.120,126,166 Laborie and colleagues measured up to 300 pM of TBH equivalent 
(by FOX method) in TNA unprotected from light, compared to 100 pM of TBH
1 OAequivalent in light protected TNA. They also showed increased levels of urinary
1
peroxides in infants receiving PN that had been exposed to light. In this study, light 
exposure was not quantified. Containers were placed into a water bath located near a 
large window. As experiments were carried out during the winter months, light intensity 
was relatively low. This fact might explain the lack of difference between light 
protected and not protected solutions.
Compared to EVA bags, oxygen barrier bags had previously been reported to offer 
protection from LPO generation.160 It is difficult to compare results from this study with 
the work undertaken by Steger and colleagues because their experimental design was 
very different. They investigated LPO generation in 20% lipid emulsion stored in 
containers for TNA for up to a month. Differences in LPO between different containers 
only became apparent after several days. This study measured LPO in TNA in regular 
intervals during 48 hours. The time period might have been too short to detect 
differences. It is also possible that the amount of oxygen already present in the solution 
due to the compounding process was of such concentration that the protection from 
further oxygen diffusion through the container wall was insignificant.
Silvers and colleagues investigated the role of light exposure of PN in the 
administration set on total peroxides generated during the infusion process, and then 
found that this significantly contributed to the LPO concentration administered to
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patients.66 It was therefore considered important not only to measure LPO in containers, 
but also at the end of a simulated infusion in order to calculate total LPO administered 
to patients. Infusions were simulated for a neonate weighing 1 kg and receiving 3g of 
lipids per day, either as 15 mL of 20% lipid emulsion or 150 mL of TNA. Infusion rates 
were therefore calculated to be 0.6 mL/hour for 20% lipid emulsions and 6.3 mL/hour 
for TNA.
Results showed that some LPO were generated during the infusion process (Table 5.11 
and Table 5.12). More LPO per litre of emulsion were found in 20% lipid emulsions, 
but this can be attributed to the ten times higher concentration of lipids in those 
emulsions.
Additional LPO generated during the simulated infusion process can be considered 
insignificant, when compared to LPO concentrations generated in the container during 
storage.
Throughout this study, no differences in LPO generation were detected between 
ClinOleic and Ivelip. This was significant because, as previously mentioned, differences 
would have been expected due to the different concentrations of unsaturated fatty acids 
and a-tocopherol in each of these two lipid emulsions.
The absence of differences detected in-vitro does not mean that amounts of 
polyunsaturated fatty acids and a-tocopherol do not influence oxidative stress caused by 
lipid infusion in-vivo. Antebi and colleagues performed a study comparing ClinOleic to 
soybean-based emulsion.170 They measured concentrations of thiobarbituric-acid- 
reactive substance in lipid emulsions incubated with phenylhydrazine. They found that 
ClinOleic was more resistant to oxidation. This might indicate that, although this study 
of LPO in lipid emulsions did not show a decreased level of peroxides, the level of in- 
vivo resistance to a hyperoxic environment might be higher with ClinOleic.
A surprising outcome of the application of the ferrous thiocyanate method was that 
results were relatively variable with time. It had been expected that LPO levels would 
be lowest at time zero, and then either increase with time or remain constant, as is the 
case in some published reports.160 However, on several occasions, LPO levels dropped 
after 12 hours or 24 hours. A similar observation was reported by Laborie and 
colleagues; in the presence of lipids, total peroxides were lower after six hours than
1 Ofiafter one hour. These investigators did not interpret this occurrence. It can be
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hypothesised that LPO react further to form a non-oxidising product, and this would 
account for the reduction in detectable LPO. This observation requires further 
investigation.
Using all the results generated, it was possible to calculate an example of total LPO 
exposure for a neonate receiving lipid infusions over 48 hours.
Additionally, this calculation exercise enabled the investigation of the primary aim of 
the study; the LPO concentrations administered in separate lipid infusion and TNA were 
directly compared.
This calculation showed that a neonate would be exposed to 3.6 to 20.9 pM LPO over 
48 hours. Highest intakes occurred with 20% lipid emulsions, which had been stored for 
6 days before administration. TNA with ClinOleic revealed similar amounts of LPO. 
Lowest intake occurred with fresh 20% lipid emulsion and with TNA containing 
micronutrients and Ivelip.
Currently, it is not known if these levels of LPO pose a clinically relevant risk to 
patients. It is also not known how clinically relevant Pharmacopoeia limits of LPO in 
intravenous lipid emulsions are, especially in premature neonates, whose oxidative 
defence might be impaired.
The primary research question for this laboratory study was to investigate a new aspect 
in the discussion about whether or not lipid emulsions should be administered 
separately or as TNA.
In conclusion, no major differences were found in the amount of LPO potentially 
administered to patients receiving lipids separately or as TNA. It is crucial that all 
pharmaceutical and clinical aspects are taken into consideration when discussing the 
preferred administration route of intravenous lipids.
Further validation work is recommended in order to compare this method with other 
methods that measure lipid peroxides exclusively, for example HPLC. Total peroxides 
should also be investigated for comparison. Further application of this method could 
include measurement of different formulae solutions, which contain electrolytes and 
minerals, and the comparison of different commercial PN products. The influence of 
phototherapy on LPO formation also warrants further investigation. Most importantly, 
toxicological consequences of infusing LPO need to be investigated, especially in
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premature neonates who are at risk of having impaired antioxidative defences. This will 
enable realistic and relevant limits for LPO in PN solutions to be established.
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6. Overall discussion and conclusions
The overall objective of this research project was to gain a better understanding of 
neonatal and paediatric PN in Europe and to contribute to discussions related to the 
optimisation of care. One focus throughout the project was the use of standard PN.
Also, the aim was to focus in more detail on one aspect of administration practice 
related to the use of intravenous lipid emulsions.
A variety of research methodologies were employed, including qualitative and 
quantitative methods for questionnaire and interview surveys, non-interventional 
clinical research, and laboratory-based pharmaceutical and analytical techniques.
6.1. Summary of findings
The practice of neonatal and paediatric PN in Europe was studied for the first time. 
Prescribers were usually physicians, although in the UK pharmacists also performed 
prescribing roles. Major differences were found between the countries with regard to the 
aseptic preparation of PN solutions. In the UK, aseptic compounding units were usually 
available, but this was not the case in many of the other countries studied. In Italy, 
compounding of PN commonly took place on the ward, and in Germany, additions were 
regularly made on the ward.
Aseptic manipulation of PN bags increases the risk of microbial contamination. 
Therefore this risk should be kept to a minimum, and compounding should take place in 
controlled aseptic environments. Details about the environment in which manipulations 
occurred on the wards were not investigated, but it can be assumed that this practice 
increases the risk of microbial contamination compared to the practice of only 
permitting manipulations within licensed aseptic facilities in pharmacy departments. 
In-line filters have been recommended for PN administration in paediatric PN, and this 
study found that filters were indeed used frequently. Over one quarter of hospitals did 
not use administration filters at all; neonates and children in these hospitals were, 
therefore, at risk of receiving increased amounts of particulate matter from PN.
Light protection has been investigated with regard to vitamin stability and peroxidation, 
and it was shown to be beneficial to protect both PN container and administration set,
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especially if phototherapy light is used. ’ ’ This study found light protection of 
containers to be common practice, but the administration set was rarely protected. 
Investigations of lipid peroxidation found that light protection did not influence 
peroxide generation. However, hydrogen peroxide generation and vitamin stability were 
not studied; light protection might be required to protect PN solutions from these 
instabilities.
Prescribing practice was audited in ten GH and TH in the UK and in six University 
hospitals in Europe. The most important single factor contributing to differences in 
prescribed nutrition was the day after first commencement of PN. Body weight only had 
a small impact on macronutrient prescribing. Concurrent enteral feeding also had little 
effect on PN prescribing practice. Administration of prescribed PN was satisfactory in 
most cases, but, in approximately one third of cases, less than 80% of prescribed PN 
was administered. Reasons for this were not investigated, but it is important to note that 
this discrepancy might contribute significantly to underfeeding. Generalisability of 
results is limited, as data were collected from a relatively small number of hospitals.
The survey showed that StSol were used in several hospitals. For neonates, these 
solutions were typically unlicensed in-house manufactured solutions. The main reasons 
for the introduction of StSol included resource pressures on pharmacy compounding 
facilities and desirability of increased quality control with StSol compared to 
individually compounded bags.
Perceptions of prescribers regarding the composition of an ideal StSol differed greatly. 
Detailed analysis of prescribing practice revealed that amino acids and glucose 
concentrations in PN prescribed for neonates increased greatly during the course of PN, 
especially in TH and ITH. As a result, decisions about the introduction of StSol should 
take into consideration that concentration requirements differ from patient to patient, 
especially during the first few days of PN.
Peroxidation of lipid emulsions was studied in more detail as one aspect of PN risk 
management. A novel assay, which was used for this application for the first time, was 
successfully validated.
Lipid peroxidation was greatly increased if the emulsions were stored in syringes for 
more than fours days prior to administration.
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6.2. Conclusions
• Compounding practice of parenteral nutrition solutions was diverse throughout 
Europe and optimal aseptic conditions were not always applied.
• Standardised parenteral nutrition was used in several hospitals in Europe; 
calculations based on typical fluid intake indicated that these solutions might not 
provide sufficient nutrients to neonatal patients.
• Prescribed parenteral nutrition was usually administered to neonatal patients in 
satisfactory amounts, but prescribers should be aware that in some cases insufficient 
amounts were administered and that constant monitoring of nutritional intake might 
be required to ensure satisfactory intake.
• Amino acid intake in premature neonates was below current recommendations. This 
was due to low amounts of amino acids prescribed for parenteral nutrition.
• The ferric thiocyante assay, performed in chloroform, provided a useful tool for 
quantification of lipid peroxides in emulsions for intravenous feeding.
• Lipid peroxides were generated in large amounts when intravenous lipid emulsions 
were stored for more than four days.
• Lipid emulsion given separately from the binary solutions potentially increases the 
amount of lipid peroxides infused when the emulsion is stored for several days in 
syringes.
• Nutritional care of neonatal and paediatric patients can potentially be optimised by 
ensuring nutritional adequacy of standardised nutrition, by developing international 
guidance for aseptic manipulation of containers for parenteral nutrition, and by 
internal monitoring of nutritional intake in neonates.
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6.3. Future work
This project has identified areas for future investigations that were beyond the scope of 
this work.
With regard to StSol further assessment of nutritional adequacy is recommended.
Results from both the survey and neonatal nutrition study indicate that some of the 
StSol currently in use might not provide adequate nutrition support. It is desirable that 
future work compares standard versus individual prescribing in terms of clinical and 
nutritional outcomes.
This project has uncovered that several hospitals use StSol, and the author of this thesis 
estimates that the number of StSol used will rise in the future due to issues related to 
good manufacturing practice, clinical governance, and the way in which hospitals obtain
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manufacturing licences. ’ It is important that all healthcare professionals undertaking 
standardisation are encouraged to ensure that nutritional support is at least equal to that 
in individualised PN regimes. Pharmacy departments should also investigate how StSol 
affect their service, both in terms of patient safety and efficacy. The overall changes in 
pharmaceutical and clinical practice linked to the introduction of StSol should also be 
investigated with regard to cost effectiveness.
Continuous development of practice guidelines for prescribing, compounding, and 
administration of PN is a key role for national and international special interest groups. 
Furthermore, a multi-centre randomised controlled trial should be undertaken 
comparing StSol to individualised regimens in neonates. Only a rigorous trial of this 
kind would allow a true comparison of both practices. Such a trial could be performed 
in a double blind fashion where only the pharmacy department know whether the PN 
bag is standard or not. Outcome measurements could include total daily energy intake, 
biochemical imbalances, growth and weight gain, and other clinical indicators, such as 
occurrence of sepsis, length of hospitalisation, and progression of enteral feeding. 
Additional measures could include timesaving for the pharmacy department and 
reduction in prescribing time. Although such a trial is possible, several difficulties with 
regard to the execution can be envisaged: a multi-centre trial would have to be 
conducted to have access to sufficient patient numbers, and to make the trial relevant to 
other hospitals. In order to compare the different centres, their practice (e.g. 
compounding and prescribing practice) would have to be somewhat standardised. 
Alternatively, each centre could act as their own comparison. Such a trial would be 
lenghy and expensive to undertake.
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Discrepancies between prescribed and administered PN occurred frequently. Future 
studies should investigate this area further; a focus on reasons why prescribed PN was 
not administered. It might then be possible to improve nutrition support by developing 
strategies that allow more complete administration of PN.
The clinical study gave an overview of practice in general district hospitals (GH) and 
teaching hospitals (TH) in the UK. General hospitals in other European countries were 
not included because of the infeasibility of sufficient data collection. Investigating 
practice in general hospitals across the continent could widen the international scope of 
this part of the project.
With regard to oxidative stress and PN, more work is required in order to understand the 
clinical implications of infusing solutions that are contaminated by peroxides. This is 
the only way it is possible to define relevant limits in PN solutions, particularly for 
neonates and children. Clinical studies have already been undertaken investigating 
urinary peroxides after infusion of lipid emulsion.166 Further studies should focus on the 
relationship between LPO levels in solutions for infusion, comparing those to urinary or 
plasma LPO levels. Long-term outcome related to oxidative stress, for example, 
occurrence of retinopathy of prematurity, should also be studied.
In the meantime, analytical methods must be carefully reviewed for suitability. For 
further validation purposes, the assay developed for this project should be compared to 
HPLC methods.
In general, lipids are usually given separately to paediatric patients, and almost always 
given separately to neonates. It would be desirable if future investigation focused on 
improved clinical outcomes, such as comparing the amounts of lipids given by TNA or 
separate infusion.
The electronic data collection tool was successfully utilised during the clinical study. In 
future, this tool could be developed further to allow automatic assessment of practice, 
e.g. monitoring of prescribing and nutritional intake. During the course of the study it 
became clear that many prescribers do not have access to such a system that allows 
them to overview their own PN practice. It would be desirable that prescribers and 
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APPENDIX 1:
Questionnaire for exploratory interviews
Pharmacy Practice Research Unit Bettina Kliittgens
School of Pharmacy and Pharmacology
University of Bath October
Claverton Down 
Bath BA2 7AY 
England
European Practice in Paediatric Parenteral Nutrition
Please tick one box for each question unless otherwise specified.
Section A: General Information
1. Is your hospital a specialised children’s or neonatal hospital?
a) Children’s:
□  Yes □  No




□  Yes □  No
If no, do you have a specialist Neonatal unit?
□  Yes
□  No
2. How many children’s/ neonatal beds are there in your hospital?
Children’s
Neonates
3. How many paediatric patients (neonates and children) are receiving 
intravenous nutrition in an average week in your hospital?
□ 0-1 □  11-15
□  2-5 □  16-20
□ 6-10 □ >20
1
4. Please describe your role in the supply o f parenteral nutrition.
5. Who is involved for the decision making in parenteral nutrition prescribing? 









□ Other (Please specify:.........
 )
6. Do you supply parenteral nutrition for paediatric patients at home?
□  No
□  Yes 
If yes,
a) How many patients receive parenteral nutrition at home in a typical week?
b) What is the approximate percentage of solutions that are supplied as all-in- 
one?
2
Section B: Supply of Parenteral Nutrition
7. Is there a unit in your hospital that compounds parenteral nutrition?
□  Yes □  No
8. What guidelines do you use to define nutritional targets of parenteral 
nutrition?
(Please tick as many boxes as necessary)
□  In-house policy
□  Local/Regional recommendations
□  Computer Program
□  National recommendations
□  International recommendations
□  None
□  Other
Please specify the one/ones you ticked:
9. Do you use computer programs to support the prescribing of parenteral 
nutrition?
□  Yes □  No
If yes, which one/ones?
10. Do you use computer programs to support the compounding of parenteral
nutrition?
□  Yes □  No
If yes, which one/ones?
3
11. What ingredients do you use for the compounding of parenteral nutrition in





12. How do you supply the fat emulsion? (Tick as many boxes as necessary) 
Please specify age groups and approx. percentages
□  Separately..............................................................................
□  All-in-one..............................................................................
13. What is your policy about the addition of vitamins to parenteral nutrition in 
different age groups.
a) When do you start including vitamins?
b) How many days per week do you include vitamins in parenteral nutrition?
4
c) Do you include Vitamin K in parenteral nutrition?
□  Yes □  No
If yes, please specify the use of 
vitamin K in different age groups (i.e. 
amount of Vitamin K and number of 
days per week).
14. What is your policy about the addition of trace elements to parenteral nutrition 
solutions.
a) When do you start including trace elements?
b) Which trace elements do you include? (If you use a commercially available 
mixture please specify the brand.)
15. a) What shelf life do you assign for the nutritional solutions and why?
b) What would be the ideal shelf life for parenteral nutrition solutions?
5
16. What kinds of end-control do you use for the compounded individual bag? 







a Other (Please specify:...
Section C: Standardisation
17. Do you use jore-mixed standard solutions for some patients?
□  Yes -Please answer question 18 to 25.
□  No -Please go to 26 (page 9).
18. Why did you decide to use one standardised solution for some patients?
19. In which year did you introduce the standard regimen/regimens?
20. How do you produce these standard solutions?
□  Bags are prepared every day
□  Bags are produced in batches o f ...............bags (Please specify)
□  Other (Please specify:.................................................................)
6
21. Where does the formulation for standardisation come from?
(Tick as many boxes as necessary)
□  Developed in-house
□  Other Hospital
□  Regional recommendations
□  National recommendations
□  Other (Please specify:................................................................................ )
22. Do you have different standard solutions for different age groups?
□  Yes 
If yes, what are these age 
groups?
If no, which age group receives 
standard nutritional solutions?
□  No
23. Do you use commercially available solutions as standard solutions?
□  Yes 
If yes, which one/ones?
□  No
7
24. Do you produce the standard TPN solution/solutions in-house?
□  No
□  Yes
If yes, please specify what ingredients the solution/solutions contains and 
where/when each solution is used.
Solution 1 Solution 2 Solution 3 Solution 4
Used for:
Glucose □ a □ □
Electrolytes □ a □ □
Amino acids □ a □ □
Vitamins □ □ a □
Trace elements □ □ □ □
Fat □ □ □ □
Other (please □ □ □ □
specify................. . . . .)
25. What kinds of end-control do you use for the compounded standard solutions?







Other (Please specify:........................................................ )
Please go now to the end of the questionnaire.
8
26. Why do you compound each bag individually?
27. Have you taken any steps towards standardising your parenteral nutrition for 
children and neonates?
□  Yes □  No
(Tick as many boxes as necessary)
□  Children
□  Neonates
28. Would you be prepared to use standardised solutions?
□  Yes □  No
If no, why not?
Please include copies of (where applicable):
□  Standard formulas
□  Nutritional targets
□  Compounding protocols
□  Other documents that you might consider to be relevant for this survey
Thank you for taking the time to complete this questionnaire.
I will send you a copy of my results after visiting hospitals in France, Germany, Italy, 
Spain, and the UK.
If you wish to comment on paediatric parenteral nutrition and the standardisation of 
nutritional solutions, please use the space on the back of this page.
9
APPENDIX 2:
Cover letter and questionnaire for postal survey (cover letter in five 




Bath BA2 7AY 
England
Department of Pharmacy and Pharmacology Phone+44-1225-323107 
Fax +44-1225-826114
Mail: prpbuk@bath.ac.uk
Bath, April 2001 
Dear ,
I would very much like you and your hospital to participate in a major European survey 
into the practice of neonatal and paediatric parenteral nutrition.
I am a research Pharmacist at the University of Bath. I work with Graham Sewell, Professor 
for Pharmacy Practice at the University of Bath, and Tony Nunn, Chief Pharmacist at Alder 
Hey Children’s Hospital Liverpool.
The aim of this survey is to evaluate how paediatric parenteral nutrition is managed in 
Europe, and if there is a potential for standardisation in different age or weight groups.
By answering the attached questionnaire, you and your hospital will be part of this European- 
wide survey. It will take approximately 30 minutes to answer and you may need to consult 
other healthcare professionals to answer some of the questions. In return we will keep you 
informed of the results and outcome of this survey.
Your answers will be treated in the strictest confidence.
This research project is supported by Baxter Healthcare Ltd.
Please contact me, if you have comments or questions about any aspect of this work.






Department of Pharmacy and Pharmacology 
Bath BA2 7AY 
England
Bath, April 2001 
Sehr geehrte ,
ich wiirde mich sehr dariiber freuen, wenn Sie ur.d Ihre Klinik an einer europaischen 
Studie zu Verfahrensweisen bei der parenteralen Ernahrung von Kindern und 
Neugeborenen teilnehmen wiirden.
Ich forsche auf dem Gebiet der klinischen Pharmazie an der University of Bath, England. Ich 
arbeite zusammen mit Professor Graham Sewell, Professor ftir klinische Pharmazie an der 
Universitat in Bath, und Tony Nunn, Leiter der Krankenhausapotheke am Alder Hey 
Children’s Hospital in Liverpool.
Ziel dieser Studie ist die Beantwortung der Frage, wie die padiatrische parenterale Ernahrung 
in Europa gehandhabt wird, und ob eine Standardisierung bei verschiedenen Alters- oder 
Gewichtsgruppen moglich ist.
Mit der Beantwortung des beigefiigten Fragebogens nehmen Sie und Ihre Klinik an dieser 
europaweiten Studie teil. Die Beantwortung des Fragebogens dauert etwa 30 Minuten, wobei 
Sie gegebenenfalls andere Kollegen konsultieren miissen, um einige der Fragen zu 
beantworten. Ihre Antworten werden selbstverstandlich steng vertraulich bleiben.
Wenn Sie mochten, werden wir Sie uber die Ergebnisse dieser Studie auf dem Laufenden 
halten.
Dieses Forschungsprojekt wird von der Firma Baxter Healthcare Ltd. unterstiitzt.
Bei Fragen oder Kommentaren zu alien Aspekten dieser Arbeit stehe ich Omen geme jederzeit 
zur Verfiigung.










Bath BA2 7AY 
England
Department of Pharmacy and Pharmacology Tel: +44-1225-323107 
Fax.: +44-1225-826114
Mail: prpbuk@bath.ac.uk
Bath, avril 2001 
Cher ,
J’ai le plaisir de vous inviter, ainsi que votre etablissement hospitalier, a participer a une 
importante enquete europeenne sur les pratiques en nutrition parenterale neonatale et 
pediatrique.
Je suis pharmacien chercheur a l'Universite de Bath, en Angleterre. Je travaille en 
collaboration avec Graham Sewell, Professeur de Pharmacie a l'Universite de Bath et Tony 
Nunn, Pharmacien chef a l'Hopital des enfants Alder Hey de Liverpool.
L'objectif de cette enquete est d'evaluer les differents modes de nutrition parenterale 
pediatrique en Europe et de determiner s'il est possible de standardiser les pratiques en 
fonction du groupe d'age et de poids des enfants.
Si vous et votre etablissement hospitalier acceptez de prendre part a cette enquete conduite a 
l'echelon europeen, nous vous demandons de repondre au questionnaire joint. Seules 
30 minutes seront necessaires pour le completer, mais il se peut que vous deviez consulter vos 
professionals de la sante pour repondre a certaines questions. Nous vous tiendrons informes 
en retour, des resultats et des conclusions de cette etude.
Votre reponse sera evidemment traitee confidentiellement.
Ce projet de recherche est finance par la societe Baxter Healthcare Ltd.
Pour tout commentaire ou toute question sur l'un des aspects de ce travail, n'hesitez pas a me 
contacter a tout moment.
En vous remerciant par avance et dans l'attente de votre reponse, veuillez agreer l'expression 







Bath, April 2001 
Egregi
UNIVERSITY OF
f i t  BATH
Department of Pharmacy and Pharmacology
Bath BA2 7AY
England
Sarei molto lieta della vostra partecipazione e di quella degli ospedali in cui svolgete le 
vostre attivita ad un'importante indagine europea sulla pratica della nutrizione 
parenterale neonatale e pediatrica.
Lavoro come ricercatrice presso la Facolta di Farmacia deH'Universita di Bath.
Collaboro con il prof. Graham Sewell, docente di Analisi dei farmaci presso questa Universita 
e con il dott. Tony Nunn, Farmacista Capo presso 1'Alder Hey Children’s Hospital di 
Liverpool.
Lo scopo di questa indagine e di valutare le modalita di gestione della nutrizione parenterale 
in Europa e di individuare la possibility di standardizzazione per diversi gruppi di eta o di 
peso.
Rispondendo al questionario allegato, voi e il vostro ospedale parteciperete a questa indagine 
a carattere europeo. II completamento del questionario richiede circa 30 minuti e, per 
rispondere ad alcune domande, potra essere necessario consultare altri medici. In cambio, vi 
terremo informati dei risultati e dell'esito dell'indagine.
Le vostre risposte saranno trattate con il massimo della confidenzialita.
Questo progetto di ricerca e finanziato da Baxter Healthcare Ltd.
Sono a disposizione in qualsiasi momento per eventuali chiarimenti o commenti sui diversi 
aspetti del progetto.
Potere inviare il questionario anche via fax al numero: 0044-1225-826114











Direction de correo electronico: 
prpbuk@bath.ac.uk
Bath, April 2001 
Querido :
Le agradeceria mucho si usted y su hospital pudieran participar en un importante 
estudio europeo sobre la practica de la nutricion parenteral con neonatos y ninos.
Trabajo como farmaceutico de investigacion en la Universidad de Bath y colaboro con Prof. 
Graham Sewell, Profesor de Practica de Farmacia en la Universidad de Bath, y Dr. Tony 
Nunn, Jefe de Farmacia del Hospital infantil Alder Hey, en Liverpool.
El objetivo de este estudio consiste en evaluar la forma en la que se administra la nutricion 
parenteral pediatrica en Europa, asi como en averiguar si existe potencial para realizar una 
estandarizacion en diferentes grupos de edad o peso.
Al rellenar el cuestionario adjunto, usted y su hospital formaran parte de este gran estudio 
europeo. Necesitara aproximadamente 30 minutos para responder a todas las preguntas y es 
posible que tenga que consultar a otros profesionales de asistencia sanitaria para responder a 
algunas de ellas. Por nuestra parte, nosotros le informaremos de los resultados y de las 
consecuencias de este estudio.
Este proyecto de investigacion esta apoyado por Baxter Healthcare Ltd.
Si tiene comentarios o preguntas acerca de algun aspecto de este trabajo, no dude en ponerse 
en contacto conmigo.
Quedo a la espera de sus noticias.
Sin otro particular le saluda atentamente,
Bettina Kliittgens.
European Practice in 
Paediatric Parenteral 
Nutrition
Pharmacy Practice Research Group 




Department o f Pharmacy and Pharmacology 
University o f Bath, BA2 7AY Bath, England
Phone: +44 1225 323107 
F ax :+44 1225 826114
U N I V E R S I T Y  OF
BATH
1 -
PART ONE: Practice of parenteral nutrition 
Section A: General information
1. How many neonatal/children’s beds are there in your hospital?
Neonates ...................
Children............... ...................
2. How many paediatric patients receive intravenous nutrition on an
a v e r a g e  day in your hospital?
Neonates: □ 0-1 □ 8-10 □ 17-19
□ 2-4 □ 11-13 □ 20-25
□ 5-7 □ 14-16 □ >25
Children: □ 0-1 □ 8-10 □ 17-19
□ 2-4 □ 11-13 □ 20-25
□ 5-7 □ 14-16 □ >25
3. What is the job title of the person/persons involved in the decision 






Section B: Supply of parenteral nutrition
4. Is there a unit in your hospital that compounds parenteral nutrition?
□  Yes □  No
5. Do you use guidelines for the prescribing of parenteral nutrition?
□  Yes □  No
If yes, which ones?
6. What ingredients are used for the compounding of parenteral nutrition in 
different age groups? Please specify which manufacturers product you 
use.
________________________________ Neonates_________________Children______
Fat ................................  ................................
Amino acid ................................  ................................
Water-soluble Vitamins ................................  ................................
Fat-soluble Vitamins ................................  ................................
Trace elements............................................................  ................................
7. How is the fat emulsion supplied? (Tick as many boxes as necessary)
Please specify the approximate percentages of patients receiving the 
different formulations.
_____________________________Neonates______________ Children____________
□  Separately .............. % ............. %
□  All-in-one .............. % ............. %
8. What is the policy about the addition of vitamins to parenteral nutrition in 
different age/weight groups:
a) On which day after introducing parenteral nutrition do you start
including vitamins?
_______________________ Neonates Children
Water-soluble vitamins ............. .............
Fat-soluble vitamins ............. .............
b) How many days per week do the patients receive vitamins?
_______________________ Neonates Children
Water-soluble vitamins ............. .............
Fat-soluble vitamins ............. .............
9. What is the policy about the addition of trace elements to parenteral 
nutrition in different age/weight groups?
a) On which day after introducing parenteral nutrition do you start 
including trace elements?
Neonates  Children..............
b) How many days per week do the patients receive trace elements?
Neonates  Children..............
10. What is the maximum shelf life assigned to the compounded parenteral 
nutrition bag?
11. Are filters used during the administration of parenteral nutrition?
□  Yes, always □  Yes, sometimes □  No
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12. Is some kind of light protection used during the administration of 
parenteral nutrition?
For the bag: □  Yes, always □  Yes, sometimes □  No
For the tubing: □  Yes, always □  Yes, sometimes □  No








□ O th e r .......................
14. Is parenteral nutrition for paediatric patients prepared on the ward?
□  Yes, regularly □  Yes, rarely □  No
15. Are ingredients added to the nutrition solution on the ward?
□  Yes, regularly
(in approx. m ore  than 
20%  o f bags)
I f  yes , please specify 
the ingredient added 
on the ward:
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□  Yes, rarely □  No
(in approx. less than 20% 
o f  bags)
I f  ves. please specify the 
ingredient added on the 
ward:
Section C: Standardisation
16. Do you use standard solutions for some patients (i.e.: In-house batch 
production or commercially available ready-to-use solutions)?
□  Yes -► Please answer questions 17 to 21 and continue with part 2 (page 8).
□  No -► Please go to question 22 (page 7) and continue with part 2 (page 8).
17. Why did you decide to use standardised solutions for some patients?
18. In which year were standard solution/solutions introduced?
19. Where does the formulation for standardisation come from?
(Please include a copy o f  the standard solutions used i f  possible.)
20. Are commercially available ready-to-use nutrition solutions used in your 
hospital?
□  Yes, always □  Yes, sometimes □  No
If  yes, which one/ones?
21. In case standard solutions are produced in your hospital: What kinds of 







□ O th e r ...................
>  Please go now to page 8
22. What are the reasons for the individual compounding of parenteral 
nutrition in your hospital?
23. Have any steps been taken towards standardising the parenteral nutrition 
for children and neonates?
□  Yes □  No
If yes:
□  for Neonates
□  for Children
24. Would your hospital be prepared to use standardised solutions?
□  Yes □  No
If yes, why? If no, why not?
7
PART TWO: Standard solutions
The next pages show different options of nutrient concentration 
for five age/weight groups.
If you were to design a standard solutions for paediatric 
patients, which quantity of nutrients would you find most 
suitable for the majority (or a large part) o f your patients for 
different age/weight groups?
Please cross one point on the line:
Example: \ /
A •------- •  • ------- •------- •----- Y  > < < t ------- •
You can choose between gram o f glucose or kcal o f glucose, 
and between using grams of nitrogen or gram of amino a c id :
Example:
Glucose (g) 7 8 9 10 11 12 13 14 15 16 17
or
Glucose (kcal) 28 32 36 w 44 48 52 56 60 64 68A
Nitrogen (g) 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.5 0.55 0.6A
or
Am ino acid (g) 1.0 •— 1.25 —•— 1.5 ■ ♦— 1.75 — •— 2.0 —•— 2.25 — •— 2.5 —•— 2.75• 3.0 —•— 3.25 —•— 3.5 —•
8
1. Premature Neonates
Please suggest a standard solution for premature neonates. 
Cross ONE point for each component.
Requirements per kilogram per 24 hrs
Volum e (mL)
80 90 100 110 120 130 140 150 160 170 180
Nitrogen (g)
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6
or
Am ino acid (g) 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 3.25 3.5
Glucose (g) 
or
7 8 9 10 11 12 13 14 15 16 17
Glucose (kcal) 28 32 36 40 44 48 52 56 60 64 68
Fat (g) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Sodium (mmol) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0




Please suggest a standard solution for neonates.
Cross ONE point for each component.
Requirements per kilogram per 24 hrs
Volum e (mL)
80 90 100 110 120 130 140 150 160 170 180
Nitrogen (g)
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6
or
Am ino acid (g) 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 3.25 3.5
G lucose (g) 
or
7 8 9 10 11 12 13 14 15 16 17
G lucose (kcal) 28 32 36 40 44 48 52 56 60 64 68
Fat (g) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Sodium (mmol) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Potassium (mmol) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Comments:
3. Children < 10 kg
Please suggest a standard solution for children < 10kg.
Cross ONE point for each component.
Requirements per kilogram per 24 hrs
Volum e (mL)
40 50 60 70 80 90 100 110 120 130 140
Nitrogen (g)
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6
or
Am ino acid (g) 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 3.25 3.5
Glucose (g) 
or
5 6 7 8 9 10 11 12 13 14 15
Glucose (kcal) 20 24 28 32 36 40 44 48 52 56 60
Fat (g) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Sodium (mmol) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Potassium (mmol) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Comments:
4. Children 11-20 kg
Please suggest a standard solutions for children from 10-20 kg. 
Cross ONE point for each component.
Requirements per kilogram per 24 hrs
Volum e (mL)
40 50 60 70 80 90 100 110 120 130 140
Nitrogen (g)
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.4f 0.5 0.55 0.6
or
Am ino acid (g) 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 3.25 3.5
Glucose (g) 
or
5 6 7 8 9 10 11 12 13 14 15
Glucose (kcal) 20 24 28 32 36 40 44 48 52 56 60
Fat (g) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Sodium (mmol) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Potassium (mmol) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Comments:
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5. Children 21 -3 0 kg
Please suggest a standard solutions for children from 21-30 kg.
Cross ONE point for each component.
Requirements per kilogram per 24 hrs
Volume (mL)
40 50 60 70 80 90 100 110 120 130 140
Nitrogen (g)
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6
or
Amino acid (g) 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0 3.25 3.5
Glucose (g) 
or
5 6 7 8 9 10 11 12 13 14 15
Glucose (kcal) 20 24 28 32 36 40 44 48 52 56 60
Fat (g) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Sodium (mmol) 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Potassium (mmol) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Comments:
Thank you for taking the time to complete this 
questionnaire.
I f  y o u  w i s h ,  w e  w i l l  i n f o r m  y o u  a b o u t  t h e  r e s u l t s  o f  t h i s  
s u r v e y :
□  Y e s ,  p l e a s e  s e n d  r e s u l t s  o f  t h i s  s u r v e y ,
□  N o ,  p l e a s e  d o  n o t  s e n d  r e s u l t s  o f  t h i s  s u r v e y .
I f  y o u  h a v e  a n y  c o m m e n t s ,  q u e r i e s ,  o r  s u g g e s t i o n s ,  p l e a s e  d o  
n o t  h e s i t a t e  t o  c o n t a c t  m e .
P l e a s e  i n c l u d e  c o p i e s  o f  s t a n d a r d  f o r m u l a t i o n s  a n d  n u t r i t i o n a l  
r e c o m m e n d a t i o n s  y o u  u s e ,  o r  o t h e r  d o c u m e n t s  t h a t  y o u  
c o n s i d e r  h e l p f u l  i n  t h i s  s u r v e y .
B e t t i n a  K l i i t t g e n s
Please place your stamp here, if  you wish.
APPENDIX 3:
South-West multicentre ethics committee: letter of acknowledgement
of neonatal nutrition studv
«/
mm
South West Multi-centre Research Ethics Committee
16 April 2002
Dear Ms Kliittgens
Re: International Audit of Parenteral Nutrition Intake in Neonates
As requested following e-mail communication and receipt of amended documents for 
the above audit, the South West MREC has considered them in an advisory capacity.
It has been noted that both the Protocol (Fourth Version 8 April 2002) and the Plan of 
Data Analysis (Third Version 8 April 2002) incorporate the suggestions made by the 
South West MREC regarding making it explicit that the project is an audit.
The Committee believes that the project as proposed in the documents received does 
not fall within the current remit of a NHS Research Ethics Committee and, 
accordingly, there is not a requirement for it to be subject to ethical review.
Yours sincerely
Ms Bettina Kliittgens









Tel: 01803 861947 
Fax: 01803 861914 
Email: swm rec@sw-devon-h a . swest, nhs.uk
Barrie Behenna
Chairman
The C entral Office for Research Ethics C o m m ittee s  is responsible for the  
onerational manaaement o f  Multi-centre Research Ethics Com m ittees
APPENDIX 4:
Invitation and reply form for UK participants of neonatal nutrition 
study
Bettina Kliittgens
R esearch Pharm acist
E-mail: prpbuk@bath.ac.uk 
Clinical Pharmacy & Pharmacy Practice Research
Department of Pharmacy and Pharmacology
Bath BA2 7AY United Kingdom
Telephone +44 1225 384142 
Facsimile +44 1225 386114
22nd March 2002 
Dear
International Non-Interventional Survey of Parenteral Nutrition Intake in N eonates
I work as a Research Pharmacist at the University of Bath.
I would like to invite you and your neonatal team to take part in this international survey, 
which will investigate the potential for standardization of neonatal parenteral nutrition.
This survey is part of a three-year PhD project studying clinical and pharmaceutical aspects of 
paediatric parenteral nutrition.
If you decide to take part in this survey, your time commitment or that of your staff will be 
minimal, as I will collect the data, and you will be informed about the results of the survey.
All information collected about your patients will be anonymous and kept in secure facilities.
A copy of the survey protocol has been sent to the South W est Multicentre Ethics Committee.
P lease send your reply before the 19th of April, using the enclosed form and free return 
envelope.
P lease contact me if you would like to find out more about the study, or if you have any 
questions.
I am looking forward to hearing from you.
Yours sincerely,
UNI VERS ITY OF
BATH
Bettina Kliittgens
International Non-Interventional Survey of 
Parenteral Nutrition Intake in Neonates






Date: / / Signed:
APPENDIX 5:
Confidentiality agreement for neonatal nutrition study
CONFIDENTIALITY AGREEMENT
THIS AGREEMENT is made on the day of 2002
BETWEEN
1 THE UNIVERSITY OF BATH of Claverton Down Bath BA2 7AY ('the University') and
2
whose address office is at ('the Recipient’)
BACKGROUND
A The University possesses valuable confidential information relating to a research project to be carried out by the
University’s Department of Pharmacy and Pharmacology under the supervision of Ms Bettina Kluettgens (‘the Project’). 
The project will be carried out by means of a study entitled ‘International Audit of Parenteral Nutrition Intake in Neonates’ 
(‘the Study’).
B The Recipient wishes to review confidential information relating to the Project and the Study with a view to
deciding whether to take part in the Study and the University is willing to disclose such confidential information to the 
Recipient on the terms and conditions set out in this Agreement
IT IS agreed:-
1 IN this Agreement:-
'the Information' shall mean all and any information relating to the Project and/or the Study obtained directly or indirectly 
by the Recipient from the University, whether in written or oral or any other form and including without limitation data, 
methods, techniques, specifications and any information relating to these items
2 THE Recipient hereby undertakes to keep the Information confidential and not to disclose the Information to any 
third party except as provided by this Agreement or with the University's prior written consent nor make any use whatsoever 
of the Information except for the sole purpose of considering whether to participate in the Study as outlined above and in 
order to obtain local ethics committee approval. The provisions of this Clause shall extend (without limiting its generality) 
to any information, which comes to the knowledge of the Recipient as a result of any visit to the University's premises
3 THE Recipient may disclose such parts of the Information as may be necessary to those of its employees and 
agents or local ethics committee personnel who need to know the same for the purposes of this Agreement, but shall ensure 
that such employees, agents and personnel are aware of and abide by the provisions of this Agreement (and shall if 
requested by the University obtain from all such employees, agents and personnel a written undertaking in terms to be 
approved by the University to be bound by like obligations as to confidentiality as are accepted by the Recipient)
4 THE provisions of this Agreement shall not apply to information:-
(a) which at the time of disclosure is already in the public domain or subsequently comes into the public domain 
otherwise than by any act or omission of the Recipient, its employees, servants or agents
(b) which the Recipient can show by written records was already rightfully in its possession at the date of disclosure
(c) which the Recipient can show by written records was subsequently to the date of disclosure obtained from an 
independent third party under no obligation of confidence to the University
5 IF the Recipient decides that they do not wish to participate in the Study or to enter into any other agreement with 
the University in respect of the subject matter of the Information, they shall promptly deliver up to the University all 
Information and all copies or embodiments of it in their possession or in that of its servants, agents or employees and shall 
in any event do so within fourteen days of any request by the University in writing
6 THIS Agreement shall not be construed as granting to the Recipient any licence or other rights to use the 
Information except for the purposes specifically set out herein
7 THIS Agreement shall endure for a period of 7 years from the disclosure to the Recipient of the Information and 
be subject to English Law and to the non-exclusive jurisdiction of the High Court of Justice in England
SIGNED by ...............................................
duly authorised by
and on behalf of
THE UNIVERSITY OF BATH
SIGNED by 
duly authorised by 
and on behalf of 
The Recipient
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PICC Peripherally Inserted Central Catheter








Infusion of a mixture of at least amino acids and glucose 
Newborn baby from birth to 27 days of age (ICH 
guidelines)
Mixture of amino acids and glucose, and sometimes 
electrolytes and vitamins
Total Nutrient Admixture: Lipid is infused together with 
the binary solution as pre-mixed solution (‘All-in-One’) 
Filter used close to the patient when administering the 
parenteral nutrition solution




Start of data collection: May 2002
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3 Introduction
PN is a life saving treatment, especially in the neonatal patient group. A recent audit 
found that as many as 43% of hospitals have introduced some form of standardization 
for their paediatric PN (unpublished data). The main reasons for this are 
pharmaceutical and economical. Several hospitals have published their experience 
with the use of neonatal standard feeding solutions M. Currently, no commercial 
feeding solution is available for neonates, although some commercial products are 
suitable for children.
The increase in use of standardized PN has not been accompanied by an increase in 
knowledge regarding the safety of such treatment. It is therefore of great importance 
to investigate the risks and benefits of standardizing PN for neonates. Beecroft and 
co-workers have investigated the adherence of prescribers to the recommendations of 
a computer program 5. They found that 82% of prescriptions deviated from the 
recommendations, but the authors estimate that up to two third of prescriptions could 
be given as standardized feed with an adjusted regimen.
4 Audit Objectives
4.1 First Objective
Investigate prescribing practice in neonatal centres, in terms of variability of nutrition 
composition and differences between prescribed and administered PN.
4.2 Second Objective
Investigate the potential for introducing standard PN solutions for neonates, by means 
of comparing prescribed and delivered PN to the following standard solution 
(in 100 mL):
Glucose 12 g








Neonatal PN Audit Audit Protocol
This standard has been developed as a combination of information from an 
international audit (unpublished data), and subsequent discussions with specialists in 
the field of neonatal PN.
5 Audit Plan
5.1 Number of Observations
One observation is defined as the nutrition prescribed and received by one patient in 
24 hours.
5.1.1 Observations per Centre
For each centre, data are collected for a period of 14 days, according to the 
inclusion/exclusion requirements (see 5.2).
Each centre includes a minimum of 5 patients.
A minimum of 15 observations amongst all patients is collected.
If less than 15 total observations have been collected or less than 5 patients been 
included after 14 days, the data collection continues until both requirements have 
been met.
5.1.2 Choice and Number o f Centres 
Centres will be chosen in two different ways:
In several European countries, hospitals with renowned expertise in neonatal nutrition 
are invited to participate. These centres will undertake the audit prospectively and a 
local data collector is employed.
In the UK, in addition to the centres described above, 5-8 hospitals are selected in a 
randomised way to participate retrospectively. All UK hospitals are invited, providing 
they treat at least 300 neonatal patients in an average year (Source: Neonatal Nurses 
Association Yearbook 2001), and providing their records will allow a retrospective 
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5.2 Patient Population
Neonates receiving parenteral nutrition
5.2.1 Inclusion Criteria
Neonates receiving at least approximately half o f daily nutrition volume from PN for 
any clinical reason (According to ICH guidelines, neonates are no older than 27 days) 
Minimum requirement for inclusion is the infusion of glucose and amino acids.
5.2.2 Exclusion Criteria
More than approximately half of nutrition volume from EN and/or oral feeding 
Patient is more than 27 days old 
Infusion of glucose alone
5.3 Data Collection
Three different forms are used for data collection:
Information about the Centre: This form (one page) asks for general information 
about the audit centre and only needs to be filled in once at the start of data collection. 
Information about Subject: This form (one page) asks for general information about 
the patient and only needs to be filled in once when the patient is enrolled.
Information about Nutrition: This form (two pages) collects data about PN 
prescription and PN/EN administration and needs to be filled in for every day of 
parenteral nutrition.
5.3.1 Audit Centre details
Country; Name of hospital
Total number of neonatal beds
Number of neonatal intensive care beds
Average number of surgical neonates per year
Average number of neonatal patients f!500g birth weight per year
Use of administration filters (Binary solution, lipid, both, no filter used)
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5.3.2 Patient details
Patient identification number
Gender; Birth weight; Date of Birth; Gestational age;
Apgar Score (1 min/5 min)




Body weight at date of observation
Venous access (Central, peripheral, PICC)
Clinical situation/history: Surgery, fluid restriction, Congenital malformation,
metabolic disorder, sepsis (significant), Organ failure leucopoenia, other
5.3.4 Nutrition Prescription 
For PN:
Parenteral Nutrition given as standard solution or not 
Lipid administration (Separately or as TNA)
Lipid solution (20%; 30%)
Volume (Lipid emulsion; binary solution; ternary solution; total volume)
Amount of glucose, amino acids, sodium and potassium
5.3.5 Nutrition Administered
Volume of PN (Lipid emulsion; binary solution; ternary solutions; total volume) 
Volume of EN 
Volume of breast milk
6 Organisation of Audit
6.1 Centres of Expertise
In the centres of expertise throughout Europe, the data collection will take place in a 





Neonatal PN Audit Audit Protocol
At the end of every day, the data collector will send a fax to the project manager, 
including data collection forms about new patients and all nutrition report forms of 
the day. At the end of the 14 days of audit (or more days if  needed), the data collector 
signs the document and the complete folder will be sent by post to the project 
manager. Before the start of the audit, each hospital will be sent a data collection 
folder, which will contain the following items:
• Cover sheet: Data collection form for audit centre
• 20 plastic wallets with the data collection form for patients as cover sticker and 
one data collection form for nutrition inside
• 30 spare data collection forms for nutrition information
• Fax cover sheet for daily faxes to project manager
• Copy of all relevant documents
6.2 Other centres
In the other centres in the UK, data will be collected by the project manager in a 
retrospective way. A similar folders as mentioned in 6.1 will be used.
7 Plan of Data Analysis
Please refer to separate document.
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International Audit of Parenteral 
Nutrition Intake in Neonates
Plan of Data Analysis
1 Definition: Criteria of Analysis
Data collected from European expert centres will be analysed separately from the UK 
based data.
Feedback will be sent to each participating centre about their results.
1.1 Primary analysis
Quantification o f differences between prescribed and administered parenteral nutrition 
The volumes o f prescribed and administered parenteral nutrition will be compared for 
each observation, with regard to:
• Binary solution volume
• Lipid emulsion volume
• TNA volume
If in more than 50 cases the volume administered is below 80% o f the prescribed 
volume of parenteral nutrition, those cases will be analysed separately according to 
the nutrition administered.
1.2 Secondary analysis
Parenteral nutrition prescription data will be compared to standard solution.
The standard solution will be used as defined in the study protocol and the following 
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Component o f  PN Standard (lOOmL) Range 80-120% Range 70-130%
Glucose (g) 12 9.6-14.4 8.4-15.6
Amino acids (g) 2.5 2-3 1.7-3.3
Lipid (g) 2 1.6-2.4 1.4-2.6
Sodium (mmol) 1.5 1.2-1.8 1-2
Potassium (mmol) 1.5 1.2-1.8 1-2
Level o f agreement between prescription & standard Good Moderate
The nutrition solution will be compared to the standard with regard to all five 
components:
• Glucose, Amino acids, Lipid, Sodium, Potassium
Analysis will also be performed on combinations and single components:
• Macronutrients (Glucose, Amino acids, Lipid)
• Binary solutions (Glucose, Amino acids)
• Glucose only








Neonatal PN Audit Plan o f Data Analysis
2 Sub-populations
The data will be analysed according to several sub-populations.
Case will be split into:
SUB-POPULATION NUMBER OF GROUPS
Type of centre 1. Expert
2. Other
Country One expert centre per country
Birth weight 1. < 1500g
2. >= 1500g
Day of PN 1. 1st Day
2. 2nd-3rd Day
3. 4,h-6th Day
4. > 7th Day
Type of nutrition 1. Full PN (>80% of kcal from PN)
2. Partial PN (50-80% of kcal from PN)
Venous access 1. Peripheral
2. Central/PICC
Clinical situation 1. Ventilation: Yes
2. UV-Therapy: Yes
3. Body temperature >3 8°C
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All cases X X X X X X X X
Type of centre X X X X X X
Country X
Birth weight X X X X X
Day of PN X X X
Type of nutrition X
Venous access X X
Clinical situation X X
Pathologies X X
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4 Descriptive Statistics
4.1 Audit centre
Audit centres will be characterised by the number of total beds, number of neonatal 
beds and number of yearly neonatal admissions.
Quantification of the use of administration filters and the type of filers used
4.2 Subjects
Distribution of male versus female subjects
Mean and standard deviation of birth weight
Mean and standard deviation of gestational age
Mean and standard deviation of Apgar score at lmin/5min
4.3 Sub-population







D ata  collection  form s and gu idance for use o f  data co llection  form s
Neonatal PN Audit
Centre ID | |-| |
Data Collection Form -  Study Centre
International audit o f parenteral nutrition 
intake in neonates
INFORMATION ABOUT THE AUDIT CENTRE
This form is only to be filled in ONCE for each centre
Country
Name of hospital
Total number o f neonatal beds |__ |___|
Number o f designated neonatal intensive care beds |__ |___|
Average number o f surgical neonates per year |__ |__ |__ |
Average number o f neonates f!500g birth weight treated per year
Use o f administration filters (tick as many boxes as necessary)
□ Binary Solution □ No filters are used
□ Lipid Emulsion
□ Ternary nutrient admixture
Project Manager Bettina Kliittgens Phone: +44 1225 384142
University o f Bath Mobile: +44 7968594030





Signature o f data collector:
Telephone number Date | || |/| | |/2002
Final VersionConfidential 1 1 3 th May 2002 | 1/1
Neonatal PN Audit 
Data Collection Form - Patient
Patient ID:
INFORMATION ABOUT THE PATIENT
Patient identification number 1 1-1 1 -
ONLY include patient:
• No older than 27 days
• Receiving at least intravenous glucose and amino acids 
This form is only to be filled in ONCE for each patient
Gender □ Male
□ Female
Date o f Birth 1 1 H |/2002
Birth weight L I __ l  I g Apgar lm in 1 |
Gestational age |__ |__ weeks Apgar 5min L J
Date o f first parenteral nutrition * |___|___|/|___|___|/2002
* In this sequence of PN. If the patient has received PN before, but interrupted the 
treatment, please give the restarting date.
Patient history (please tick as many boxes as appropriate)
□ Surgery □ Sepsis (significant)
□ Fluid restriction □ Organ failure
□ Congenital malformation □ Leucopoenia
□ Metabolic disorders □ Other
(Please specify)
Final VersionConfidential 13th May 2002 1/1
Neonatal PN Audit
Subject ID: |-| |-| | | Observation N°: | | |
Data Collection Form - Nutrition
NUTRITION INFORMATION
(E^jj11 ^ ■ If patient receives less than approx. half o f total nutrition volume from
parenteral nutrition
-> All information relates to prescribed/administered nutrition in 24 hours
Date o f observation |__ |___|/|__ |___|/2002
Body weight at day o f observation |__ |___|__ |__ | g
Venous access
□  Central line (tip o f catheter ends in a central vein/right atrium)
□ Peripheral line (tip o f catheter ends in a peripheral vein)
Total fluid administered in 24 hours
(Including enteral and parenteral nutrition volumes, flushes, drugs clear fluids; 
excluding blood products)
|__ |___|___|___| mL
Final VersionConfidential 13th May 2002 1/2
Neonatal PN Audit
Subject ID: | |-|_ |-| | | Observation N°: | | |
Data Collection Form - Nutrition
PARENTERAL NUTRITION PRESCRIPTION
Prescription is for standard bag □  Yes □  No
(Only if  standard given unchanged)
Lipid given separately □  Yes □  No
Lipid given in form of □  20% □  30% emulsion
Volume Lipid Emulsion 1 LI 1 mL
Volume Binary solution | | 1 Li 1 mL
or
Volume Tertiary solutions | | 1 LI mL
Total volume 1 LI 1 mL
Amino acids 1 1 LI 1 g Sodium | 1 14 | mmol
Glucose 1 1 LI 1 g Potassium l#l | mmol
Lipid 1__ LI__ 1 g
PARENTERAL NUTRITION ADMINISTERED
Volume Lipid Emulsion | LI 1 mL
Volume Binary solution | | LI 1 mL
or
Volume Tertiary solutions | | | BI
__!•II
Total volume | | | LI 1 mL
ENTERAL/ORAL NUTRITION ADMINISTERED
Enteral Product
Name   Volume I I I LI I mL
Breast milk |__ |__ |__ |.|__ I mL
Confidential Final Version 13th May 2002 2/2
Neonatal PN Audit Plan o f  Data Analysis
International Audit of Parenteral 
Nutrition Intake in Neonates
Plan of Data Analysis
1 Definition: Criteria of Analysis
Data collected from European expert centres will be analysed separately from the UK 
based data.
Feedback will be sent to each participating centre about their results.
1.1 Primary analysis
Quantification o f differences between prescribed and administered parenteral nutrition 
The volumes o f prescribed and administered parenteral nutrition will be compared for 
each observation, with regard to:
• Binary solution volume
• Lipid emulsion volume
• TNA volume
If in more than 50 cases the volume administered is below 80% o f the prescribed 






Neonatal PN Audit Plan o f Data Analysis
1.2 Secondary analysis
Parenteral nutrition prescription data will be compared to standard solution.
The standard solution will be used as defined in the study protocol and the following 
ranges will be applied to all components of the nutrition solution:
Component o f PN Standard (lOOmL) Range 80-120% Range 70-130%
Glucose (g) 12 9.6-14.4 8.4-15.6
Amino acids (g) 2.5 2-3 1.7-3.3
Lipid (g) 2 1.6-2.4 1.4-2.6
Sodium (mmol) 1.5 1.2-1.8 1-2
Potassium (mmol) 1.5 1.2-1.8 1-2
Level o f agreement between prescription & standard Good Moderate
Data will also be compared to currently used standard solutions and to current 
recommendations of nutritional intake.
The nutrition solution will be compared to the standard with regard to all five 
components:
• Glucose, Amino acids, Lipid, Sodium, Potassium
Analysis will also be performed on combinations and single components:
• Macronutrients (Glucose, Amino acids, Lipid)
• Binary solutions (Glucose, Amino acids)
• Glucose only








Neonatal PN Audit Plan o f Data Analysis
2 Sub-populations
The data will be analysed according to several sub-populations. 
Case will be split into:
SUB-POPULATION NUMBER OF GROUPS
Type of centre 1. Expert
2. Other
Country One expert centre per country
Birth weight 1. < 1500g
2. >= 1500g
Day of PN 1. 1st Day
2. 2"d-3rd Day
3. 4th-6th Day
4. > 7th Day
Type of nutrition 1. Full PN (>80% of nutrition volume 
from PN)
2. Partial PN (50-80% of nutrition 
volume from PN)
Venous access 1. Peripheral
2. Central / Peripherally inserted Central 
Catheter





Neonatal PN Audit Plan o f Data Analysis





































All cases X X X X X X X X
Type of centre X X X X X X
Country X
Gestational age X X X X X
Day of PN X X X
Type of nutrition X
Venous access X X
Pathologies X X






Neonatal PN Audit Plan o f Data Analysis
4 Descriptive Statistics
4.1 Audit centre
Audit centres will be characterised by the number of surgical beds, number of 
neonatal intensive care beds and number of yearly neonatal admissions < or = 1500g. 
Quantification of the use of administration filters and the type of filers used
4.2 Subjects
Distribution of male versus female subjects
Mean and standard deviation of birth weight
Mean and standard deviation of gestational age
Mean and standard deviation of Apgar score at lmin/5min
4.3 Sub-population







Electronic data collection tool for neonatal nutrition study 
(Microsoft Access file -  2.7 MB)
Directions for use:
Insert disk into appropriate drive
Open file ‘NeonatalNutritionDataCollectionTool’
Data entry frames open automatically
Examples of electronic data collection tool








Click on button to open window
New Centre
Centre ID Number Total number of neonatal beds
Number of designated 
intensive care bedsCountry
Hospital Average number of surgical 
patients per year
Avarage number of neonatal 





. . . . . . . . . .
Back to Main 
Menu
New Patient ONLY include patients no older than 27 days, and who receive a t least amino acids 
and glucose
Patient ID Number Apgar lmin
Apgar 5minr
HHUjjiHHaHnnraaHHs&nnHi mIiH E H
Date of first PN
*In this sequence of PN. If the patient has 
received PN before, but interrupted the 

















Back to Main 
Menu
Nutrition AdministeredPrescription
Q  Standard solution 
□  Lipid separately
Volume Lipid mL
Volume BinaryLipid emulsion mL
Volume TertiarymLVolume Lipid mL




Amino acids Enteral Product









V alid ation  certificate  for class 2 aseptic p reparation  cab inet
C u s to m e r 's  N a m e  and  A dd ress 
C o n tac t r t ,  .............
C o . N am e...  a / s j j -    D ept ..................
A d d r e s s .............................................................. ........ ...........................................
BiGQ BIOQUELLs e r v i c e
C o n tra c t No:
'2_-/ n J l° /O
2_1 Y* Z.
Walworth Road, Andover 
Hampshire SP10 5AA United Kingdom 
Tel: +44 (0)1264 835800 
Fax: +44 (0) 1264 835801 
E-mail: support @ bioquellservice.com 
Web: www.bioquellservice.com
A division of BIOQUELL UK Ltd 
Registered No. 2520270
SERVICE REPORT No. A
C u s to m e r  O rd . No:  ...... ............ ..............................
Purpose of Visit: CONTRACT SERVICE 1/2/3/4 COWE^^ONTNG
217808
G E W ^ ^ ^ i P A I R  (Delete as necessary)
E q u ip m e n t ...  .-Jrrr-. 7 7 ^ Mode l  N o : ...........................  D ate C o m m e n c e d : . .............)J\IF! Rank Ho i / Y ns'N n
L o c a tio n :..............* 5 7 “^ ........ 7 .V    S eria l No: . . ^ ^ . ^ cJ,0"7.'7./......... D ate C om pleted: ............W E ''B an k  Hoi /Y as /N o
E x p e n s e s ................................    Parking:........  C a u se  C o d e :.............................................. R ep a ir C o d e : ..................................... ..........
Unit s ta tu s :  C o m p le te  / i Arrival time: Travelling H ours:
W /O s ta tu s : / incom plete D epartu re  tim e:. / b o O Total H ours o n  S ite:....../ .
1. CABINET FUNCTIONS
airflow in d ic a t io n s ...............\S..................... indicator b u lb s ......
an tib lo w -b ack  d e v ic e  ^ .........  f a n s ....................................
a l a r m s ....................................... .........................  run on tim e r .....................< . . . .
form alin u n i t ...........................9^ ....^ .......... g a s  so le n o id ................ ^  
lighting level ( lu x ) .......................................... UV lights (uw /cm 3) ...1$. 
so u n d  level ( d b a ) ................... .......................  earth  le a k a g e  (mA) . . <  
2. PRE-FILTERS
s ize % c h a n g e d /se rv ic e a b le
3. PRESSURE DIFFERENTAILS
HEPA filter ...................Papre-filters ................... P a
w ork z o n e - r r r r+ r T T T a
rAN SPEED SETTINGS
2—E x h au st R e c irc .
5. FILTER INTEGRITY BS.3928 DOP
eq u ip m en t ~^V. ^ c a l i b r a t e d
Main H E P A ..................................................................................... %  penetration
E x h au st H E P A ........frr....... : . . ^ F r ,3 .................................... %  penetra tion
Downflow H E P A ......'T "........'..r^r*3 ,..................................... %  penetra tion
Outflow H E P A ................................................................................%  penetra tion
Inflow H E P A  ........* 0 c > * ?  %  penetration
Com m ents:
Exact Co r
Pate Q 6 ^ <
6. AIRFLOW MEASUREMENTS (Metres per second)
equipm ent u sed  / V o  }  ca lib ra ted  J2__
Test positions an d  airflow ra te s  
MAIN ^  ^  EXHAUST
0.33 ( a<f3 0-cf3
inflow th rou gh glovs pe r is  
oxh a u s t-volum ea m V scc
RH
INFLOW o a loula te d from  cxhou. ; t  A J  c-
7. PARTS USED
QTY Part No. Description
Service/Tests a s  ind icated  above an d  overleaf carried out and 
conform to requ irem ents u n le ss  o therw ise sta ted:
Service E n g ip e ^ r^ ig n a tu re
j
A uthorised C ustom er S ig n a tu re  (Agreeing to statem ents 
contained in this report)
N am e and  Position
Signature .............................  yvX ’^..
□  W hite C opy (C u sto m e r C o p y ) □  B lue  a n d  G r e e n  C o p ie s  (O ffice C op ies) Q  Yellow C o p y ^ S e rv ic e  E n g in e e rs  C opy)
APPENDIX 10:
Calibration certificates for 20 jliL, 100 jllL, 200 |nL, and 1000 (iL 
pipettes
ANACHEM
Anachem Ltd. Anachem House, Charles Street, Luton, Bedfordshire, LU2 OEB, U.K.
Date Printed: 10-Feb-2003 CALIBRATION
ANACHEM CALL NUMBER: 109610
ORDER DETAILS PIPETTE DETAILS
Calibration Date: 10-Feb-2003 Model: P20
Account/Customer: 02009 UNIVERSITY OF BATH Serial No:T55103N
Contact: UNIVERSITY OF BATH
Thermometer: TH16
A ve Room Temp: 21,0 deg.C Barometer: AB1
A ve Water Temp: 21.0 deg.C Balance: X
Technician: Liquid Handling Dept Balance Ref: 1119493182
Air Pressure: 1005hPa Tips used: Gilson D200
Z Factor: 1.0031 pL/mg Cust Order: SH 462154-0
Humidity: 45.9% CustRef: SARAH ROBERTS 
End User:
CALIBRATION DETAILS
V ol./Spec Code | 2.000 (G7 ) | 20.000 (G9 ) |
W eighing 1 (mg) | 1.970 (pass) | 19.960 (pass) |
W eighing 2 (mg) j 2.000 (pass) | 19.960 (pass) j
W eighing 3 (mg) j 1.990 (pass) | 19.970 (pass) j
W eighing 4 (mg) j 1.990 (pass) | 19.950 (pass) j
M ean Wgt (mg) | 1.988 I 19.960
M ean Vol (pL) 1.994 (pass) | 20.022 (pass) j
A bs Inacc. (pL) -0.006 (pass) | 0 .022 (pass) |
Rel Inacc. (%) -0.300 (pass) | 0.110 (pass) j
A bs SD (pL) 0.013 (pass) | 0.008 (pass) j
CV% j 0.652 (pass) | 0 .040 (pass) j
OVERALL STATUS PASS I PASS I
SERVICING DETAILS
S p a re s  C ode Qty U sed
T/HOLDER H 23353 1
PISTON H 23845 1
6 MONTH SER V IC E WARRANTY
Technicians Signature A / ........................... Warranty Expiry Date
f 0 AUG 2003
S pecifica tion  Inform ation:
I
S p e c  C ode Min Vol (pL) Max Vol (pL) A bs SD (pL) CV%
G7 1.9 2.1 < = 0 .0 3 0  < = 1 .5 0 0
G9 19.8 20 .2 <= 0 .060 <= 0 .300
V alues Exclude Environm ental A djustm ent
P ro d u c e d  from co m p u te rise d  Liquid Handling S ystem  - (C) A n ach em  Ltd 1998 V6.1g
T elephone:+44 (0)1582 745061 F ax :+44 (0)1582 745130 www.anachem.co.uk email: lhlab@anachem.co.uk
Regd. Office: 20 Charles Street, Luton, Bedfordshire LU2 OEB Registration N°: 974301 England V.A.T. Registration N°: 196 2842 29
The calibration check was carried out using the gravimetric method as stipulated by the manufacturer, with weights that are traceable to the National Physical Laboratory.
ANACHEM
Anachem Ltd. Anachem House, Charles Street, Luton, Bedfordshire, LU2 OEB, U.K.
Date Printed: 17-Jan-2003 CALIBRATION
ANACHEM CALL NUMBER: 109118




Ave Room Temp: 



















Balance Ref: 11902938  
Tips used: Gilson D200 
Cust Order: SH 462154-0 




V ol./Spec Code | 20.000 (G10 ) 100.000 (G12 ) |
W eighing 1 (mg) | 19.900 (pass) 99.730 (pass) |
W eighing 2 (mg) j 19.930 (pass) 99.580 (pass) j
W eighing 3 (mg) j 19.950 (pass) 99.720 (pass) j
W eighing 4 (mg) j 20.010 (pass) 99.760 (pass) |
Mean W gt (mg) | 19.947 99.698
Mean Vol (pL) 20.009 (pass) 100.007 (pass) j
Abs Inacc. (pL) 0.009 (pass) 0.007 (pass) j
Rel Inacc. (%) 0.045 (pass) 0.007 (pass) |
Abs SD  (pL) 0.047 (pass) 0.080 (pass) |
CV% | 0.235 (pass) 0.080 (pass) j
OVERALL STATUS PASS I PASS I
SERVICING DETAILS





SEAL H 44604 1
6 MONTH SERVICE WARRANTY
Technicians S ignature....................... 9 ^ ...................................  Warranty Expiry Date ..t'.Z:. J.U.L
Specification Information: Spec Code Min Vol (pL) Max Vol (pL) Abs SD (pL) CV%
G10 19.65 20.35 <=0.100 <=0.500
G12 99.2 100.8 <=0.150 <=0.150
Values Exclude Environmental Adjustment \
Produced from computerised Liquid Handling System - (C) Anachem Ltd 1998 
T elephone:+44 (0)1582 745061 Fax:+44 (0)1582 745130 www.anachem.co.uk email: lhlab@anachem.co.uk
Regd. Office: 20 Charles Street, Luton, Bedfordshire LU2 OEB Registration N°: 974301 England V.A.T. Registration N°: 196 2842 29
The calibration check was carried out using the gravimetric method as stipulated by the manufacturer, with weights that are traceable to the National Physical Laboratory.
V6.1g
ANACHEM
Anachem Ltd. Anachem House, Charles Street, Luton, Bedfordshire, LU2 OEB, U.K.
Date Printed: 17-Jan-2003 CALIBRATION
ANACHEM CALL NUMBER: 109118
ORDER DETAILS PIPETTE DETAILS
Calibration Date: 17-Jan-2003 Model: P200
Account/Customer: 02009 UNIVERSITY OF BATH
Serial No: T69850K
Contact: UNIVERSITY OF BATH
Thermometer: TH16
Ave Room Temp: 21.0 deg.C Barometer: AB1
Ave Water Temp: 21.0 deg.C Balance: T
Technician: Liquid Handling Dept Balance Ref: 1117473705
Air Pressure: 998hPa Tips used: Gilson D200
Z Factor: 1.0031 pL/mg Cust Order: SH 462154-0




Vol./Spec Code | 50.000 (G13 ) | 200.000 (G15 ) |
Weighing 1 (mg) | 49.900 (pass) | 199.960 (pass) |
Weighing 2 (mg) 49.970 (pass) | 199.870 (pass) j
Weighing 3 (mg) j 49.960 (pass) | 199.900 (pass) j
Weighing 4 (mg) j 49.980 (pass) | 199.900 (pass) j
Mean Wgt (mg) | 49.952 I 199.908
Mean Vol (pL) 50.107 (pass) | 200.527 (pass) j
Abs Inacc. (pL) 0.107 (pass) | 0.527 (pass) j
Rel Inacc. (%) 0.214 (pass) | 0.263 (pass)
Abs SD (pL) 0.036 (pass) | 0.038 (pass) j
CV% | 0.072 (pass) | 0.019 (pass)
OVERALL STATUS PASS I PASS I
SERVICING DETAILS
NO SPARE PARTS USED
Technicians Signature.................. /lO G Y . Warranty Expiry Date
1 ?  JUL 20Q3
Specification Information: S p e c  C o d e Min Vol (pL) Max Vol (pL) A bs SD  (pL) CV%
G 13 49.5 50.5 <= 0 .2 0 0  <= 0 .400
G 15 198.4 201.6 < = 0 .3 0 0  < = 0 .1 5 0
V a lu e s  E xclude Environm ental Adjustment |
P ro d u c ed  from com puterised  Liquid H andling S y stem  - (C) A nachem  Ltd 1998 
T elephone:+44 (0)1582 745061 F ax :+44 (0)1582 745130 www.anachem.co.uk email: lhlab@anachem.co.uk
Regd. Office: 20 Charles Street. Luton. Bedlordshire LU2 OEB Registration N“: 974301 England VAT. Registration N°: 196 2842 29
The calibration check was carried out using the gravimetric method as stipulated by the manufacturer, with weights that are traceable to the National Physical Laboratory.
V6.1g
ANACHEM
AnachOifttfil. R rfiE ^ & o u se , Charles S t r ^ t ^ p B S f f i f lS h ir e ,  LU2 OEB, U.K. 0  A LIB RAT IO N
ANACHEM CALL NUMBER: 108120
ORDER DETAILS PIPETTE DETAILS
Calibration Date: 06-D ec-2002 Model: P1000
Account/Customer: 02009  UNIVERSITY OF BATH
Serial No: T53730K
Contact: UNIVERSITY OF BATH
Thermometer: TH13
Ave Room Temp: 21 .0  deg.C Barometer: AB1
Ave Water Temp: 2 1 .0  deg.C Balance: J
Technician: Liquid Handling Dept Balance Ref: J31974
Air Pressure: 1009hPa Tips used: Gilson D1000
Z Factor: 1.0031 pL/mg Cust Order: SH 461739-
Humidity: 46.0% CustRef: SARAH ROBERTS 
End User:
CALIBRATION DETAILS
Vol./Spec Code | 200.000 (G16 ) | 1000.000 (G18
Weighing 1 (mg) | 199.430 (pass) | 996.130 (pass)
Weighing 2 (mg) j 198.670 (pass) | 994.300 (pass)
Weighing 3 (mg) j 199.050 (pass) | 995.850 (pass)
Weighing 4 (mg) j 198.740 (pass) | 995.690 (pass)
Mean Wgt (mg) | 198.973 I 995.493
Mean Vol (pL) 199.589 (pass) | 998.579 (pass)
Abs Inacc. (pL) -0.411 (pass) | -1.421 (pass)
Rel Inacc. (%) -0.206 (pass) | -0.142 (pass)
Abs SD  (pL) 0.348 (pass) | 0.818 (pass)
CV% | 0.174 (pass) | 0.082 (pass)
OVERALL STATUS PASS I PASS
SERVICING DETAILS
Spares Code Qty Used
PISTON H23847 1
6 MONTH SERVICE WARRANTY
Technicians Signature (V Warranty Expiry Date 0 6 JUN 2 0 0 3
Specification Information: S p e c  Code Min Vol (pL) Max Vol (pL) A bs S D  (pL) CV%
G16 197 203 <= 0.600 <= 0.300
G18 992 1008 <= 1.500 <=0.150
V alues Exclude Environmental Adjustment
Produced from com puterised Liquid Handling System  - (C) Anachem Ltd 1998 V6.1g
Telephone: +44 (0)1582 745061 Fax: +44 (0)1582 745130 www.anachem.co.uk email: lhlab@anachem.co.uk
Regd. Office: 20 Charles Street, Luton, Bedfordshire LU2 OEB Registration N’ : 974301 England V.A.T. Registration N°: 196 2842 29
The calibration check was carried out using the gravimetric method as stipulated by the manufacturer, with weights that are traceable to the National Physical Laboratory.
APPENDIX 11:
Presentation of results at conferences and educational meetings
Results obtained during the course of this research project have been 
presented at the following conferences and educational meetings:
BAPEN, Harrogate, November 2000: Annual Meeting of the British Association for 
Parenteral and Enteral Nutrition. Results from the literature were presented orally and 
as a poster.
BAPEN, Harrogate, November 2001: Annual Meeting of the British Association for 
Parenteral and Enteral Nutrition. Results from the survey were presented orally and as 
a poster. The abstract was also published in the Proceedings of the Nutrition Society, 
Volume 61, Supplement 11A (Appendix 11)
Nutriforum, Bristol, May 2002: Clinical and Practical Choices for the Future 
(Chair: Dr. John Puntis) Educational meeting approved by the College of Pharmacy 
Practice and all medical Royal Colleges.
BPC, Manchester, September 2002: Results from the survey were presented as a 
poster. The abstract was also published in the International Journal of Pharmacy 
Practice, Supplement: Pharmacy Practice Research, R77 (Appendix 11)
Nutriforum, Leeds, March 2003: Clinical Nutrition. You Have a Choice
(Chair: Mr. John McFie) Educational meeting approved by the College of Pharmacy
Practice and all medical Royal Colleges.
APPENDIX 12:
Manuscripts submitted for publication
The following manuscripts have been submitted for publication:
B U Kliittgens, G J Sewell, and A J Nunn: Current clinical practice in neonatal and 
pediatric parenteral nutrition in Europe. Journal o f  European Hospital Pharmacy
B U Kliittgens, A J Nunn, and G J Sewell: Standardized Neonatal and Pediatric 
Parenteral Nutrition in Europe. Clinical Nutrition
B U Kliittgens, G J Sewell, A J Nunn, and A Le Brun: Retrospective observational 
study of parenteral nutrition prescribing for infants. Archives o f Diseases in 
Childhood (Fetal and Neonatal Edition)
APPENDIX 13:
Published abstracts: BAPEN 2000, BAPEN 2001, BPC 2002
Literature comparison of basic parenteral nutrition solutions for neonates, is standardisation 
possible? By B.U. KLUETTGENS G.J. SEWELL 1 and A.I. NUNN 2, 1 University o f  Bath, Bath 
BA2 7A ¥  and 2 Alder Hey Royal Liverpool Children’s NHS Trust Liverpool L12 2AP
Commercial complete parenteral nutrition solutions are not available for neonates. Therefore, 
nutritional solutions have to be compounded in hospital pharmacies. In order to increase safety and 
reduce cost, hospitals may introduce standard feeding regimens (Digel, 1998). The literature has been 
searched, using EMBASE, The Web of Science, and Medline, for publications about standardised 
nutrition for the neonatal patient group. Data has been retrieved from England, Spain, and Germany. 
Discussions with collegues have revealed that several other centers use standardised parenteral 
nutrition for neonates, but have not published their results.
Standardisation of parenteral nutrition for neonates may involve the preparation of a single formula 
where the volume infused is altered according to the patient’s weight. This is only applicable for stable 
patients without special requirements since if a different quantity of any one volume is required, then 
the amount of all others is also altered. In a recent article, is has been estimated that up to two third of 
neonates could be given a range of pre-compounded standard solutions (Beecroft et al, 1999).
The most recent data available on standardised regimens is listed below. In San Sebastian, Spain, a 
concentrate is manufactured, which can be diluted according to the patients needs (Aldamiz-Echevrria 
et al, 1995). The comparison shows that individually developed regimens in different European 
countries do not differ substantially.
Requirements 
per kg in 24hrs
Plymouth, UK 
(Unpublished data)
Essen, Germany Heilbronn, Germany 
(Willimsky et al, 2000)
San Sebastian, 
Spain
Volume 150 150 150 150
Glucose 14 15 15 10
Nitrogen 0.3 0.38 0.38 0.32
Sodium - 4.5 4.5 4.0
Potassium - 2.0 3.0 2.5
Calcium - 1.5 1.5 1.2
Magnesium - 0.2 0.17 0.28
Phosphate - 1.5 1.5 1.0
Chloride - 3.5 4.5 4.0
Standardising parenteral nutrition and producing the solutions in batches makes more extensive 
quality assurance possible and commercial manufacture practicable, and therefore increases the safety 
of this treatment. A high quality and safe parenteral nutrition is especially important in these most 
susceptible patients. The reviewed data supports suggestions that a wide-ranging standardisation of 
neonatal parenteral nutrition is feasible.
Future directions of this study include a questionnaire directed at key European centres aiming to 
evaluate the practice of supplying parenteral nutrition to paediatric patients, the development of 
standard regimens, and stability studies on a standardised regimen, including peroxide formation.
Aldamiz-Echevarria L, Bachiller Cacho MP, Gayan Lere MJ, Paisan Grisolia L, Lopez Arzoz, Barcia Romero MJ 
& Albisu Andrade Y (1995) Anales espanoles de pediatria  43 (3), 203-207 
Beecroft C, Martin H & Puntis JWL (1999) Clincial Nutrition  18 (2), 83-85 
Digel S (1998) Krankenhauspharmazie  19 (2), 62-65
Willimsky S, Kilian R, Geier N, Schwartz M, Runge H & Kachel W (2000) Monatsschrift fur Kinderheilkunde 
148,713-718
European survey of current practice in the delivery of parenteral nutrition to neonates and 
children. By B.U. KLITTGENS l, G.J. SEWELL 1 and A.J. NUNN 2, 1 University o f Bath, Bath 
BA2 7A Y  and 2 Alder Hey Royal Liverpool Children’s NHS Trust, Liverpool L I 2 2AP
As part of a project to determine whether standard parenteral nutrition admixtures could be used 
more widely in neonatal and paediatric practice a survey has been undertaken in five European 
countries, including Spain, Italy, France, Germany and the UK. The objective was to characterize 
current practice in the provision of parenteral nutrition for neonates and children. A total of 90 
hospitals were included in this study, covering nearly 10,000 pediatric beds.
The survey was undertaken in the form of a postal questionnaire aimed at clinicians and 
pharmacists.
In order to define the delivery of parenteral nutrition the following issues have been 
addressed:
■ Where are the parenteral nutrition solutions compounded?
■ Is fat infused separately or as All-in-One mixtures?
■ When are vitamins and trace metals commenced?
■ Are filters and light protection used during drug administration?
■ Is any form of standard admixture used?
Results show that in some issues the five countries differ considerably: In the UK 90% of hospitals 
have a compounding unit for parenteral nutrition, in Germany and Italy parenteral nutrition is still 
regularly compounded on wards with only a third of hospitals providing a pharmacy compounding 
unit. In France and Spain commercial manufacturers often provide the compounding service, with 
only half of the hospitals providing a pharmacy-based service.
The lipid emulsion is usually given as a separate infusion to neonates (81%) and to most 
children (51%).
Vitamins and trace metals are usually given from day one for seven days per week. A 
minority of hospitals only include the micronutrients 3-4 days a week and some start the supply 
seven days after starting parenteral nutrition support.
Filters are used in 54% of hospitals. The parenteral nutrition bag is frequently protected 
form light (47%), but the use of light protecting tubing is less common (14%).
Despite the lack of international recommendations regarding the use of standard 
formulations, 43% of hospitals have indicated that they have introduced some kind of standard 
bag. The reasons for the introductions of standardized bags are: Convenience (24%), capacity 
problems regarding the compounding of individual bags (19%) and increased safety with the use 
of standard bags (11%).
29% of respondents have indicated that they would not be prepared to introduce standard 
regimens for their neonates and children.
The practice of parenteral nutrition delivery varies considerable throughout Europe. 
Although little is published on the use of standardized parenteral nutrition, many have introduced 
standard regimens and there continues to be a lively discussion regarding this issue.
Further work is required to explore the different European practices and to establish whether 
tailored or standard regimens provide better nutritional intake.
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Introduction
Parenteral nutrition for neonates and children is highly complex and involves many health-care 
professionals. Little is known about the clinical and pharmaceutical practice o f paediatric parenteral 
nutrition in different European countries.
Objectives
The aim o f this survey was to identify similarities and differences in the way parenteral nutrition is 
prescribed, compounded and administered in five European countries (France, Germany, Italy, Spain, 
and the UK).
Method
A postal questionnaire survey was undertaken, addressing 218 hospitals. Hospitals where selected with 
the help o f personal contacts in each country. Questions were asked regarding prescribing practice, 
compounding facilities, involvement o f different health-care professionals, use o f filters, and use o f  
standardized, pre-compounded formulae.
Results
The overall response rate was 45% (France 45%; Germany 44%; Italy 29%; Spain 36%; UK 71%). 
Prescribing o f parenteral nutrition is usually carried out by clinicians (80%), although sometimes 
Pharmacists prescribe (6%). Special compounding facilities are present in most UK (87%) and Spanish 
hospitals (64%), but less often in Germany (35%), France (40%), and Italy (50%).
Table 1 shows the extent o f the use o f filters and light protection overall
Yes, always Yes, sometimes No
Use o f  Filter (N=98) 57% 16% 27%
Light protection (bag) (N=97) 48% 24% 28%
Light protection (tubing) (N=92) 15% 24% 61 %
The lipid emulsion is usually given as a separate infusion to neonates (81%) and to most children (51%). 
Vitamins and trace metals are typically given from the first day o f parenteral nutrition for seven days per 
week. A minority o f hospitals only include the micronutrients 3-4 days a week and some start the supply 
seven days after starting parenteral nutrition support.
Standardized, pre-compounded nutrition formulae are used in 43% of hospitals. These include 
commercially available solutions, externally produced solutions to internal specification, or in-house 
manufactured solutions.
Discussion
Differences in clinical and pharmaceutical practice in the five European countries are mainly related to 
the involvement of different professionals. This is probably related to cultural differences and different 
roles o f clinician, pharmacists, and nurses. In Germany, Pharmacists are only rarely involved in the 
compounding o f parenteral nutrition, and in France external suppliers are used. Other elements o f  
parenteral nutrition support show widespread similarities between the study countries.
Although little is published about the use o f standardized parenteral nutrition, many neonatal and 
paediatric centres have introduced standard regimens and there is currently considerable interest in this 
issue \  Standardising parenteral nutrition and producing the solutions in batches makes more extensive 
quality assurance possible and commercial manufacture practicable, and therefore increases the safety o f  
this treatment. The compounding process becomes less time consuming and more economic.
Further work is needed to investigate the nutritional adequacy and safety o f standardized parenteral 
nutrition.
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